WO2008067709A1 - Substituted cyclobutane compounds, preparation methods and pharmaceutical uses thereof - Google Patents

Substituted cyclobutane compounds, preparation methods and pharmaceutical uses thereof Download PDF

Info

Publication number
WO2008067709A1
WO2008067709A1 PCT/CN2007/002768 CN2007002768W WO2008067709A1 WO 2008067709 A1 WO2008067709 A1 WO 2008067709A1 CN 2007002768 W CN2007002768 W CN 2007002768W WO 2008067709 A1 WO2008067709 A1 WO 2008067709A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
halogen atom
decyloxy
groups
Prior art date
Application number
PCT/CN2007/002768
Other languages
French (fr)
Chinese (zh)
Inventor
Mingwei Wang
Na Li
Qing Liu
Lilin Lin
Yueyun Zhang
Jiayu Liao
Original Assignee
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences filed Critical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Publication of WO2008067709A1 publication Critical patent/WO2008067709A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Definitions

  • the present invention relates to a compound having a substituted cyclobutane structure, a preparation method thereof, and a glucagon-like peptide
  • Glucagon like peptide-1 receptor (GLP-1R) modulators prevent and/or treat metabolic disorders (including but not limited to diabetes, insulin resistance and obesity, etc.), cardiovascular disease, neurodegenerative Medical use of diseases such as Alzheimer's disease.
  • metabolic disorders including but not limited to diabetes, insulin resistance and obesity, etc.
  • cardiovascular disease including but not limited to diabetes, insulin resistance and obesity, etc.
  • neurodegenerative Medical use of diseases such as Alzheimer's disease.
  • Type 1 diabetes Disorders of glucose metabolism, especially diabetes, have become a major threat to human health and life in modern society. It is predicted that diabetes patients worldwide are increasing at a rate of 6% per year. By the end of 2006, there were 320 million patients (China's '60 million people, ranking second). Diabetes is a group of clinical syndromes caused by the interaction of genetic and environmental factors. It is mainly divided into type 1 and type 2. The basic pathophysiology of type 1 diabetes is absolute insulin secretion, and clinical treatment is mainly supplemented with insulin. It is also known as insulin-dependent diabetes. Type 2 diabetes accounts for more than 95% of the diseased population.
  • Insulin resistance is a key factor in the development and progression of type 2 diabetes.
  • Therapeutic drugs for type 2 diabetes include sulfonylureas, biguanides, other insulin sensitizers, and ancillary measures.
  • the potassium ion channel is closed, and the potassium ion efflux is blocked, which leads to depolarization of the cell membrane, causing the Ca 2+ channel to be released, resulting in extracellular calcium influx.
  • the increase in intracellular calcium concentration triggers the release of insulin.
  • the first generation such as toluene propyl propyl urea
  • the second generation including glibenclamide (glibenclamide), gliclazide (Damecon), glipizide (mepyrazin) ) and gliclazide (sugar leveling) and the like.
  • the biguanide hypoglycemic agent can suppress appetite, increase the binding of insulin to the receptor, promote the anaerobic glycolysis of glucose, inhibit tissue respiration, and inhibit hepatic gluconeogenesis. Mainly there are metformin, phenformin and butyl bismuth.
  • hypoglycemic agents mainly include Thiazolidinediones (such as troglitazone, rosiglitazone, pioglitazone, etc.), P 3-adrenergic receptor modulators, glucagon receptor antagonists, Fatty acid metabolism interfering drugs, ⁇ -glycosidase inhibitors (such as acarbose, voglibose, miglitol, etc.) and aldose reductase inhibitors.
  • Thiazolidinediones such as troglitazone, rosiglitazone, pioglitazone, etc.
  • P 3-adrenergic receptor modulators such as glucagon receptor antagonists
  • Fatty acid metabolism interfering drugs such as acarbose, voglibose, miglitol, etc.
  • aldose reductase inhibitors such as acarbose, voglibose, miglitol, etc.
  • GLP-1R Glucagon like peptide-1 receptor
  • GPCR G protein-coupled receptor
  • GLP-1 In vitro, GLP-1 promotes differentiation of embryonic stem cells into islets A secretory cell-like cell (J Endocrinol. 2005, 186: 343-52). GLP-1 acts on the central body to promote cell survival and reduce apoptosis, reduce the neurotoxicity of amyloid peptides, inhibit the progression of neurodegenerative diseases, and promote learning and memory. Therefore, it has recently been proposed to use GLP-1 for Alzheimer's. Treatment of the disease (Ann NY Acad Sci, 2004, 1035: 290-315; Nat Med, 2003, 9: 1173-1179; Curr Alzheimer Res, 2005, 2: 377-385; J Pharmacol Exp Ther, 2002, 302: 881 - 888). In addition, GLP-1 also plays an important role in the cardiovascular system.
  • GLP-1R has the effect of lowering blood pressure and dilating blood vessels.
  • Acute injection of GLP-1 can improve left ventricular systolic function in cardiac hypertrophy experiments. It also reduces myocardial cell damage in the presence of myocardial ischemia and reperfusion (J. Hypertens, 2003, 21: 1125 - 1135; Am J Physiol Endocrinol Metab, 2004, 287: E1209 - E1215; Circulation, 2004, 110 : 955 - 961 ; Diabetes, 2005, 54 : 146 - 151). Due to the above-mentioned clear physiological effects, since the discovery of this target in the mid-1980s, the search for small molecule agonists of GLP-1R has been a research hotspot of many new drug development institutions in the world.
  • GLP-1 innovative drugs such as the GLP-1 derivative developed by Danovo Nordisk in Denmark (trade name Liraglutide; entering Phase III clinical trials) and Amylin Pharmaceuticals and Lilly in the United States.
  • the company's joint development of the GLP-1 analogue Exendin-4 (trade name Exenatide; has been approved for listing in April last year, this year's sales are expected to exceed $1 billion).
  • GLP-1 and its peptide analogs there have been no reports of successful development of non-peptide small molecule GLP-1R agonists. Due to the inconvenient oral administration of peptide drugs, the search for non-peptide GLP-1R regulators and the development of new anti-diabetic drugs with independent intellectual property rights are the common concerns of many new drug research institutions.
  • a still further object of the invention is to provide a pharmaceutical composition comprising a compound represented by the following formula I or ⁇ ;
  • a further object of the present invention is to provide a compound represented by the following formula I or ⁇ as a glucagon-like peptide- 1 Receptor modulators for medical use in the prevention and/or treatment of metabolic disorders, including but not limited to diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease.
  • the present invention provides a glucagon-like peptide-1 receptor modulator, which increases the prevention and/or treatment of metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases ( Members of drugs such as Alzheimer's disease.
  • the present invention relates to a compound represented by the following formula I or II, or a pharmaceutically acceptable salt thereof: And all of its stereo and optical isomers, or prodrugs having the same pharmacological effects, esters thereof, solvates thereof or metal complexes thereof.
  • X and Y are respectively (CH Stud, n is 0-2; 0; S or NH.
  • R 2 is each independently a substituent of any of the following: hydrogen; halogen; alkane; cycloalkyl hydrocarbon; hydroxyl group; nitro group; carboxyl group; aldehyde group; alkoxy group; amine group; amine group; amide group; Amido; thiol; sulfhydryl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted thienyl; substituted or unsubstituted pyrrolyl;
  • R 3 , ! ⁇ independently of any of the following substituents: hydrogen; anthracene; cycloalkane; alkoxy; amine; amine alkyl; amide; carboxamide; thiol; substituted or unsubstituted aryl; Substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • the compounds of the above formulae I and II are characterized in that: X, Y are respectively (CH 2 ) n, n is 0-2; 0; S or NH, Rmony R 2 are each independently:
  • R 5 is any of the following substituents: H; - fluorenyl; - any one, two or three substituted C-containing groups including a halogen atom, a decyloxy group of d-C 6 or a hydroxyl group, - a fluorenyl group of C 6 ; a C 2 - (: 6 alkenyl group; any one, two or three substituted C 2 -C 6 alkenyl groups including a halogen atom, an alkoxy group of d- or a hydroxyl group C 2 - (: 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group including a halogen atom, C "C 6 decyloxy group or hydroxyl group”; C 3 - a C 6 cycloalkyl group; any one, two or three substituted (: 3 - C 6 cycloalkyl) groups containing a halogen atom, C, -C
  • R 6 is any one of the following substituents: H; a fluorenyl group of d-C e ; containing any one, two or three including a halogen atom, an alkoxy group or a hydroxyl group of (:, - (: 6 ) Substituted (VC 6 alkyl; C 2 - (: 6 alkenyl; containing any one, two or three substituted (including a halogen atom, C, -C 6 decyloxy or hydroxy group): 2 -(: 6 alkenyl; (: 2 -( 6 alkynyl; containing any one, two or three substituted ⁇ -C 6 including a halogen atom, (alkoxy group of Ce or a hydroxyl group) alkynyl; C 3 -C 6 cycloalkyl group embankment; contain any halogen atoms include, d-Ce alkoxy or hydroxy the embankment, including one
  • R 7 and R s are each independently a substituent of any of the following: H; ( ⁇ -(: 6 fluorenyl; any one, two or three containing a halogen atom, an alkoxy group of CG or a hydroxyl group) Substituted ( ⁇ -(: 6 fluorenyl; (: 2 -(: 6 alkenyl; any one, two or three substituted C containing a halogen atom, a fluorenyloxy group or a hydroxy group) 2 -alkenyl; C 2 -C 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group containing a halogen atom, a decyloxy group or a hydroxyl group of d-Ce ; C 3 -C 6 cycloalkyl group embankment; includes any halogen atom-containing, dC e the embankment or a hydroxyl group, including one, two or three
  • R 9 is any one of the following substituents: H; (:, -(: 6 fluorenyl; any one, two or three substitutions including a halogen atom, d-(alkoxy group or hydroxy group) a fluorenyl group of d-Cs; (: 2 -( 6 alkenyl; any one, two or three substituted C 2 - C 6 containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group) Alkenyl; C 2 -C 6 alkynyl; any one, two or three substituted C 2 -C fi alkynyl group containing a halogen atom, C,-C 6 decyloxy or hydroxy group; a C 3 -C fi cyclodecyl group; any one, two or three substituted C 3 -C 6 cyclodecyl groups containing a halogen atom, a C,
  • Ru each independently is any one of the following substituents: H; Ct- (: 6 alkyl; any one, two or three substituted d including a halogen atom, d- alkoxy group or a hydroxyl group - fluorenyl; (: 2 - (: 6 alkenyl; any one, two or three substituted C 2 - containing: a halogen atom, C, -C e methoxy or hydroxy group (: 6 alkenyl; ( 2- ( 6 alkynyl; any one, two or three substituted C 2 - ( ⁇ alkynyl group) including a halogen atom, a decyloxy group of CrC 6 or a hydroxyl group; C a cycloalkyl group of 3 -C e ; any one, two or three substituted C:,-C 6 cyclodecyl groups including a halogen atom, a C, or a C
  • R 13 are each independently a substituent of any of the following: H; C "indenyl group of C 6 ; any one or two of a fluorenyl group or a hydroxy group including a halogen atom, C, -C fi or Three substituted (:, -(: 6 alkyl); alkenyl; any one, two or three substituted ( 2 -(:) containing a halogen atom, a decyloxy group or a hydroxyl group of d-: 6 alkenyl; C 2 - (: 6 alkynyl group; a halogen atom includes contain any, or a hydroxyl group dC embankment 6 of the inner one, two or three substituents of C 2 - (alkynyl; C a cycloalkyl group; any one, two or three substituted C 3 -C 6 cycloalkyl groups including a halogen atom, a dec
  • R 6 is any one of the following substituents: H; (: 6 fluorenyl; or any one, two or three substituted dC 6 including a halogen atom, ( 6 alkoxy group or hydroxyl group) Alkyl; (: 2 -(: 6 alkenyl; any one, two or three substituted (including 2 -( 6 alkenyl; C) containing a halogen atom, a fluorenyloxy group or a hydroxy group 2 - (: 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl groups containing a halogen atom, a C, a C 6 decyloxy group or a hydroxyl group; C 3 - a cyclic fluorenyl group of C 6 ; a C 2 -C B cyclodecyl group containing a halogen atom, a decyloxy group or a hydroxyl group of a Ct-C
  • R 7 and R 8 are each independently a substituent of any of the following: H; C "indenyl group of C e ; any one or two of a decyloxy group or a hydroxyl group including a halogen atom, C, -C 6 Or a three-substituted alkyl group; a C 2 - (: 6 alkenyl group; any one, two or three substituted groups including a halogen atom, an alkoxy group of d- or a hydroxyl group ( 2- ( 6 ) alkenyl group; (: 2 - (: 6 alkynyl group; a halogen atom include containing, C, - one, two or three of any alkoxy or hydroxy-substituted C 6 of the inner (: 2 - (: 6 Alkynyl; C 3 -C e cycloalkyl; any one, two or three substituted C 3 -C 6 cyclodecyl groups containing a
  • R 9 is any one of the following substituents: H; C, -C 6 fluorenyl; any one, two or three substituted d including a halogen atom, ( 6 decyloxy or hydroxy group) - an alkyl group of c 6 ; an alkenyl group of c 2 -c 6 ; any one, two or three substituted C 2 - (: 6 ) including a halogen atom, an alkoxy group of d-Ce or a hydroxyl group Alkenyl; C 2 -alkynyl; any one, two or three substituted c 2 -c 6 alkynyl group containing a halogen atom, c,-c 6 alkoxy group or hydroxyl group; C 3 a cycloalkyl group of _C 6 ; a mono-, two- or three-substituted c 3 -c 6 cyclodecyl group containing a halogen atom, a de
  • R 3 and R 4 are:
  • R,. , Ru each independently is any one of the following substituents: H; a fluorenyl group of d-C 6 ; any one, two or three substituted groups including a halogen atom, a C _C 6 methoxy group or a hydroxyl group
  • Three substituted c 2 - (: 6 alkynyl; c 3 - c 6 cycloalkyl; any one, two or three containing an alkoxy group including a halogen atom, c, -c 6 or a
  • a thiophenyl group containing a halogen atom, a C "C 4 alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a thiol group, a methylthio group, an ethylthio group, etc.
  • R 2 is each independently:
  • R 14 is any one of the following substituents: H; (: "(: 6 alkyl; containing any one, two or three including a halogen atom, (": 6 alkoxy or hydroxy group Substituted ( ⁇ -(: 6 fluorenyl; (: 2 - (: 6 alkenyl; containing any one, two including a halogen atom, (:, - (: 6 alkoxy or hydroxy) Or three substituted (: 2 -(: 6 alkenyl; C 2 - ⁇ alkynyl; any one, two or three substituted C 2 containing a halogen atom, an alkoxy group or a hydroxyl group) -C 6 alkynyl; C 3 -C 6 cycloalkyl; any one, two or three substituted ( 3 - C 6 ring) containing a halogen atom, d-alkoxy or hydroxy group Alkyl; aryl; benzyl; furyl; pyranyl
  • Substituted pyridyl containing a halogen atom, d-(alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Arbitrarily One, two or three substituted furanyl groups; containing a halogen atom, an alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group Any one, two or three substituted pyranyl groups including an ethylthio group; containing a halogen atom, ( ⁇ -(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group) Any one, two or three substituted thienyl
  • R 6 is any one of the following substituents: H; C, - (: 6 fluorenyl; any one, two or three substituted including a halogen atom, a decyloxy group or a hydroxyl group of d- embankment group; C 2 -C 6 alkenyl group; a halogen atom include containing, C, - any C 6 alkoxy or hydroxy embankment inner one, two or three substituents of C 2 - C 6 alkenyl group; C 2 - (: 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group including a halogen atom, a decyloxy group or a hydroxyl group; a C 3 - C e ring a fluorenyl group containing any one, two or three substituted c 3 -c e including a halogen atom, a decyloxy group or a hydroxyl group of a Ct
  • One, two or three substituted pyranyl groups containing a halogen group including a halogen atom, c, - ⁇ , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, Any one, two or three substituted thienyl groups including a methylthio group, an ethylthio group; an alkyl group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group Base, amide group, carboxamide group, sulfhydryl group, methylthio group, ethylthio group Any one, two or three substituents pyrrolyl; - (alkanoyl; containing optionally include a halogen atom, a hydroxy
  • R 3 and R 4 are:
  • R 7 and R are each independently a substituent of any of the following: H; d-alkyl; any one, two or three substituted groups including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group.
  • R 3 and R 4 are:
  • R 9 is any one of the following substituents: H; an fluorenyl group; any one, two or three substituted groups including a halogen atom, a -C methoxy group or a hydroxyl group (;-(: 6 ⁇ ) Any one, two or three substituted C 2 - (: 6 alkenyl; C 2 -C alkynyl group containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; Any one, two or three substituted C 2 -C 6 alkynyl groups including a halogen atom, an alkoxy group of C Ce or a hydroxyl group; a C 3 -C 6 cycloalkyl group; containing a halogen atom Any one, two or three substituted C 3 -C 6 cycloalkyl groups of d- alkoxy or hydroxy; aryl; benzyl; furyl; pyranyl; thienyl; a
  • halogen atom Containing any one including a halogen atom, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, ethylthio group) , two or three substituted pyranyl groups; containing a halogen atom, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, fluorenyl group, A Any one, two or three substituted thienyl groups including a thio group or an ethylthio group; containing an alkyl group including a halogen atom, d-c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, Amid
  • a decanoyl group of C, -C 6 an alkanoyl group of any one, two or three substituted dcs including a halogen atom, an alkoxy group of CrCe or a hydroxyl group; an alkenoyl group of c 2 -c 6 ; a halogen atom, d- (: any embankment 6 alkoxy or hydroxy, including one, two or three substituents of c 2 -c 6 alkenyl group; a c 2 -c 6 alkynyl group; a halogen atom-containing include, Any one, two or three substituted c 2 -c 6 alkynyl groups of c, - ⁇ alkoxy or hydroxy; c 3 -c 6 cycloalkanoyl; containing an alkane including a halogen atom, C Any one, two or three substituted C 3 - (; 6 cyclodecanoyl; adamantyl, substituted
  • R 15 , R ie are each independently a substituent of any of the following: H; an fluorenyl group; any one, two or three substituted Cs including a halogen atom, a decyloxy group or a hydroxyl group of d-, An alkyl group of C 6 ; a C 2 -C 6 alkenyl group; any one, two or three substituted C 2 - ( 6 alkenyl groups) containing a halogen atom, an alkoxy group of CrCe or a hydroxyl group; a C 2 -C 6 alkynyl group; any one, two or three substituted groups including a halogen atom, C "C 6 alkoxy group or a hydroxyl group (: 2 - (: 6 alkynyl group; C 3) a cycloalkyl group of C fi ; a C 2 -C 6 cyclodecyl group containing a halogen
  • a fluorenyl group including a halogen atom, C-C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, a Any one, two or three substituted furanyl groups including a thio group; a fluorenyl group including a halogen atom, C-C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carbon group amide groups, mercapto, methylthio, ethylthio, including one, two or three of the substituents pyranyl; containing a halogen atom include, _ (4 embankment group, a nitro group, a carboxyl group, an aldehyde group,
  • R6 is any of the following substituent groups: H; d- (group 6 of the embankment; includes any containing a halogen atom, C "C 6 alkoxy or hydroxy embankment inner one, two or three substituents of C, - (: 6 alkyl; C 2 - C fi alkenyl group; or a hydroxyl group optionally having embankment include a halogen atom, the inner one, two or three substituents of C 2 - C fi alkenyl; C a 2- C6 alkynyl group; any one, two or three substituted c 2 -c 6 alkynyl groups including a halogen atom, a decyloxy group or a hydroxyl group; a C 3 -C e cyclodecyl group; Any one, two or three substituted ( 3 -(: 6 cyclodecyl; aryl; benzyl; furyl; pyranyl; thiophene) containing
  • a halogen atom (:, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, ethylthio group, etc.) Any one, two or three substituted pyranyl groups; containing an alkyl group including a halogen atom, C, -C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group Any one, two or three substituted thienyl groups including a mercapto group, a methylthio group, an ethylthio group; a mercapto group including a halogen atom, dC 4 , a nitro group, a carboxyl group, an aldehyde group, an alkyl group,
  • R 7 and R 8 are each independently a substituent of any of the following: H; a fluorenyl group of d-Ce; any one, two or three substituents including a halogen atom, a hydroxyl group of CC e or a hydroxyl group; a d-C 6 fluorenyl group; a C 2 -C 6 alkenyl group; any one, two or three substituted (including 2 -(:) containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; 6 alkenyl; C 2 -C 6 alkynyl group; a halogen atom-containing optionally include, d- or hydroxyl group of the embankment, including one, two or three substituents of C 2 -C 6 alkynyl group; a C a 3- C 6 cycloalkyl group; a C 2 -C fi cyclodecyl group containing an alk
  • R 9 is any one of the following substituents: H; C, -C fi fluorenyl; any one, two or three substituted C's including a halogen atom, a -oxy group or a hydroxyl group C 6 fluorenyl; C 2 -alkenyl; containing any one, two or three substituted C 2 - (: 6 olefins including a halogen atom, (": 6 decyloxy or hydroxy group a C 2 -C 6 alkynyl group; any one, two or three substituted C 2 -C e alkynyl groups including a halogen atom, an alkoxy group of d- or a hydroxyl group; C 3 -C embankment 6 cycloalkyl group; a halogen atom-containing optionally include, d- alkoxy or hydroxy group including one, two or three substituents of (: 3 - C 6 cycloalkyl; aryl; benzy
  • R 3 , ⁇ are - K x i Ri respectively .
  • R in, Ru are each independently any of the following substituent groups: H; C, - alkyl; containing optionally include halogen atoms, C "C 6 alkoxy or hydroxy, including one, two or three Substituted d-alkyl; C 2 -( ⁇ alkenyl; any one, two or three substituted C 2 - C s containing a halogen atom, a decyloxy group or a hydroxyl group of d- Alkenyl; C 2 -C 6 alkynyl group; a halogen atom include containing, C, - ⁇ alkoxy or hydroxy embankment any inner one, two or three substituents of c 2 - C 6 alkynyl group; a C a cycloalkyl group of 3 - C 6 ; any one, two or three substituted c 3 -c 6 cycloalkyl groups including a halogen atom, an alkoxy group of C- or a
  • the compound or a pharmaceutically acceptable salt thereof is provided in the form of a pharmaceutical composition, either alone or in combination with a pharmaceutically acceptable carrier or excipient.
  • the invention also provides a medicament comprising the above compound for preventing and/or treating metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases (eg Alzheimer's) Ill).
  • the invention relates to methods of preventing and/or treating metabolic disorders, including but not limited to diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease.
  • the method comprises administering to a subject in need or willing to receive treatment or prevention an effective amount of a compound which selectively modulates the glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof for preventing or treating the above Disease or symptom.
  • the above metabolic disorders including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases (such as Alzheimer's disease), etc., by administering an effective amount of the following Formula I or a compound represented by II or a pharmaceutically acceptable salt thereof for prevention or treatment:
  • X and Y are respectively (CH, n is 0-2; 0; S or .NH.
  • R, R 2 are each independently one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxyl; aldehyde; alkoxy; amine; amidoxime; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • R 3 , R 4 are each independently any one of the following substituents: hydrogen; anthracene; cyclononene; anthracene; amine; amidoxime; amide; carboxamide; alkylthio; Substituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • the present invention relates to a combination preparation comprising a compound having a selective modulation of a glucagon-like peptide-1 receptor, particularly a function of activating the receptor, or a pharmaceutically acceptable salt thereof Or alone or in combination with a pharmaceutically acceptable carrier or excipient.
  • This compound has the structure of the following formula I or II:
  • X and Y are respectively (CH, n is 0-2; 0; S or NH.
  • R 2 is each independently any one of the following substituents: hydrogen; halogen; anthracene; a cyclic hydrocarbon; a hydroxyl group; a nitro group; a carboxyl group; an aldehyde group; an anthracene group; an amine group; an amine group; an amide group; Carboxamide; fluorenyl; sulfhydryl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • R 3 each independently of any of the following substituents: hydrogen; anthracene; cyclononene; alkoxy; amine; alkane Amide; carboxamide; alkylthio; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted a thienyl group; a substituted or unsubstituted pyrrolyl group.
  • the present invention provides a kit comprising the above combined preparation.
  • the present invention further provides the use of the above combined preparations for the prevention and/or treatment of metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases (eg Alzheimer's). Disease, etc., to achieve selective stimulation of the glucagon-like peptide-1 receptor, improve the patient's symptoms and quality of life.
  • metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases (eg Alzheimer's). Disease, etc., to achieve selective stimulation of the glucagon-like peptide-1 receptor, improve the patient's symptoms and quality of life.
  • metabolic disorder refers to a related symptom and/or disease caused by metabolic disorders such as sugar, fat or protein caused by various causes.
  • diabetes refers to a multi-pathogenic metabolic disease characterized by chronic hyperglycemia accompanied by disorders of sugar, fat and protein metabolism caused by insulin secretion and/or dysfunction.
  • the metabolic disorders in the body are not well controlled, leading to chronic complications of tissues such as the eyes, kidneys, nerves, blood vessels and heart, resulting in blindness, gangrene in the lower limbs, Uremic, stroke or myocardial infarction, even life-threatening.
  • insulin resistance refers to a decrease in the sensitivity of tissues surrounding the body to insulin, and target tissues such as muscles and fats are resistant to insulin-induced glucose uptake. Insulin resistance is prevalent in type 2 diabetes, accounting for more than 90%, and is one of the main factors in the development of type 2 diabetes.
  • obesity refers to an excess of body fat, a male weighing more than 25% of the ideal body weight, or a woman weighing more than 30% of the ideal body weight. Genetic factors, hypothalamic disease, endocrine disorders, overeating and too little activity are all causes of obesity.
  • Alzheimer's disease As used herein, Alzheimer's disease (Alzheimer's disease, also known as Alzheimer's dementia) is a progressive degenerative disease of the nervous system, clinically characterized by chronic impairment of intelligence and memory. Chronic loss.
  • cardiovascular disease includes heart disease, pulmonary heart disease, hypertension, and hyperlipidemia. It has the characteristics of "high incidence, high mortality, high disability rate, high recurrence rate” and “more complications”.
  • an "effective amount" of a compound used to treat a particular disease means sufficient improvement or to some extent Reduce the amount of symptoms associated with this disease.
  • This dose can be administered in a single dose or in accordance with a therapeutic regimen. This dose cures the disease, but is typically administered to improve the condition. Repeated administration to improve symptoms may be desirable.
  • pharmaceutically acceptable salts, esters or other derivatives include any salt, ester or derivative which is readily prepared by one skilled in the art using known methods.
  • the compounds thus derived and produced can be administered to animals and humans without toxic effects.
  • the compound is either pharmaceutically active or a prodrug.
  • treatment means that the disease and symptoms are improved in any way, or other beneficial changes. Treatment also includes the use of the compounds of the invention in medicine.
  • administration of a particular pharmaceutical composition to "improve" the symptoms of a particular disease means any reduction, whether permanent, temporary, prolonged, transient, can be attributed to or associated with the pharmaceutical composition. Relevant application.
  • substantially pure means sufficiently uniform that no impurities can be detected by standard analytical methods used by those skilled in the art to evaluate purity, such as thin layer chromatography (TLC), gel electrophoresis, and High performance liquid chromatography (HPLC). Or sufficiently pure also means that even further purification does not alter the physicochemical properties detectable by the substance, such as enzymatic activity and biological activity.
  • Methods for producing substantially chemically pure compounds for purification are well known to those skilled in the art. However, a substantially chemically pure compound can be a stereoisomer or a mixture of isomers. In this case, further purification may increase the specific activity of the compound.
  • prodrug refers to a compound that is administered in vivo and which can be metabolized or converted into a biologically, pharmaceutically or therapeutically active form.
  • the pharmaceutically active compound will be modified to reproduce the active compound by metabolic processes.
  • Prodrugs can be designed to alter their metabolic stability, or to transport precursors of properties, to mask their side effects or toxicity, to improve the taste of the drug, or to alter other properties.
  • substantially are the same or are either hooked or similar, and the understanding of the relevant art may vary in the context, and is generally at least 70%, preferably at least 80%, more preferably at least 90%, The optimal is at least 95% identical.
  • composition refers to any mixture. It may be a solution, suspension, liquid, powder, ointment, aqueous, non-aqueous or any combination thereof.
  • object as used herein includes humans and animals, for example, dogs, cats, cows, pigs, rodents, and the like.
  • metabolic disorders including but not limited to diabetes, insulin resistance and obesity
  • cardiovascular disease including but not limited to diabetes, insulin resistance and obesity
  • neurodegenerative diseases such as Alzheimer's disease
  • the present invention provides a modulator of glucagon-like peptide-1 receptor function, which increases the prevention and/or treatment of metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases.
  • metabolic disorders including but not limited to diabetes, insulin resistance and obesity
  • cardiovascular diseases including but not limited to diabetes, insulin resistance and obesity
  • neurodegenerative diseases including neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders (such aspirin, diabetes, diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases.
  • Sexual diseases such as
  • the present invention relates to a compound represented by the following formula I or II, or a pharmaceutically acceptable salt thereof:
  • X and Y are respectively (CH, n is 0-2; 0; S or NH.
  • R t , R 2 are each independently any one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxy; aldehyde; methoxy; amine; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • R 3 , R 4 are each independently any one of the following substituents: hydrogen; anthracene hydrocarbon; a cyclic anthracene: anthracenyloxy; an amine group; an amine group; an amide group; a carboxamide group; a thiol group; Substituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • the compound of the present invention may be a specific stereoisomer, such as the R- or S-configuration, or a mixture thereof, for example, a racemic mixture.
  • the compounds contemplated herein include all classes of pharmaceutically active compounds, or solutions or mixtures thereof. Also included are hydration types thereof, such as aqueous solutions, hydrolysates or ionized products of these compounds; and these compounds may contain different amounts of bound water molecules.
  • the compounds of the invention may be prepared or synthesized according to any suitable method.
  • the compound is prepared by the synthetic method cited in Section F below.
  • the compound or a pharmaceutically acceptable salt thereof is provided in the form of a pharmaceutical composition, either alone or in combination with a pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention may be prepared in the form of their pharmaceutically acceptable salts with any suitable acid.
  • suitable acid for example, inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.; organic acids such as formic acid, acetic acid, propionic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, etc.; Sulfonic acid such as methanesulfonic acid, ethylsulfonic acid, etc.; arylsulfonate An acid such as benzenesulfonic acid or p-toluenesulfonic acid can be used.
  • the present invention relates to methods for preventing and/or treating metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease.
  • the method comprises administering to a subject in need or willingness to receive treatment or prevention an effective amount of a compound that selectively agonizes the glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof for treating or preventing the above-mentioned diseases. Or symptoms.
  • the above disease is treated or prevented by administering an effective amount of a compound represented by the following formula I or II or a pharmaceutically acceptable salt thereof:
  • X and Y are respectively (CH 2 ) march, n is 0-2; 0; S or NH.
  • R, R 2 are each independently one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxy; aldehyde; alkoxy; amine; amidoxime; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • R 3 each independently of any of the following substituents: hydrogen; alkane; cycloalkylene; alkoxy; amine; amine alkyl; amide; carboxamide; thiol; substituted or unsubstituted aryl Substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • Any subject can be controlled by this method, preferably a mammal, more preferably a human.
  • the method can be used to control metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases (such as Alzheimer's disease).
  • a preferred disease or condition is any disease or condition caused or accompanied by insulin secretion and/or dysfunction.
  • the invention may be used alone or in combination with other diabetes therapeutics, including insulin sensitizers that are already on the market or to be marketed. compound of.
  • Any suitable metabolic disorder (including but not limited to diabetes, insulin resistance, and obesity) therapeutic agents can be used in combination with the compounds of the present invention.
  • typical insulin sensitizers include rosiglitazone and pioglitazone.
  • the above insulin sensitizer is not administered when the compound of the invention is used. More preferred The compound of the present invention is used to treat or prevent a disease or symptom caused by the use of the above-mentioned diabetes treatment drugs (including insulin sensitizers) which have been marketed or will be marketed to cause drug resistance or side effects.
  • diabetes treatment drugs including insulin sensitizers
  • Administration of the compounds of the invention alone or in combination with other suitable diabetes therapeutics including insulin sensitizers can be by any suitable method.
  • it can be administered by intracavitary injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, orally or topically, with a compound of the present invention, or with a pharmaceutically acceptable salt thereof.
  • the method further comprises performing a diagnosis and prognosis assessment of the disease or condition of the subject to whom it is administered.
  • Any suitable method can be used to diagnose and assess the associated disease or condition and its prognosis.
  • Diagnosis and prognosis can be based on detecting and/or identifying any or all of the in vivo material, such as glycated hemoglobin, enzymes, antigens, antibodies, nucleic acids or other pathological and clinical markers, and related symptoms.
  • a diagnostic or prognostic method disclosed in International Patent No. WO 01/44815 and U.S. Patent No. 5,571,674 can be used.
  • the invention also relates to a combination formulation comprising a compound that selectively modulates glucagon-like peptide-1 receptor function, or a pharmaceutically acceptable salt thereof, and one or more Therapeutic drugs for metabolic disorders include insulin sensitizers.
  • such a combination comprises a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutic agent for one or more metabolic disorders including an insulin sensitizer, which is represented by the following formula I or ⁇ :
  • X and Y are each (CH 2 ) n and n is 0-2; 0; S or NH.
  • RR 2 is each independently one of the following substituents: hydrogen; halogen; anthracene; cycloalkyl; hydroxy; nitro; carboxy; aldehyde; alkoxy; amine; amine alkyl; Amido; thiol; sulfhydryl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted thienyl; substituted or unsubstituted pyrrolyl.
  • R 3 , R 4 are each independently any of the following substituents: hydrogen; anthracene; cyclononene; anthracene; amine; amine sulfhydryl; amide; carbonamide; thiol; Substituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
  • Any suitable therapeutic agent for diabetes can be used in the combination formulations of the invention.
  • one or more of the above-described diabetes therapeutic agents including insulin sensitizers may be included in the combined preparation of the present invention.
  • a method of treating or preventing a disease or condition caused or accompanied by insulin secretion and/or dysfunction comprising administering an effective amount to a subject in need and willing to receive treatment or prevention The above combined preparation, or a pharmaceutically acceptable salt thereof, thereby treating or preventing the above diseases or symptoms.
  • kits comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and the use of the above compound or a pharmaceutically acceptable salt thereof for controlling secretion and/or secretion by insulin Instructions for the use of a disease or condition caused by or associated with a dysfunction.
  • kits comprising the combination described above and instructions for using the combination to treat or prevent a disease or condition caused or accompanied by insulin secretion and/or dysfunction.
  • the compounds of the invention are formulated for any suitable route of administration, for example, intraluminal, subcutaneous, intravenous, intramuscular, intradermal Injection, oral or topical.
  • the method can be administered by injection in a single dose in an ampoule, or in a multi-dose container with an added buffer.
  • the formulations may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles.
  • the formulations may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in a powder form with a suitable vehicle, sterile non-pyrogenic water or other solvent before use.
  • the topical medicament of the present invention may be a foam, a gel, an ointment, an ointment, a transdermal patch, or a paste.
  • compositions and methods for administration that may be used in the present invention include, but are not limited to, U.S. Patents 5,736,154, 6,197, 801 Bl, 5,741,511, 5, 886, 039 5, 941, 868, 6, 258, 374B1 and 5, 686, 102.
  • the size of the dose to be treated or prevented will vary depending on the severity of the condition and the route of administration.
  • the dose and frequency of administration will vary with age, weight, health status, and individual patient response.
  • Dosage forms include tablets, lozenges, lenticular capsules, dispersing agents, suspending agents, solutions, capsules, films and the like.
  • the compound of the present invention may be in accordance with a general pharmaceutical mixing technique with a pharmaceutical carrier or excipient such as ⁇ -cyclodextrin and 2-hydroxypropyl- ⁇ -cyclodextrin. Finely mixed.
  • a pharmaceutical carrier or excipient such as ⁇ -cyclodextrin and 2-hydroxypropyl- ⁇ -cyclodextrin. Finely mixed.
  • a special carrier a local or parenteral route, may be employed.
  • parenteral dosage forms such as compositions for intravenous injection or infusion
  • similar pharmaceutical vehicles can be employed, water, glycols, oils, buffers, sugars, preservatives, liposomes, etc., which are well known to those skilled in the art. .
  • parenteral compositions examples include, but are not limited to, 5% W/V Dextrose, saline or other solution.
  • the total dose of the compound of the present invention, alone or in combination with other preparations, can be administered in vial vials in a volume of from about 1 ml to about 2000 ml. The amount of diluent will vary depending on the total dose administered.
  • the invention also provides a kit for achieving a therapeutic regimen.
  • the kit comprises an effective amount of a compound of the invention in a pharmaceutically acceptable form, alone or in combination with other agents, in one or more containers.
  • the preferred pharmaceutical form is in combination with sterile saline, dextrose solution, buffer solution, or other pharmaceutically acceptable sterile liquid.
  • the composition may be lyophilized or dried; in this case, the kit optionally further comprises a pharmaceutically acceptable solution, preferably a sterile solution, in a container to reconstitute the complex A solution for injection purposes is formed.
  • Typical pharmaceutically acceptable solutions are physiological saline and dextrose solutions.
  • the kit of the present invention further comprises a needle or syringe and/or a packaged alcohol pad for injection of the composition, preferably in a sterile form. Instructions for use by a doctor or patient may optionally be included.
  • the raw materials (0601 - 0610) used in the present invention were synthesized in accordance with the synthesis method described in the Chinese patent (Application No.: 200310109331. 0).
  • the invention is implemented by the following steps:
  • HP1100 HPLC system with binary gradient pump, online vacuum degasser, autosampler, column oven and photodiode array detector.
  • the column is ZORBAX SB-C18 (2.11 x 150 mm, 3. 5 ⁇ )
  • the mobile phase is acetonitrile/water 65: 35
  • the flow rate is 0. 2 ml/min
  • the detection wavelength is 254.
  • the melting point is IA6304 type melting point.
  • NMR was measured by Varian Mercury-300 and Varian Mercury Plus 400 NMR (solvent: CDCl :i , CD 3 0D or DMSO-de);
  • ESI-MS was measured by AB Mariner mass spectrometer, EI by Measured by a Finnigan MAT95 mass spectrometer.
  • the materials used in the synthesis are commercially available products unless otherwise specified. The following specific examples are intended to further illustrate the invention but are not intended to limit the invention.
  • Example 13 Preparation of compound GLP-D-3 NMR calibration: ⁇ H 2. 50 ppm (DMSO-d 6 ).
  • Example 15 Preparation of compound GLP-D-5 NMR calibration: ⁇ H 2. 50 ppm (DMS0-d e ).
  • Example 17 Preparation of compound GLP-D-7 NMR calibration: ⁇ H 2. 50 ppm (DMSO-d 6 ).
  • Example 20 Preparation of compound GLP-D-10 NMR calibration: ⁇ H 2. 50 ppm (DMSO-d 6 ).
  • Example 24 Preparation of compound GLP-D-14 NMR calibration: ⁇ H 2. 50 ppra (DMS0-d 6 ).
  • Example 26 Preparation of Compound GLP-D- R 16 bandit calibration: ⁇ H 2. 50 ppm (DMSO- d 6).
  • GLP-1R is a G protein-coupled receptor.
  • GLP-1R binds to an agonist, the G a subunit of the G protein is activated to stimulate adenylate cyclase, resulting in an increase in intracellular cAMP levels. Since the cAMP response element exists in the promoter region of the proinsulin gene, cAMP binds to the response element to initiate transcription of the pre-insulin gene, thereby stimulating insulin expression and secretion (Diabetes, 2000, Vol. 49: 1156-1164).
  • HEK 293 human embryonic kidney cell strain stably transfected with a GLP-1R receptor gene expression vector and a luciferase reporter gene expression vector regulated by a cAMP response element was used to detect its response to a test compound (Cell). Biology, 1992, Vol. 89: 8641-8645; Proc. Natl. Acad. Sci. USA 1987, Vol. 84: 3434-3438). A sample that induces expression of a luciferase reporter gene when screened for a compound is considered to have GLP-1R agonistic activity.
  • DMEM medium (GIBC0 company)
  • Forma Carbon Dioxide Incubator Forma
  • Victor 2 plate reader Wood 2 plate reader
  • Test compound GLP-A-1, GLP-B-3, GLP-B-6, GLP-B-7
  • HEK293/GLP1R+Luc cells were inserted into 96-well culture plates at 20,000/100 ⁇ /well, and cultured overnight at 37 ° C in DMEM medium containing 10% fetal calf serum and 500 ⁇ ⁇ / ⁇ 1 G418.
  • the GLP-1 standard and the test compounds GLP-A-1, GLP-B-3, GLP-B-6, and GLP-B-7 were each diluted to a certain concentration gradient, and then added to the above 96 wells at 1 ⁇ M/well. In microplates. Incubate for 6 hours at 37° (:, 5% CO 2 ). Luciferase activity was measured by the Steady-G1 0 TM Luciferase Assay System Kit, and the Victor 2 reader was used for reading.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Substituted cyclobutane compounds represented by formula I or II. The preparation method of these compounds and uses thereof as glucagons like peptide-1 receptor(GLP-1R) regulators for preventing and/or treatment of metabolic disorders, which include but not limit to diabetes, insulin-resistance and obesity etc., cardiovascular diseases and neurodegenerative diseases such as Alzheimer's diseases etc..

Description

一类具有取代环丁烷结构的化合物、 及其制备方法和医学用途 技术领域  Compound with substituted cyclobutane structure, preparation method thereof and medical use thereof
本发明涉及一类具有取代环丁垸结构的化合物、 制备方法以及其作为胰高血糖样肽一 The present invention relates to a compound having a substituted cyclobutane structure, a preparation method thereof, and a glucagon-like peptide
1受体 (Glucagon like peptide- 1 receptor, GLP-1R) 调节剂在预防和 /或治疗代谢紊乱 性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症等)、 心血管疾病、 神经退行性疾 病 (如 Alzheimer' s病) 等的医学用途。 Glucagon like peptide-1 receptor (GLP-1R) modulators prevent and/or treat metabolic disorders (including but not limited to diabetes, insulin resistance and obesity, etc.), cardiovascular disease, neurodegenerative Medical use of diseases such as Alzheimer's disease.
背景技术  Background technique
糖代谢紊乱, 特别是糖尿病, 已成为现代社会严重威胁人类健康与生命的主要疾病。 据预测, 全世界糖尿病患者正以每年 6%的速度递增, 到 2006年末已有 3. 2亿患者(我国 为' 6000万人, 占居第二位)。 糖尿病是一组由遗传和环境因素相互作用而引起的临床综合 症, 主要分为 1型和 2型, 其中 1型糖尿病的基本病理生理为绝对性胰岛素分泌不足, 临 床治疗以补充胰岛素为主, 故又称为胰岛素依赖型糖尿病。 2 型糖尿病占患病群体的 95% 以上, 临床研究发现绝大多数 2型糖尿病患者可合成正常甚至过量的胰岛素, 但因靶细胞 对胰岛素的敏感性降低 (也称 "胰岛素抵抗" ), 导致胰岛素相对不足, 又称为非胰岛素 依赖型糖尿病。 胰岛素抵抗是 2型糖尿病发生和发展过程中的关键因素。 2型糖尿病的治 疗药物包括磺脲类、 双胍类、 其他胰岛素增敏剂及辅助措施等。 磺脲类降糖药物与胰腺 β 细胞膜的受体结合后, 关闭钾离子通道, 阻断钾离子外流, 导致细胞膜去极化, 促使 Ca2+ 通道幵放, 造成胞外钙离子内流, 胞内钙离子浓度增加后, 触发胰岛素的释放。 按其问世 先后分为两代, 第一代如甲苯磺丙脲, 第二代包括格列本脲 (优降糖)、 格列齐特 (达美 康), 格列吡嗪 (美吡哒) 和格列喹酮 (糖适平) 等。 双胍类降糖药物能抑制食欲, 增加 胰岛素与受体的结合, 促进细胞对葡萄糖的无氧酵解, 抑制组织呼吸, 抑制肝糖元异生。 主要有二甲双胍、 苯乙双胍和丁双胍等。 其他降糖药主要包括噻唑烷二酮类 (Thiazolidinediones ) 药物 (例如曲格列酮、 罗格列酮、 吡格列酮等)、 P 3-肾上腺素 受体调节剂、 胰高血糖素受体拮抗剂、 脂肪酸代谢干扰药、 α -糖苷酶抑制药 (例如阿卡 波糖、 伏格列波糖、 米格列醇等) 以及醛糖还原酶抑制剂等。 Disorders of glucose metabolism, especially diabetes, have become a major threat to human health and life in modern society. It is predicted that diabetes patients worldwide are increasing at a rate of 6% per year. By the end of 2006, there were 320 million patients (China's '60 million people, ranking second). Diabetes is a group of clinical syndromes caused by the interaction of genetic and environmental factors. It is mainly divided into type 1 and type 2. The basic pathophysiology of type 1 diabetes is absolute insulin secretion, and clinical treatment is mainly supplemented with insulin. It is also known as insulin-dependent diabetes. Type 2 diabetes accounts for more than 95% of the diseased population. Clinical studies have found that most patients with type 2 diabetes can synthesize normal or even excess insulin, but the sensitivity of target cells to insulin is reduced (also known as "insulin resistance"). Relatively insufficient insulin, also known as non-insulin dependent diabetes. Insulin resistance is a key factor in the development and progression of type 2 diabetes. Therapeutic drugs for type 2 diabetes include sulfonylureas, biguanides, other insulin sensitizers, and ancillary measures. After the sulfonylurea hypoglycemic agent binds to the receptor of the pancreatic β-cell membrane, the potassium ion channel is closed, and the potassium ion efflux is blocked, which leads to depolarization of the cell membrane, causing the Ca 2+ channel to be released, resulting in extracellular calcium influx. The increase in intracellular calcium concentration triggers the release of insulin. According to its advent, it was divided into two generations, the first generation such as toluene propyl propyl urea, the second generation including glibenclamide (glibenclamide), gliclazide (Damecon), glipizide (mepyrazin) ) and gliclazide (sugar leveling) and the like. The biguanide hypoglycemic agent can suppress appetite, increase the binding of insulin to the receptor, promote the anaerobic glycolysis of glucose, inhibit tissue respiration, and inhibit hepatic gluconeogenesis. Mainly there are metformin, phenformin and butyl bismuth. Other hypoglycemic agents mainly include Thiazolidinediones (such as troglitazone, rosiglitazone, pioglitazone, etc.), P 3-adrenergic receptor modulators, glucagon receptor antagonists, Fatty acid metabolism interfering drugs, α-glycosidase inhibitors (such as acarbose, voglibose, miglitol, etc.) and aldose reductase inhibitors.
胰高血糖素样肽- 1受体 (Glucagon like peptide-1 receptor, GLP-1R) 属于 B类型 的 G 蛋白偶联受体 (G protein-coupled receptor, GPCR)。 当机体摄入营养物质时, 肠 内分泌细胞释放的肠肽激素一胰高血糖素样肽- 1 (Glucagon like peptide-1 , GLP- 1 ), 通过与 GLP-1R 高度特异性地结合使其活化, 刺激胰岛素分泌, 抑制胰高血糖素的产生, 使餐后血糖降低并维持在恒定水平。 生理条件下, GLP- 1 剌激胰岛素分泌的作用依赖于血 糖浓度, 不会因持续分泌而发生低血糖。 GLP-1还具有促进 Ρ 细胞的增殖和分化, 以及神 经调节功能, 延迟胃排空, 降低食欲。 在体外, GLP- 1 能促进胚胎干细胞分化为具有胰岛 素分泌功能的类 细胞(J Endocrinol. 2005, 186: 343-52)。 GLP-1 作用于中枢能促进细 胞存活而减少凋亡, 降低 -淀粉样肽的神经毒, 抑制神经退行性病变的进程以及促进学 习和记忆, 所以最近有人提出将 GLP- 1用于 Alzheimer' s病的治疗 (Ann N Y Acad Sci, 2004, 1035 : 290-315 ; Nat Med, 2003, 9 : 1173-1179 ; Curr Alzheimer Res, 2005, 2 : 377 - 385 ; J Pharmacol Exp Ther, 2002, 302 : 881 - 888)。 另外, GLP-1在心血管系统中也有重要作 用。 它具有降低血压和扩张血管的作用, 急性注射 GLP-1能在心肌肥大实验中改善左心室 的收缩功能。 它还能在心肌缺血后再灌注的情况下减轻心肌细胞的损伤 (J. Hypertens, 2003, 21 : 1125 - 1135 ; Am J Physiol Endocrinol Metab, 2004, 287 : E1209 - E1215 ; Circulation, 2004, 110 :955 - 961 ; Diabetes, 2005, 54 : 146 - 151)。 由于上述明确的生 理效应, 自 80年代中期发现该靶点以来, 寻找 GLP- 1R的小分子激动剂乃是国际许多新药 开发机构的研究热点。 Glucagon like peptide-1 receptor (GLP-1R) belongs to type B G protein-coupled receptor (GPCR). When the body ingests nutrients, the gutagonal peptide-1 (GLP-1) released by the enteroendocrine cells is activated by highly specific binding to GLP-1R. It stimulates insulin secretion, inhibits the production of glucagon, and lowers postprandial blood glucose and maintains it at a constant level. Under physiological conditions, the effect of GLP-1 on insulin secretion is dependent on blood glucose levels, and hypoglycemia does not occur due to continued secretion. GLP-1 also promotes proliferation and differentiation of sputum cells, as well as neuromodulation, delaying gastric emptying and reducing appetite. In vitro, GLP-1 promotes differentiation of embryonic stem cells into islets A secretory cell-like cell (J Endocrinol. 2005, 186: 343-52). GLP-1 acts on the central body to promote cell survival and reduce apoptosis, reduce the neurotoxicity of amyloid peptides, inhibit the progression of neurodegenerative diseases, and promote learning and memory. Therefore, it has recently been proposed to use GLP-1 for Alzheimer's. Treatment of the disease (Ann NY Acad Sci, 2004, 1035: 290-315; Nat Med, 2003, 9: 1173-1179; Curr Alzheimer Res, 2005, 2: 377-385; J Pharmacol Exp Ther, 2002, 302: 881 - 888). In addition, GLP-1 also plays an important role in the cardiovascular system. It has the effect of lowering blood pressure and dilating blood vessels. Acute injection of GLP-1 can improve left ventricular systolic function in cardiac hypertrophy experiments. It also reduces myocardial cell damage in the presence of myocardial ischemia and reperfusion (J. Hypertens, 2003, 21: 1125 - 1135; Am J Physiol Endocrinol Metab, 2004, 287: E1209 - E1215; Circulation, 2004, 110 : 955 - 961 ; Diabetes, 2005, 54 : 146 - 151). Due to the above-mentioned clear physiological effects, since the discovery of this target in the mid-1980s, the search for small molecule agonists of GLP-1R has been a research hotspot of many new drug development institutions in the world.
多家国际著名跨国医药公司均在幵发 GLP-1类创新药物, 如丹麦 Novo Nordisk公司 开发的 GLP- 1衍生物(商品名为 Liraglutide; 进入三期临床试验)和美国 Amylin医药公 司和礼来公司联合开发的 GLP- 1类似物 Exendin-4 (商品名 Exenatide; 已于去年 4月份 批准上市, 今年销售额预计超出 10亿美元)。 目前除了 GLP-1及其多肽类似物外, 尚无任 何有关非肽类小分子 GLP- 1R激动剂获得成功开发的报道。 由于多肽药物不便口服, 寻找 非肽类 GLP- 1R 调节剂, 幵发具有自主知识产权的新型抗糖尿病药物是目前许多新药研究 机构所共同关注的方向。  A number of internationally renowned multinational pharmaceutical companies are in the process of inventing GLP-1 innovative drugs, such as the GLP-1 derivative developed by Danovo Nordisk in Denmark (trade name Liraglutide; entering Phase III clinical trials) and Amylin Pharmaceuticals and Lilly in the United States. The company's joint development of the GLP-1 analogue Exendin-4 (trade name Exenatide; has been approved for listing in April last year, this year's sales are expected to exceed $1 billion). In addition to GLP-1 and its peptide analogs, there have been no reports of successful development of non-peptide small molecule GLP-1R agonists. Due to the inconvenient oral administration of peptide drugs, the search for non-peptide GLP-1R regulators and the development of new anti-diabetic drugs with independent intellectual property rights are the common concerns of many new drug research institutions.
发明内容  Summary of the invention
本发明的目的在于提供一类由以下通式 I或 Π表示的化合物及其药学上可以接受的 本发明的另一目的在于提供一种制备由以下通式 I或 Π表示的化合物的方法; 本发明的又一目的在于提供一种含有由以下通式 I或 π表示的化合物的药物组合物; 本发明的再一目的在于提供由以下通式 I或 Π表示的化合物作为胰高血糖样肽 -1受 体调节剂在预防和 /或治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖 症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s病) 等的医学用途。  It is an object of the present invention to provide a compound represented by the following formula I or hydrazine and a pharmaceutically acceptable object of the invention to provide a process for the preparation of a compound represented by the following formula I or hydrazine; A still further object of the invention is to provide a pharmaceutical composition comprising a compound represented by the following formula I or π; a further object of the present invention is to provide a compound represented by the following formula I or Π as a glucagon-like peptide- 1 Receptor modulators for medical use in the prevention and/or treatment of metabolic disorders, including but not limited to diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease.
本发明提供胰高血糖样肽一 1受体调节剂, 增加了预防和 /或治疗代谢紊乱性疾病(包 括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s病)等药物的成员。 本发明涉及由以下通式 I或 II表示的化合物, 或其药物 学上可接受的盐:
Figure imgf000005_0001
及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化 物或其金属配合物。
The present invention provides a glucagon-like peptide-1 receptor modulator, which increases the prevention and/or treatment of metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases ( Members of drugs such as Alzheimer's disease. The present invention relates to a compound represented by the following formula I or II, or a pharmaceutically acceptable salt thereof:
Figure imgf000005_0001
And all of its stereo and optical isomers, or prodrugs having the same pharmacological effects, esters thereof, solvates thereof or metal complexes thereof.
其中 X和 Y 分别为(CH „, n为 0- 2; 0; S或者 NH。  Where X and Y are respectively (CH „, n is 0-2; 0; S or NH.
其中 , R2各自独立地为下列任意一种取代基: 氢; 卤素; 烷烃; 环垸烃; 羟基; 硝 基; 羧基; 醛基; 烷氧基; 胺基; 胺垸基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基; Wherein R 2 is each independently a substituent of any of the following: hydrogen; halogen; alkane; cycloalkyl hydrocarbon; hydroxyl group; nitro group; carboxyl group; aldehyde group; alkoxy group; amine group; amine group; amide group; Amido; thiol; sulfhydryl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted thienyl; substituted or unsubstituted pyrrolyl;
R3, !^各自独立地为下列任意一种取代基: 氢; 垸烃; 环烷烃; 烷氧基; 胺基; 胺烷 基; 酰胺基; 碳酰胺基; 垸硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 R 3 , ! ^ independently of any of the following substituents: hydrogen; anthracene; cycloalkane; alkoxy; amine; amine alkyl; amide; carboxamide; thiol; substituted or unsubstituted aryl; Substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
优选地, 上述式 I和 II的化合物的特征在于: X, Y 分别是 (CH2) n, n为 0-2; 0; S 或者 NH, R„ R2分别各自独立为:
Figure imgf000005_0002
Preferably, the compounds of the above formulae I and II are characterized in that: X, Y are respectively (CH 2 ) n, n is 0-2; 0; S or NH, R „ R 2 are each independently:
Figure imgf000005_0002
其中 R5为下列任意一种取代基为 H; -^的垸基; 含有包括卤素原子、 d- C6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 C,-C6的垸基; C2- (:6的烯基; 含有包括卤素 原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的烯基; C2- (:6的 炔基;含有包括卤素原子、 C「C6的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3- C6的环烷基; 含有包括卤素原子、 C,- C6的烷氧基或羟基在内的任意一个、 两个 或者三个取代的(:3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 ( ,_(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 ( 的院基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括! ¾素原子、 (:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 d-c4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; c6的烷酰基; 含 有包括卤素原子、 c,-^的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c,- CB的垸 酰基; c2- C6的烯酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 C2- C6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 (^-(:6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-cB的环垸酰基; 含有包括卤素 原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环垸酰基; 金 刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 吡喃甲酰基; X (CH , n为 0-2; 0; S或者 NH时; Wherein R 5 is any of the following substituents: H; - fluorenyl; - any one, two or three substituted C-containing groups including a halogen atom, a decyloxy group of d-C 6 or a hydroxyl group, - a fluorenyl group of C 6 ; a C 2 - (: 6 alkenyl group; any one, two or three substituted C 2 -C 6 alkenyl groups including a halogen atom, an alkoxy group of d- or a hydroxyl group C 2 - (: 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group including a halogen atom, C "C 6 decyloxy group or hydroxyl group"; C 3 - a C 6 cycloalkyl group; any one, two or three substituted (: 3 - C 6 cycloalkyl) groups containing a halogen atom, C, -C 6 alkoxy group or a hydroxyl group; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing fluorenyl group including a halogen atom, d-C 4 , nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a thiol group containing a halogen atom, (, _(: 4 ) Any one, two or three substituted pyridyl groups, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; Any one, two or three of a halogen atom, a fluorenyl group of d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group a substituted furanyl group; containing a halogen atom, a ketone group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a thiol group, a methylthio group, an ethylthio group, etc. Any one, two or three substituted pyranyl groups; containing a ? 3⁄4 atom, (: 4 alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, Any one, two or three substituted thienyl groups including an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; an alkyl group including a halogen atom, dc 4 , a nitro group, a carboxyl group, or an aldehyde group Any one, two or three substituted pyrrolyl groups such as a nonyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; a cyanyl group of 6 ; containing a halogen atom Any one, two or three substituted c, - C B decanoyl groups, c, -^ alkoxy or hydroxy group; c 2 - C 6 enoyl group; containing a halogen atom, d- Any one, two or three substituted C 2 -C 6 alkenoyl groups such as a decyloxy group or a hydroxyl group; a C 2 -C 6 alkynyl group; containing a halogen atom, (^-(: 6 oxime) Any one, two or three substituted c 2 -c 6 alkynyl groups, including a hydroxyl group; a c 3 -c B cyclodecanoyl group; a decyloxy group or a hydroxyl group containing a halogen atom, d-Ce Any one, two or three substituted c 3 -c 6 cyclodecanoyl groups; adamantyl formyl, substituted gold垸-formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; pyranoyl; X (CH, n is 0-2; 0; S or NH;
R3) R4分别为:
Figure imgf000006_0001
其中 R6为下列任意一种取代基: H; d- Ce的垸基; 含有包括卤素原子、 (:,-(:6的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 (VC6的烷基; C2- (:6的烯基; 含有包括卤素 原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:2-(:6的烯基; (:2-( 6的 炔基;含有包括卤素原子、 ( Ce的烷氧基或羟基在内的任意一个、两个或者三个取代的 ^- C6 的炔基; C3-C6的环垸基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d-C4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (^-( 4的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 0>的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; - 的垸酰基; 含 有包括卤素原子、 -G的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C,-C6的垸 酰基; c2-ce的烯酰基; 含有包括卤素原子、 d-cfi的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-cfi的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 d- 的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3- c6的环烷酰基; 含有包括卤素 原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c3- 的环垸酰基; 金 刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 为(CH2)„, n为 0- 2; 0; S或者 NH;
R 3) R 4 are:
Figure imgf000006_0001
Wherein R 6 is any one of the following substituents: H; a fluorenyl group of d-C e ; containing any one, two or three including a halogen atom, an alkoxy group or a hydroxyl group of (:, - (: 6 ) Substituted (VC 6 alkyl; C 2 - (: 6 alkenyl; containing any one, two or three substituted (including a halogen atom, C, -C 6 decyloxy or hydroxy group): 2 -(: 6 alkenyl; (: 2 -( 6 alkynyl; containing any one, two or three substituted ^-C 6 including a halogen atom, (alkoxy group of Ce or a hydroxyl group) alkynyl; C 3 -C 6 cycloalkyl group embankment; contain any halogen atoms include, d-Ce alkoxy or hydroxy the embankment, including one, two or three substituents of C 3 - C 6 cycloalkyl group of the embankment; Aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing alkyl group including a halogen atom, dC 4 , nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substituted pyridyl groups, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; a halogen atom, (^ - (alkyl, nitro, carboxyl, aldehyde, alkoxy embankment, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including any one of 4, two Or three substituted furanyl groups; containing a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group Any one, two or three substituted pyranyl groups; containing a halogen atom, (^-(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carbon) Any one, two or three substituted thienyl groups including an amide group, a fluorenyl group, a methylthio group, an ethylthio group; an alkyl group including a halogen atom, 0>, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group , amine, amide, carboxamide, sulfhydryl, a Any one, two or three substituted pyrrolyl groups including a thiol group; a decanoyl group; any one, two or three groups including a halogen atom, an alkoxy group of -G or a hydroxyl group Substituted C, -C 6 decanoyl; c 2 -c e enoyl; any one, two or three substituted c 2 -c containing a halogen atom, a decyloxy group or a hydroxyl group of dc fi fi enoyl; C 2 - C 6 alkynyl group; a halogen atom-containing optionally include, d- or hydroxyl group of the embankment, including one, two or three substituents of c 2 -c 6 alkynyl group; and c 3 - c 6 cycloalkanoyl; containing halogen Any one, two or three substituted c 3 -cyclodecanoyl groups of an atom, d-alkoxy or hydroxy group; adamantyl formyl, substituted adamantyl formyl; aroyl; benzoyl; furan Acyl; pyranoyl; thiophene; pyrrolyl; (CH 2 ), n is 0-2; 0; S or NH;
或者 R3, 分别为:
Figure imgf000007_0001
Or R 3 , respectively:
Figure imgf000007_0001
其中 R7, Rs各自独立为下列任意一种取代基: H; (^-(:6的垸基;含有包括卤素原子、 C G 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 (^-(:6的垸基; (:2-(:6的烯基; 含有 包括卤素原子、 - 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- 的烯基; C2 - C6的炔基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取 代的 C2- C6的炔基; C3-C6的环垸基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意 一个、 两个或者三个取代的 C3-C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯 基; 吡啶基; 含有包括卤素原子、 d- (:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺 基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有 包括卤素原子、 0<的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯 基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 -(;4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- (:4的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、( C4的垸基、硝基、羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (:,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; C,-C6的烷酰基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 d- C6的烷酰基; C2-Cfi的烯酰基; 含有包括卤素原子、 (^-(:6的垸氧基或羟基在内的 任意一个、两个或者三个取代的 c2- cfi的烯酰基; c2- c6的炔酰基; 含有包括卤素原子、 c,-c6 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-ce的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 d-c6的烷氧基或羟基在内的任意一个、 两个或者三个取代的(:3-(6的 环垸酰基; 金刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X (CH2) n, n为 0-2; 0; S或者 NH; X2为(CH2)„, n为 0- 2; 0; S或者 NH; Wherein R 7 and R s are each independently a substituent of any of the following: H; (^-(: 6 fluorenyl; any one, two or three containing a halogen atom, an alkoxy group of CG or a hydroxyl group) Substituted (^-(: 6 fluorenyl; (: 2 -(: 6 alkenyl; any one, two or three substituted C containing a halogen atom, a fluorenyloxy group or a hydroxy group) 2 -alkenyl; C 2 -C 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group containing a halogen atom, a decyloxy group or a hydroxyl group of d-Ce ; C 3 -C 6 cycloalkyl group embankment; includes any halogen atom-containing, dC e the embankment or a hydroxyl group, including one, two or three substituents of C 3 -C 6 cycloalkyl group embankment; an aryl group; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing a halogen atom, d- (: 4 alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substitutions of 0, alkyl, nitro, carboxy, aldehyde, decyloxy, amino, amide, carboxamido, decyl, methylthio, ethylthio Pyridyl; containing a halogen atom, -(; 4 fluorenyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted furanyl groups; containing a halogen atom, d- (: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, Any one, two or three substituted pyranyl groups including a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, (a thiol group of a C4 group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group) Any one, two or three substituted thienyl groups including a amide group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and an alkyl group including a halogen atom, (:, -(: 4 ), Nitro, carboxyl, aldehyde, decyloxy, amine, amide, Amide groups, mercapto, methylthio, ethylthio, including one, two or three substituents pyrrolyl; C, -C 6 alkanoyl; include a halogen atom-containing, or hydroxyl group dC embankment 6 of Any one, two or three substituted d-C 6 alkanoyl groups; C 2 -C fi alkenoyl group; containing a halogen atom, (^-(: 6 alkoxy group or hydroxyl group) Any one, two or three substituted c 2 - c fi enoyl groups; c 2 - c 6 alkynyl groups; any one containing a halogen atom, c, -c 6 alkoxy group or a hydroxyl group, Two or three substituted c 2 -c e acetylene groups; c 3 -c 6 cyclodecanoyl group; any one, two or three containing a halogen atom, an alkoxy group of dc 6 or a hydroxyl group Substituted (: 3 -( 6 cyclodecanoyl; adamantyl, substituted adamantyl; aroyl; benzyl; furanoyl; pyranoyl; thiophene; pyrroyl; X (CH 2 ) n , n is 0-2; 0; S or NH; X 2 is (CH 2 ) „, n is 0-2; 0; S or NH;
或者 R3, 分别为-
Figure imgf000007_0002
其中 R9为下列任意一种取代基: H; (:,-(:6的垸基; 含有包括卤素原子、 d- ( 的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 d-Cs的垸基; (:2-( 6的烯基; 含有包括卤素 原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- C6的烯基; C2- C6的 炔基;含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-Cfi 的炔基; C3- Cfi的环垸基; 含有包括卤素原子、 C,- C6的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (^(^的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 -(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- C4的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 - 的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 d-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; 的烷酰基; 含 有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C,-C6的垸 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d-c6的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- c6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素 原子、 d- cfi的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3 - cfi的环垸酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X (CH2)„, n为 0-2; 0; S或者 NH;
Or R 3 , respectively -
Figure imgf000007_0002
Wherein R 9 is any one of the following substituents: H; (:, -(: 6 fluorenyl; any one, two or three substitutions including a halogen atom, d-(alkoxy group or hydroxy group) a fluorenyl group of d-Cs; (: 2 -( 6 alkenyl; any one, two or three substituted C 2 - C 6 containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group) Alkenyl; C 2 -C 6 alkynyl; any one, two or three substituted C 2 -C fi alkynyl group containing a halogen atom, C,-C 6 decyloxy or hydroxy group; a C 3 -C fi cyclodecyl group; any one, two or three substituted C 3 -C 6 cyclodecyl groups containing a halogen atom, a C, or a C 6 decyloxy group or a hydroxyl group; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, (^(alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide) group, any carbon amide group, a mercapto group, methylthio, ethylthio, including one, two or three aryl group substituents; include a halogen atom-containing, - (: 4 Any one, two or three substituted pyridyl groups including a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one or two including a halogen atom, an alkyl group of d-C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and the like. Or three substituted furanyl groups; containing a halogen atom, a thiol group of d-C 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methyl group, Any one, two or three substituted pyranyl groups including an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carbon amide group Any one, two or three substituted thienyl groups including a thiol group, a thiol group, a methylthio group, an ethylthio group, a thiol group including a halogen atom, dC 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, Amine, amide, carboxamide, sulfhydryl, Any one, two or three substituted pyrrolyl groups such as a thio group or an ethylthio group; an alkanoyl group having a halogen atom, a decyloxy group having a halogen atom or d-Ce, or a hydroxyl group; Substituted C, -C 6 decanoyl; c 2 -c 6 enoyl; any one, two or three substituted c 2 - including a halogen atom, an alkoxy group of dc 6 or a hydroxyl group An alkenoyl group of c 6 ; an alkynyl group of c 2 -c 6 ; an alkyne having any one, two or three substituted c 2 -c 6 groups including a halogen atom, a decyloxy group of d-c 6 or a hydroxyl group; Acyl; c 3 -c 6 cyclodecanoyl; any one, two or three substituted c 3 - c fi cyclodecanoyl groups including a halogen atom, a d-c fi decyloxy group or a hydroxyl group; Adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; X (CH 2 ), n is 0-2; 0; Or NH;
或者 R3, 分别为-
Figure imgf000008_0001
其中 。, Ru各自独立为下列任意一种取代基: H; Ct- (:6的烷基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的垸基; (:2-(:6的烯基; 含有包括卤素原子、 C,-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的 烯基; (2-( 6的炔基; 含有包括卤素原子、 CrC6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2- (^的炔基; C3-Ce的环烷基; 含有包括卤素原子、 C,- C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C:,-C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 c,- c4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、(^-^的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (^-( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; 的垸酰基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 的垸酰基; c2-ce的烯酰基; 含有包括卤素原子、 c,-c6的烷氧基或羟基在内的 任意一个、两个或者三个取代的 c2-c6的烯酰基; c2-ce的炔酰基; 含有包括卤素原子、 C, - c6 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (3_(:6的 环烷酰基; 金刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH2)。, n为 0-2; 0; S或者 NH; 为(CH2) n, n为 0 - 2; 0; S或者 NH。
Or R 3 , respectively -
Figure imgf000008_0001
among them. , Ru each independently is any one of the following substituents: H; Ct- (: 6 alkyl; any one, two or three substituted d including a halogen atom, d- alkoxy group or a hydroxyl group - fluorenyl; (: 2 - (: 6 alkenyl; any one, two or three substituted C 2 - containing: a halogen atom, C, -C e methoxy or hydroxy group (: 6 alkenyl; ( 2- ( 6 alkynyl; any one, two or three substituted C 2 - (^ alkynyl group) including a halogen atom, a decyloxy group of CrC 6 or a hydroxyl group; C a cycloalkyl group of 3 -C e ; any one, two or three substituted C:,-C 6 cyclodecyl groups including a halogen atom, a C, or a C 6 methoxy group or a hydroxyl group; Benzyl; furyl; pyranyl; thienyl; Pyrrolyl; pyridyl; containing halogen atom, thiol, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted aryl groups; containing a halogen atom, a sulfhydryl group, a nitro group, a carboxy group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a group Any one, two or three substituted pyridyl groups including a thio group or an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carbon group Any one, two or three substituted furanyl groups including an amide group, a decyl group, a methylthio group, an ethylthio group; a fluorenyl group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, Any one, two or three substituted pyranyl groups including a methoxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; containing a halogen atom, (^-^) Sulfhydryl, nitro, carboxyl, aldehyde, decyloxy Any amine, amide, carboxamide, mercapto, methylthio, ethylthio, including one, two or three substituents thienyl; include a halogen atom-containing, (^ - (4 embankment group, nitro Any one, two or three substituted pyrrolyl groups of a group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; Any one, two or three substituted decanoyl groups including a halogen atom, a decyloxy group or a hydroxyl group of dC 6 ; an alkenoyl group of c 2 -c e ; containing a halogen atom, c, -c 6 Any one, two or three substituted c 2 -c 6 enoyl groups such as alkoxy or hydroxy; c 2 -c e acetylenic group; alkoxy group containing a halogen atom, C, - c 6 Or one, two or three substituted c 2 -c 6 alkynyl groups, or a c 3 -c 6 cyclodecanoyl group; or a hydroxy group including a halogen atom, dC 6 or a hydroxyl group Any one, two or three substituted ( 3 _(: 6 cycloalkanoyl; adamantyl, Substituting adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X, (CH 2 ), n 0-2; 0; S or NH; Is (CH 2 ) n , n is 0 - 2; 0; S or NH.
当 R', R2分别各自独立为:
Figure imgf000009_0001
其中^, R13各自独立为下列任意一种取代基: H; C「 C6的垸基; 含有包括卤素原子、 C,-Cfi的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:,-(:6的烷基; 的烯基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (2-(:6的 烯基; C2- (:6的炔基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2- ( 的炔基; C 的环垸基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3- C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 -(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 ( 的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 0(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- ( 的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d-c4的垸基、 硝基、羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (:,_(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; c,-c6的烷酰基; 含有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 d- C6的烷酰基; C2- Cfi的烯酰基; 含有包括卤素原子、 d- (:6的垸氧基或羟基在内的 任意一个、 两个或者三个取代的 C2-C6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 CrC6 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的炔酰基; 的环烷酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 -^的 环垸酰基; 金刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X CH , n为 0- 2; 0; S或者 NH; X2为((¾)„, n为 0-2; 0; S或者 NH时;
When R', R 2 are each independently:
Figure imgf000009_0001
Wherein, R 13 are each independently a substituent of any of the following: H; C "indenyl group of C 6 ; any one or two of a fluorenyl group or a hydroxy group including a halogen atom, C, -C fi or Three substituted (:, -(: 6 alkyl); alkenyl; any one, two or three substituted ( 2 -(:) containing a halogen atom, a decyloxy group or a hydroxyl group of d-: 6 alkenyl; C 2 - (: 6 alkynyl group; a halogen atom includes contain any, or a hydroxyl group dC embankment 6 of the inner one, two or three substituents of C 2 - (alkynyl; C a cycloalkyl group; any one, two or three substituted C 3 -C 6 cycloalkyl groups including a halogen atom, a decyloxy group or a hydroxyl group of dC 6 ; an aryl group; a benzyl group; a furyl group; Pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, -(: 4 fluorenyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, Any one, two or three substituted aryl groups including a methylthio group and an ethylthio group; containing a halogen atom, Any one, two or three substituted pyridyl groups of an alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; Containing a halogen atom, 0 (: 4 fluorenyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, B Any one, two or three substituted furanyl groups including a thio group; containing a halogen atom, d-(indenyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carboxamide) Any one, two or three substituted pyranyl groups including a thiol group, a thiol group, an ethylthio group, a thiol group including a halogen atom, dc 4 , a nitro group, a carboxy group, an aldehyde group, a decyloxy group Any one, two or three substituted thienyl groups, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, (:, _(: 4 ) Any one, two or three substituted pyrrolyl groups including a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; An alkanoyl group of -c 6 ; an alkanoyl group having any one, two or three substituted d-C 6 groups including a halogen atom, a decyloxy group of dc 6 or a hydroxyl group; a enoyl group of C 2 - C fi ; include a halogen atom-containing, d- (: any embankment 6 alkoxy or hydroxy, including One, two or three substituents of C 2 -C 6 alkenyl group; a C 2 - C 6 alkynyl group; containing any one of a halogen atom include, CrC alkoxy or hydroxy embankment 6 of the inner, two or three a substituted C 2 -C 6 alkynyl; a cycloalkanoyl; a cyclohexanoyl group containing any one, two or three substituents including a halogen atom, a decyloxy group or a hydroxyl group; Adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X CH , n is 0-2; 0; S or NH; 2 is ((3⁄4)„, n is 0-2; 0; S or NH;
R3, 分别为:
Figure imgf000010_0001
R 3 , respectively:
Figure imgf000010_0001
其中 R6为下列任意一种取代基: H; (:6的垸基; 含有包括卤素原子、 (:6的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 d-C6的烷基; (:2-(:6的烯基; 含有包括卤素 原子、 - 的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:2-( 6的烯基; C2- (:6的 炔基;含有包括卤素原子、 C,- C6的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3-C6的环垸基; 含有包括卤素原子、 Ct-Cs的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 C3-CB的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 - (^的烷基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- (^的烷基、硝基、羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 d- (^的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-Cs的烷酰基; 含 有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- C6的垸 酰基; C2_C6的烯酰基; 含有包括卤素原子、 -G的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 (;-(:6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素 原子、 C,- c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环垸酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X2为(CH2) n, n为 0- 2; 0; S或者 NH; Wherein R 6 is any one of the following substituents: H; (: 6 fluorenyl; or any one, two or three substituted dC 6 including a halogen atom, ( 6 alkoxy group or hydroxyl group) Alkyl; (: 2 -(: 6 alkenyl; any one, two or three substituted (including 2 -( 6 alkenyl; C) containing a halogen atom, a fluorenyloxy group or a hydroxy group 2 - (: 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl groups containing a halogen atom, a C, a C 6 decyloxy group or a hydroxyl group; C 3 - a cyclic fluorenyl group of C 6 ; a C 2 -C B cyclodecyl group containing a halogen atom, a decyloxy group or a hydroxyl group of a Ct-Cs; an aryl group; a benzyl group; furyl; tetrahydropyranyl; thienyl; pyrrolyl; pyridyl; include a halogen atom-containing, alkyl with 4 dC, a nitro group, a carboxyl group, an aldehyde group, embankment group, an amine group, an amide group, a carbonamide group, a mercapto group Any one, two or three substituted aryl groups including a methylthio group and an ethylthio group; containing a halogen atom, a fluorenyl group, and a nitro group Any one, two or three substituted pyridyl groups including a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substituted alkyl, nitro, carboxy, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio a furan group; containing a halogen atom, d-(^, alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted pyranyl groups; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a group Any one, two or three substituted thienyl groups including a thio group and an ethylthio group; containing a halogen atom, d-(^, alkyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, Amido, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted pyrrolyl groups; alkanoyl group of d-Cs; any one, two or three substituted ds including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group - C 6垸 Acyl; C 2 -C 6 alkenoyl; any one, two or three substituted c 2 -c 6 alkenoyl group including a halogen atom, an alkoxy group of -G, or a hydroxyl group; c 2 -c 6 Alkynyl; a acetylenic group containing a halogen atom, (--: 6 decyloxy or hydroxy group, any two, or three substituted c 2 -c 6 ; c 3 -c 6 ring; Any one, two or three substituted c 3 -c 6 cyclodecanoyl groups containing a halogen atom or a hydroxyl group including a halogen atom, C, - c 6 ; adamantyl group, substituted adamantane Formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X 2 is (CH 2 ) n , n is 0-2; 0; S or NH;
或者 R3, 分别为-
Figure imgf000011_0001
Or R 3 , respectively -
Figure imgf000011_0001
其中 R7, R8各自独立为下列任意一种取代基: H; C「 Ce的垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 烷基; C2- (:6的烯基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 (2-( 6的 烯基; (:2-(:6的炔基; 含有包括卤素原子、 C,- C6的烷氧基或羟基在内的任意一个、 两个或者 三个取代的(:2-(:6的炔基; C3- Ce的环烷基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d-C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d- C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 - 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- ( 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 C,- C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 ( -^的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; CrCe的垸酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 C,- C6的烷酰基; C2- C6的烯酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的 任意一个、两个或者三个取代的 C2- C6的烯酰基; C2-C6的炔酰基; 含有包括卤素原子、 c,-c6 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-ce的炔酰基; c3-c6的环烷酰基; 含有包括卤素原子、 d-CB的烷氧基或羟基在内的任意一个、 两个或者三个取代的 (:3_(:6的 环烷酰基; 金刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH2)„, n为 0- 2; 0; S或者 NH; X2为(CH2)„, n为 0_2; 0; S或者 NH; 或者 R3, ^分别为:
Figure imgf000012_0001
Wherein R 7 and R 8 are each independently a substituent of any of the following: H; C "indenyl group of C e ; any one or two of a decyloxy group or a hydroxyl group including a halogen atom, C, -C 6 Or a three-substituted alkyl group; a C 2 - (: 6 alkenyl group; any one, two or three substituted groups including a halogen atom, an alkoxy group of d- or a hydroxyl group ( 2- ( 6 ) alkenyl group; (: 2 - (: 6 alkynyl group; a halogen atom include containing, C, - one, two or three of any alkoxy or hydroxy-substituted C 6 of the inner (: 2 - (: 6 Alkynyl; C 3 -C e cycloalkyl; any one, two or three substituted C 3 -C 6 cyclodecyl groups containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; Aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing fluorenyl group including a halogen atom, dC 4 , nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any sub, d- C 4 alkyl with, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including one, two, or a three-substituted pyridyl group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and the like Any one, two or three substituted furanyl groups; including a halogen atom, d-(indenyl, nitro, carboxyl, aldehyde, anthracene, amine, amide, carboxamide, sulfhydryl, Any one, two or three substituted pyranyl groups including a methylthio group and an ethylthio group; a mercapto group including a halogen atom, C, -C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, Any one, two or three substituted thienyl groups including an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; and a halogen atom, a sulfhydryl group, a nitro group, Carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carbon amide Any one, two or three substituted pyrrolyl groups including a thiol group, a thiol group, a methylthio group, an ethylthio group; a decanoyl group of CrC e; an arsenyl group containing a halogen atom, d-, or a hydroxyl group One, two or three substituted C,-C 6 alkanoyl; C 2 -C 6 alkenoyl; any one or two containing a halogen atom, a decyloxy group or a hydroxyl group of d-Ce or three substituted C 2 - C 6 alkenyl group; a C 2 -C 6 alkyne group; a halogen atom include any containing, C, -C 6 alkoxy or hydroxy, including one, two or three substituents Alkynyl group of c 2 -c e ; cycloalkanoyl group of c 3 -c 6 ; any one, two or three substituted groups including a halogen atom, an alkoxy group of d-CB or a hydroxyl group (: 3 _(: 6 cycloalkanoyl; adamantyl formyl, substituted adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; X, (CH 2 ) „, n is 0- 2; 0; S or NH ; X 2 is (CH 2 ) „, n is 0_2; 0; S or NH; Or R 3 , ^ are:
Figure imgf000012_0001
其中 R9为下列任意一种取代基: H; C,- C6的焼基; 含有包括卤素原子、 (:6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 d- c6的垸基; c2-c6的烯基; 含有包括卤素 原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的烯基; C2- 的 炔基;含有包括卤素原子、 c,-c6的烷氧基或羟基在内的任意一个、两个或者三个取代的 c2-c6 的炔基; C3_C6的环烷基; 含有包括卤素原子、 C-Ce的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 c3-c6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (:,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- ( 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、(^-(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 c,-c4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 c,- c4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- 的烷酰基; 含 有包括卤素原子、 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c,-c6的烷 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d-C6的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2- c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- (:6的烷氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3- c6的环烷酰基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3- c6的环烷酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X2为(CH , n为 0- 2; 0; S或者 NH; Wherein R 9 is any one of the following substituents: H; C, -C 6 fluorenyl; any one, two or three substituted d including a halogen atom, ( 6 decyloxy or hydroxy group) - an alkyl group of c 6 ; an alkenyl group of c 2 -c 6 ; any one, two or three substituted C 2 - (: 6 ) including a halogen atom, an alkoxy group of d-Ce or a hydroxyl group Alkenyl; C 2 -alkynyl; any one, two or three substituted c 2 -c 6 alkynyl group containing a halogen atom, c,-c 6 alkoxy group or hydroxyl group; C 3 a cycloalkyl group of _C 6 ; a mono-, two- or three-substituted c 3 -c 6 cyclodecyl group containing a halogen atom, a decyloxy group or a hydroxyl group of C-Ce; an aryl group; a benzyl group; Furanyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, (:, - (: 4 alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, any carbon amide group, a mercapto group, methylthio, ethylthio, including one, two or three aryl group substituents; include a halogen atom-containing, alkyl with 4 dC, nitro Any one, two or three substituted pyridyl groups including a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substitutions of d-(indolyl, nitro, carboxy, aldehyde, decyloxy, amino, amide, carboxamido, decyl, methylthio, ethylthio) a furan group; containing a halogen atom, (^-(: 4 fluorenyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) Any one, two or three substituted pyranyl groups; containing an alkyl group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carbon Any one, two or three substituted thienyl groups including an amide group, a fluorenyl group, a methylthio group, an ethylthio group; an alkyl group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, Alkoxy, amine, amide, carboxamide, sulfhydryl, methyl sulfide Any one, two or three substituted pyrrolyl groups including a thiol group; an alkanoyl group of d-; any one, two or three substitutions including a halogen atom, a hydroxyl group or a hydroxyl group Alkanoyl group of c, -c 6 ; alkenoyl group of c 2 -c 6 ; any one, two or three substituted c 2 - c 6 containing an alkoxy group including a halogen atom, dC 6 or a hydroxyl group; Alkenoyl; c 2 -c 6 alkynyl; acetylene group containing any one, two or three substituted c 2 -c 6 including a halogen atom, d- (: 6 alkoxy group or hydroxyl group) a cycloalkanoyl group of c 3 - c 6 ; any one, two or three substituted c 3 - c 6 cycloalkanoyl groups including a halogen atom, a decyloxy group of d- or a hydroxyl group; Acyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X 2 is (CH, n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000012_0002
Or R 3 and R 4 are:
Figure imgf000012_0002
其中 R,。, Ru各自独立为下列任意一种取代基: H; d- C6的垸基; 含有包括卤素原子、 C,_C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C,- ( 的烷基; (:2-(^的烯基; 含有包括卤素原子、 C,- CB的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2-CB 烯基; C2-C6的炔基; 含有包括卤素原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或者 三个取代的 c2- (:6的炔基; c3- c6的环烷基; 含有包括卤素原子、 c,-c6的烷氧基或羟基在内 的任意一个、两个或者三个取代的 c3-ce的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 CrC4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C,-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 -^的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- (^的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d-C4的烷基、 硝基、羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 C「 C4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; C,-Ce的垸酰基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 C,-C6的垸酰基; C2- Ce的烯酰基; 含有包括 素原子、 (:,-( 6的垸氧基或羟基在内的 任意一个、 两个或者三个取代的 c2-ce的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 CrCe 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环烷酰基; 含有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的 环垸酰基; 金刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为((¾)„,, n为 0- 2; 0; S或者 NH; X2为(CH2)„, n为 0-2; 0; S或者 NH。 Where R,. , Ru each independently is any one of the following substituents: H; a fluorenyl group of d-C 6 ; any one, two or three substituted groups including a halogen atom, a C _C 6 methoxy group or a hydroxyl group An alkyl group of C,-(; 2 :( 2 -alkenyl; an arbitrary one, two or three substituted C 2 - containing a halogen atom, a C, a C B group or a hydroxyl group) C B alkenyl; C 2 -C 6 alkynyl; any one or two containing a halogen atom, an alkoxy group of dC e or a hydroxyl group Three substituted c 2 - (: 6 alkynyl; c 3 - c 6 cycloalkyl; any one, two or three containing an alkoxy group including a halogen atom, c, -c 6 or a hydroxyl group Substituted c 3 -c e cycloalkyl; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing fluorenyl group including halogen atom, CrC 4 , nitro group, carboxyl group Any one, two or three substituted aryl groups including an aldehyde group, an oxime group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substitutions of -C 4 thiol, nitro, carboxy, aldehyde, decyloxy, amine, amide, carboxamido, decyl, methylthio, ethylthio Pyridyl group; containing any of a halogen atom, an alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and the like. One, two or three substituted furanyl groups; containing a halogen atom, d- (^ alkyl group, nitro group) Any one, two or three substituted pyranyl groups, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substitutions of an alkyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group or an ethylthio group of dC 4 . a thiophenyl group; containing a halogen atom, a C "C 4 alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a thiol group, a methylthio group, an ethylthio group, etc. Any one, two or three substituted pyrrolyl groups; C,-C e decanoyl group; any one, two or three substituted C groups including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group , -C 6 decanoyl; C 2 - C e enoyl; containing any one, two or three substituted c 2 - including a prime atom, (:, - ( methoxy or hydroxy group of 6 ) c e enoyl; C 2 - C 6 alkynyl group; a halogen atom-containing include, CrCe alkoxy or Group, including any one, two or three substituents of c -C 6 alkynyl group of 2; c 3 -c 6 cycloalkyl group; a halogen atom-containing optionally include, dc embankment 6 alkoxy or hydroxy, including One, two or three substituted c 3 -c 6 cyclodecanoyl; adamantyl formyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrole Formyl; X, is ((3⁄4)„,, n is 0-2; 0; S or NH; X 2 is (CH 2 ) „, n is 0-2; 0; S or NH.
此外更优选地, 当 R2分别各自独立为:
Figure imgf000013_0001
Further preferably, when R 2 is each independently:
Figure imgf000013_0001
其中 R14为下列任意一种取代基: H; (:「(:6的烷基; 含有包括卤素原子、 (:「(:6的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 (^-(:6的垸基; (:2-(:6的烯基; 含有包括卤素 原子、 (:,-(:6的烷氧基或羟基在内的任意一个、 两个或者三个取代的(:2-(:6的烯基; C2- ^的 炔基;含有包括卤素原子、 的烷氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3-C6的环垸基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个 或者三个取代的( 3- C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- (^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C-C^的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- ( 的烷基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的呋喃基; 含有包括卤素原子、 (^的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 (^(^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- C6的垸酰基; 含 有包括卤素原子、 c,- c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C,- 的垸 酰基; c2- c6的烯酰基; 含有包括卤素原子、 c,-c6的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- c6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- ce的环垸酰基; 含有包括卤素 原子、 C-C^的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3- C6的环垸酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 乂1为0¾)„, n为 0- 2; 0; S或者 NH; Wherein R 14 is any one of the following substituents: H; (: "(: 6 alkyl; containing any one, two or three including a halogen atom, (": 6 alkoxy or hydroxy group Substituted (^-(: 6 fluorenyl; (: 2 - (: 6 alkenyl; containing any one, two including a halogen atom, (:, - (: 6 alkoxy or hydroxy) Or three substituted (: 2 -(: 6 alkenyl; C 2 - ^ alkynyl; any one, two or three substituted C 2 containing a halogen atom, an alkoxy group or a hydroxyl group) -C 6 alkynyl; C 3 -C 6 cycloalkyl; any one, two or three substituted ( 3 - C 6 ring) containing a halogen atom, d-alkoxy or hydroxy group Alkyl; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, d-(^ thiol, nitro, carboxyl, aldehyde, alkoxy, Any one, two or three substituted aryl groups including an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three of an atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group or an ethylthio group. Substituted pyridyl; containing a halogen atom, d-(alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Arbitrarily One, two or three substituted furanyl groups; containing a halogen atom, an alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group Any one, two or three substituted pyranyl groups including an ethylthio group; containing a halogen atom, (^-(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group) Any one, two or three substituted thienyl groups, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a halogen atom, a sulfhydryl group, a nitro group, a carboxy group Any one, two or three substituted pyrrolyl groups, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a decanoyl group of d-C 6 Any one, two or three substituted C,-decanoyl groups including a halogen atom, c, -c 6 or a hydroxyl group; a c 2 - c 6 alkenoyl group; any c, -c embankment 6 alkoxy or hydroxy, including one, two or three Generation c 2 -c 6 alkenyl group; a c 2 -c 6 alkynyl group; a halogen atom-containing optionally include, D- c embankment 6 alkoxy or hydroxy, including one, two or three substituents c-2 - alkynyl group of c 6 ; cyclodecanoyl group of c 3 - c e ; ring of any one, two or three substituted C 3 - C 6 containing a halogen atom, a hydroxyl group of CC^ or a hydroxyl group Decanoyl; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; 乂1 is 03⁄4) „, n is 0-2; 0; S or NH;
R3, 分别为:
Figure imgf000014_0001
R 3 , respectively:
Figure imgf000014_0001
其中 R6为下列任意一种取代基: H; C, - (:6的垸基; 含有包括卤素原子、 d- 的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 的垸基; C2-C6的烯基; 含有包括卤素 原子、 C,- C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- C6的烯基; C2- (:6的 炔基;含有包括卤素原子、 的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3- Ce的环垸基; 含有包括卤素原子、 Ct-Ce的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 c3-ce的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- 的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d-c^烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- (^的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的呋喃基; 含有包括 素原子、 c「 c4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 c,-^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 c,-c4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; - ( 的烷酰基; 含 有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d-c6的烷 酰基; c2-c6的烯酰基; 含有包括卤素原子、 (:,-(:6的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 C2- C6的烯酰基; C2-C6的炔酰基; 含有包括卤素原子、 d- 的烷氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- c6的环垸酰基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3-C6的环垸酰基; 金 刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X2为(CH , n为 0-2 ; 0; S或者 NH; Wherein R 6 is any one of the following substituents: H; C, - (: 6 fluorenyl; any one, two or three substituted including a halogen atom, a decyloxy group or a hydroxyl group of d- embankment group; C 2 -C 6 alkenyl group; a halogen atom include containing, C, - any C 6 alkoxy or hydroxy embankment inner one, two or three substituents of C 2 - C 6 alkenyl group; C 2 - (: 6 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group including a halogen atom, a decyloxy group or a hydroxyl group; a C 3 - C e ring a fluorenyl group containing any one, two or three substituted c 3 -c e including a halogen atom, a decyloxy group or a hydroxyl group of a Ct-Ce; an aryl group; a benzyl group; a furyl group; a thiol group; a pyrenyl group; a pyrrolyl group; a pyridyl group; an alkyl group including a halogen atom, d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methyl group Any one, two or three substituted aryl groups including an ethylthio group; containing a halogen atom, a dc^alkyl group, a nitro group, a carboxyl group, Any one, two or three substituted pyridyl groups including an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, d- ( Any one, two or three substituted furans of thiol, nitro, carboxy, aldehyde, alkoxy, amine, amide, carboxamido, decyl, methylthio, ethylthio Any one containing an atom, a c c 4 alkyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group, and the like. One, two or three substituted pyranyl groups; containing a halogen group including a halogen atom, c, -^, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, Any one, two or three substituted thienyl groups including a methylthio group, an ethylthio group; an alkyl group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group Base, amide group, carboxamide group, sulfhydryl group, methylthio group, ethylthio group Any one, two or three substituents pyrrolyl; - (alkanoyl; containing optionally include a halogen atom, a hydroxyl group or a dc embankment 6 of the inner one, two or three substituents dc-6 alkanoyl ; a C 2 -c 6 enoyl group; containing any one, two or more including a halogen atom, (:, - (: 6 decyloxy group or hydroxy group) Substituted by three C 2 - C 6 alkenyl group; a C 2 -C 6 alkynyl group; a halogen atom-containing optionally include, d- alkoxy or hydroxy group including one, two or three substituents of c a 2 - c 6 alkynyl group; a c 3 - c 6 cyclodecanoyl group; any one, two or three substituted C 3 -C 6 groups including a halogen atom, a decyloxy group or a hydroxyl group of d- Cyclodecanoyl; adamantyl formyl, substituted adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X 2 is (CH, n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000015_0001
Or R 3 and R 4 are:
Figure imgf000015_0001
其中 R7, R«各自独立为下列任意一种取代基: H; d- 的烷基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的垸基; C2- (:6的烯基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:2-(:6的 烯基; C2- Cfi的炔基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者 三个取代的(:2-(:6的炔基; C3-C6的环垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3-C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡淀基; 含有包括 素原子、 C,-C 烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (^-(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 C,-C4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 C C4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d- ( 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (^-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; -(:6的垸酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 的烷酰基; C2-C6的烯酰基; 含有包括卤素原子、 C,- C6的垸氧基或羟基在内的 任意一个、两个或者三个取代的 C2-C6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 d-C6 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 的炔酰基; C:,- Ce的环烷酰基; 含有包括卤素原子、 d-c6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C3-CB的 环垸酰基; 金刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH , n为 0-2; 0; S或者 NH; 为((¾)„, n为 0-2 ; 0; S或者 NH; Wherein R 7 and R« are each independently a substituent of any of the following: H; d-alkyl; any one, two or three substituted groups including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group. a fluorenyl group of d-; a C 2 - (: 6 alkenyl group; any one, two or three substituted groups including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group (: 2 - (: 6 ) Alkenyl; C 2 -C fi alkynyl; any one, two or three substituted (including 2 -(: 6 alkynyl; C) containing a halogen atom, a decyloxy group or a hydroxyl group of d- a 3 -C 6 cyclodecyl group; any one, two or three substituted C 3 -C 6 cyclodecyl groups containing a halogen atom, a C,-C 6 decyloxy group or a hydroxyl group; an aryl group; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing arginyl, C, -C alkyl, nitro, carboxy, aldehyde, alkoxy, amine, amide Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; ^ - (: any alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including 4, two or three a substituted pyridyl group; containing an alkyl group including a halogen atom, C, -C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethyl sulfide Any one, two or three substituted furanyl groups including a halogen atom; a sulfhydryl group including a halogen atom, CC 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, Any one, two or three substituted pyranyl groups including a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, a decyloxy group, Any one, two or three substituted thienyl groups including an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; and a halogen atom, (^-(: 4 alkyl group), Nitro, carboxyl, aldehyde, decyloxy, amine, amide, carbonyl Any one, two or three substituted pyrrolyl groups including an amine group, a fluorenyl group, a methylthio group, an ethylthio group; -(: 6 decanoyl group; a decyloxy group having a halogen atom, d- or a hydroxyl group; Any one, two or three substituted alkanoyl groups; a C 2 -C 6 alkenoyl group; any one or two containing a halogen atom, a C, a C 6 -oxy group or a hydroxyl group or a three-substituted C 2 -C 6 alkenoyl group; a C 2 -C 6 alkynyl group; any one, two or three substituted alkyne containing a halogen atom, a decyloxy group or a hydroxyl group of dC 6 An acyl group; a cycloalkanoyl group of C:,-C e ; a C 2 -CB cyclodecanoyl group containing a halogen atom, an alkoxy group of dc 6 or a hydroxyl group; adamantane; Formyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X, (CH, n is 0-2; 0; S or NH ; Is ((3⁄4)„, n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000016_0001
Or R 3 and R 4 are:
Figure imgf000016_0001
其中 R9为下列任意一种取代基: H; 的垸基; 含有包括卤素原子、 -C 垸氧基 或羟基在内的任意一个、 两个或者三个取代的 (;-(:6的垸基; ^- 的烯基; 含有包括卤素 原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的烯基; C2-C 炔基;含有包括卤素原子、 C Ce的烷氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3-C6的环烷基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 C3-C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 Ct- C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C, - (:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 -(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 -(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 d- c4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; c,- c6的烷酰基; 含 有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的烷 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 d- (:6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素 原子、 c,- c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3- c6的环垸酰基; 金 刚烷甲酰基、 取代金刚烷甲酰基; .芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 乂1为(012)„, n为 0- 2; 0; S或者 NH; Wherein R 9 is any one of the following substituents: H; an fluorenyl group; any one, two or three substituted groups including a halogen atom, a -C methoxy group or a hydroxyl group (;-(: 6垸) Any one, two or three substituted C 2 - (: 6 alkenyl; C 2 -C alkynyl group containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; Any one, two or three substituted C 2 -C 6 alkynyl groups including a halogen atom, an alkoxy group of C Ce or a hydroxyl group; a C 3 -C 6 cycloalkyl group; containing a halogen atom Any one, two or three substituted C 3 -C 6 cycloalkyl groups of d- alkoxy or hydroxy; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl a pyridyl group; a fluorenyl group containing a halogen atom, C t - C 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group Any one, two or three substituted aryl groups; containing a halogen atom, C, - (: 4 sulfhydryl, nitro, carboxyl Any one, two or three substituted pyridyl groups, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, d- Any one, two or three substituted furanyl groups including a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, and an ethylthio group. Containing any one including a halogen atom, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, ethylthio group) , two or three substituted pyranyl groups; containing a halogen atom, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, fluorenyl group, A Any one, two or three substituted thienyl groups including a thio group or an ethylthio group; containing an alkyl group including a halogen atom, d-c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, Amido, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted pyrrolyl groups; c, - c 6 alkanoyl group; any one, two or three substitutions including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group Alkanoyl group of d-; enoyl group of c 2 -c 6 ; enoyl group of any one, two or three substituted c 2 -c 6 containing a halogen atom, a decyloxy group or a hydroxyl group of d- a C 2 -C 6 alkynyl group; a acetylenic group having any one, two or three substituted c 2 - c 6 groups including a halogen atom, d- (: 6 decyloxy group or hydroxyl group; c 3 ; a cyclodecanoyl group of -c 6 ; any one, two or three substituted c 3 - c 6 cyclodecanoyl groups including a halogen atom or a hydroxyl group of c, - c 6 ; Acyl, substituted adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; 乂1 is (01 2 ) „, n is 0-2; Or NH;
或者 R3, 分别为:
Figure imgf000016_0002
Or R 3, respectively:
Figure imgf000016_0002
其中 Rw, R„各自独立为下列任意一种取代基: H; (:6的垸基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C,-C6的垸基; C2-Ce的烯基; 含有包括卤素原子、 C'-Ce的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的 烯基; c2- 的炔基; 含有包括卤素原子、 c,-ce的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 c2-c6的炔基; c3-c6的环垸基; 含有包括卤素原子、 c,- ce的烷氧基或羟基在内 的任意一个、两个或者三个取代的 c3-c6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d-c4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 d-c4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 c,- c4的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括 素原子、 c「c4 垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基;Wherein R w , R „ each independently is any one of the following substituents: H; (: 6 fluorenyl; any one, two or three containing a halogen atom, a decyloxy group or a hydroxyl group of d-Ce) Substituted C, -C 6 fluorenyl; C 2 -C e alkenyl; any one, two or three substituted C 2 containing a halogen atom, a C'-Ce alkoxy group or a hydroxyl group -C 6 alkenyl; c 2 -alkynyl; any one, two or three substituted c 2 -c 6 alkyne containing a halogen atom, c,-c e or a hydroxyl group a c ring group of c 3 -c 6 ; an alkoxy group or a hydroxyl group including a halogen atom, c, - c e Any one, two or three substituted c 3 -c 6 cyclodecyl; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, dc 4 Any one, two or three substituted aryl groups including a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group Containing a halogen atom, (^-(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, ethylthio group) Any one, two or three substituted pyridyl groups; containing an alkyl group including a halogen atom, dc 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methyl sulfide Any one, two or three substituted furanyl groups including a thiol group; a thiol group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, Amide, carboxamide, sulfhydryl, methylthio, ethylthio Is intended one, two or three of the substituents pyranyl; comprising pigment containing atoms, C "c 4 embankment group, a nitro group, a carboxyl group, an aldehyde group, embankment group, an amine group, an amide group, a carbonamide group, a mercapto group, Any one, two or three substituted thienyl groups including a methylthio group and an ethylthio group; containing a halogen atom, (: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, Any one, two or three substituted pyrrolyl groups such as an amide group, a carboxamide group, a fluorenyl group, a methylthio group or an ethylthio group;
C,-C6的垸酰基; 含有包括卤素原子、 CrCe的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 d-c 的烷酰基; c2-c6的烯酰基; 含有包括卤素原子、 d- (:6的垸氧基或羟基在内的 任意一个、 两个或者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 c,-^ 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环烷酰基; 含有包括卤素原子、 C 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C3- (;6的 环垸酰基; 金刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH2)„, n为 0-2; 0; S或者 NH; 为(CH ' n为 0- 2; 0; S或者 NH。 a decanoyl group of C, -C 6 ; an alkanoyl group of any one, two or three substituted dcs including a halogen atom, an alkoxy group of CrCe or a hydroxyl group; an alkenoyl group of c 2 -c 6 ; a halogen atom, d- (: any embankment 6 alkoxy or hydroxy, including one, two or three substituents of c 2 -c 6 alkenyl group; a c 2 -c 6 alkynyl group; a halogen atom-containing include, Any one, two or three substituted c 2 -c 6 alkynyl groups of c, -^ alkoxy or hydroxy; c 3 -c 6 cycloalkanoyl; containing an alkane including a halogen atom, C Any one, two or three substituted C 3 - (; 6 cyclodecanoyl; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyr Noryl; thiophene; pyrroyl; X, (CH 2 ), n is 0-2; 0; S or NH ; (CH ' n is 0-2; 0; S or NH.
当 R,, R2分别各自独立为:
Figure imgf000017_0001
其中 R15, Rie各自独立为下列任意一种取代基: H; 的垸基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C,- C6的烷基; C2-C6的烯基; 含有包括卤素原子、 CrCe的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2- ( 6的 烯基; C2-C6的炔基; 含有包括卤素原子、 C「C6的烷氧基或羟基在内的任意一个、 两个或者 三个取代的(:2-(:6的炔基; C3- Cfi的环烷基; 含有包括卤素原子、 d- 的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3-C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (^的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 - 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 C- C4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 _( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 d- (:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; c,-c6的垸酰基; 含有包括卤素原子、 c,-cfi的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 d- 的垸酰基; ( C6的烯酰基; 含有包括卤素原子、 - 的烷氧基或羟基在内的 任意一个、两个或者三个取代的 c2- c6的烯酰基; c2-ce的炔酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、两个或者三个取代的 c2- c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 ( Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3-C6的 环垸酰基; 金刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH2) n, n为 0-2; 0; S或者 NH; 为(CH2)„, n为 0- 2; 0; S或者 NH时,
When R, R 2 are each independently:
Figure imgf000017_0001
Wherein R 15 , R ie are each independently a substituent of any of the following: H; an fluorenyl group; any one, two or three substituted Cs including a halogen atom, a decyloxy group or a hydroxyl group of d-, An alkyl group of C 6 ; a C 2 -C 6 alkenyl group; any one, two or three substituted C 2 - ( 6 alkenyl groups) containing a halogen atom, an alkoxy group of CrCe or a hydroxyl group; a C 2 -C 6 alkynyl group; any one, two or three substituted groups including a halogen atom, C "C 6 alkoxy group or a hydroxyl group (: 2 - (: 6 alkynyl group; C 3) a cycloalkyl group of C fi ; a C 2 -C 6 cyclodecyl group containing a halogen atom, a decyloxy group or a hydroxyl group including d-; an aryl group; a benzyl group; Furanyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing fluorenyl group including a halogen atom, d-C 4 , nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group Any one, two or three substituted aryl groups including a mercapto group, a methylthio group, an ethylthio group; Any one, two or three substituted alkyl groups of the alkyl group, the nitro group, the carboxyl group, the aldehyde group, the decyloxy group, the amine group, the amide group, the carboxamide group, the thiol group, the methylthio group and the ethylthio group. Pyridyl; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, a Any one, two or three substituted furanyl groups including a thio group; a fluorenyl group including a halogen atom, C-C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carbon group amide groups, mercapto, methylthio, ethylthio, including one, two or three of the substituents pyranyl; containing a halogen atom include, _ (4 embankment group, a nitro group, a carboxyl group, an aldehyde group, embankment Any one, two or three substituted thienyl groups including an oxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; and a fluorene group including a halogen atom, d- (: 4 ) Any one, two or three substituted pyrrolyl groups including a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a decanoyl group of -c 6 ; a decanoyl group having any one, two or three substituted d- groups including a halogen atom, c, -c fi alkoxy group or a hydroxyl group; (C 6 enoyl group; Any one or two containing a halogen atom, an alkoxy group or a hydroxyl group Or three substituted c 2 - c 6 enoyl groups; c 2 - c e acetylene groups; containing any one, two or three substitutions including a halogen atom, a decyloxy group of d- or a hydroxyl group a acetylene group of c 2 - c 6 ; a cyclodecanoyl group of c 3 -c 6 ; a C 3 -C 6 containing any one, two or three substituents including a halogen atom, a decyloxy group or a hydroxyl group of Ce Cyclodecanoyl; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X, (CH 2 ) n , n 0-2; 0; S or NH; is (CH 2 ) „, n is 0- 2; 0; S or NH,
R3, 分别为:
Figure imgf000018_0001
R 3 , respectively:
Figure imgf000018_0001
其中 R6为下列任意一种取代基: H; d- ( 6的垸基; 含有包括卤素原子、 C「 C6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 C,- (:6的烷基; C2- Cfi 烯基; 含有包括卤素 原子、 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- Cfi的烯基; C2-C6的 炔基;含有包括卤素原子、 的垸氧基或羟基在内的任意一个、两个或者三个取代的 c2-c6 的炔基; C3-Ce的环垸基; 含有包括卤素原子、 的垸氧基或羟基在内的任意一个、 两个 或者三个取代的( 3-(:6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 Cr C4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C, - 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- ( 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、(:,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 C,-C4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 d-C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- C6的烷酰基; 含 有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的垸 酰基; c2-ce的烯酰基; 含有包括卤素原子、 c,-c6的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2- c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 c「 c6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3-c6的环烷酰基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环烷酰基; 金 刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 为(CH2) n, n为 0- 2; 0; S或者 NH; Wherein R6 is any of the following substituent groups: H; d- (group 6 of the embankment; includes any containing a halogen atom, C "C 6 alkoxy or hydroxy embankment inner one, two or three substituents of C, - (: 6 alkyl; C 2 - C fi alkenyl group; or a hydroxyl group optionally having embankment include a halogen atom, the inner one, two or three substituents of C 2 - C fi alkenyl; C a 2- C6 alkynyl group; any one, two or three substituted c 2 -c 6 alkynyl groups including a halogen atom, a decyloxy group or a hydroxyl group; a C 3 -C e cyclodecyl group; Any one, two or three substituted ( 3 -(: 6 cyclodecyl; aryl; benzyl; furyl; pyranyl; thiophene) containing a halogen atom, a decyloxy group or a hydroxyl group; a pyrrolyl group; a pyridyl group; an alkyl group including a halogen atom, Cr C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethyl sulfide Any one, two or three substituted aryl groups, including a halogen atom, a C, a fluorenyl group, a nitro group, a carboxyl group Any one, two or three substituted pyridyl groups including an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, d- ( Any one, two or three substituted furanyl groups including a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, and an ethylthio group. Containing a halogen atom, (:, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, ethylthio group, etc.) Any one, two or three substituted pyranyl groups; containing an alkyl group including a halogen atom, C, -C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group Any one, two or three substituted thienyl groups including a mercapto group, a methylthio group, an ethylthio group; a mercapto group including a halogen atom, dC 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group Base, amide group, carboxamide group, sulfhydryl group, methylthio group, B Group, including any one, two or three substituents pyrrolyl; dC 6 alkanoyl; include a halogen atom-containing, dC e embankment any group or hydroxyl group, including one, two or three substituents D- of 垸 An acyl group; an alkenoyl group of c 2 -c e ; an acyl group of any one, two or three substituted c 2 - c 6 containing an alkoxy group or a hydroxyl group including a halogen atom, c, -c 6 ; 2 -c 6 alkynyl group; a halogen atom include any containing, c "c embankment 6 alkoxy or hydroxy, including one, two or three substituents of c 2 - 6 alkynyl group c; c 3 -c 6 a cycloalkanoyl group; any one, two or three substituted c 3 -c 6 cycloalkanoyl groups including a halogen atom, a decyloxy group of d- or a hydroxyl group; an adamantyl formyl group, a substituted diamond rim Acyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; (CH 2 ) n , n is 0- 2; 0; S or NH ;
或者 R3, 分别为:
Figure imgf000019_0001
Or R 3 , respectively:
Figure imgf000019_0001
其中 R7, R8各自独立为下列任意一种取代基: H; d-Ce的垸基; 含有包括卤素原子、 C Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- C6的垸基; C2-C6的烯基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (:2-(:6的 烯基; C2-C6的炔基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2-C6的炔基; C3-C6的环烷基; 含有包括卤素原子、 C,- C6的烷氧基或羟基在内 的任意一个、两个或者三个取代的 C3-Cfi的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (:,-( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C,- C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 -(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d-C4的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d- C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (^-(;4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-Ce的烷酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 d-Ce的烷酰基; c2-c6的烯酰基; 含有包括卤素原子、 Cr"C6的烷氧基或羟基在内的 任意一个、 两个或者三个取代的 c2-c6的烯酰基; c2- c6的炔酰基; 含有包括卤素原子、 c,-c6 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或者三个取代的 (:3-(:6的 环烷酰基; 金刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH , π为 0- 2; 0; S或者 NH; 为(CH , n为 0- 2; 0; S或者 NH; 或者 R3, R4分别为:
Figure imgf000020_0001
Wherein R 7 and R 8 are each independently a substituent of any of the following: H; a fluorenyl group of d-Ce; any one, two or three substituents including a halogen atom, a hydroxyl group of CC e or a hydroxyl group; a d-C 6 fluorenyl group; a C 2 -C 6 alkenyl group; any one, two or three substituted (including 2 -(:) containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; 6 alkenyl; C 2 -C 6 alkynyl group; a halogen atom-containing optionally include, d- or hydroxyl group of the embankment, including one, two or three substituents of C 2 -C 6 alkynyl group; a C a 3- C 6 cycloalkyl group; a C 2 -C fi cyclodecyl group containing an alkoxy group or a hydroxyl group including a halogen atom, C, or C 6 ; an aryl group; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, (:, -( 4 fluorenyl, nitro, carboxyl, aldehyde, decyloxy, amine, Any one, two or three substituted aryl groups including an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; , C, - C 4 alkyl with arbitrary, a nitro group, a carboxyl group, an aldehyde group, embankment group, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including one, two, or a three-substituted pyridyl group; containing a halogen atom, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carboxamide group, mercapto group, methylthio group, ethyl sulfide Any one, two or three substituted furanyl groups including a halogen atom; a sulfhydryl group including a halogen atom, dC 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, Any one, two or three substituted pyranyl groups including a mercapto group, a methylthio group, an ethylthio group; a mercapto group including a halogen atom, d-C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group Any one, two or three substituted thienyl groups, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; and an alkyl group including a halogen atom, (^-(; 4 ) , nitro, carboxyl, aldehyde, alkoxy, amine, amide, carbon Any one, two or three substituted pyrrolyl groups such as an amide group, a fluorenyl group, a methylthio group or an ethylthio group; an alkanoyl group of d-Ce; a fluorenyl group containing a halogen atom, d- or a hydroxyl group Any one, two or three substituted d-Ce alkanoyl groups; c 2 -c 6 alkenoyl groups; any one or two containing a halogen atom, a Cr "C 6 alkoxy group or a hydroxyl group Or three substituted c 2 -c 6 alkenoyl groups; c 2 - c 6 alkynyl groups; any one, two or three containing a halogen atom or a hydroxyl group including a halogen atom, c, -c 6 Substituted c 2 -c 6 alkynyl; c 3 -c 6 cyclodecanoyl; any one, two or three substituted (including a halogen atom, an alkoxy group of d-Ce or a hydroxyl group): 3- (: 6 cycloalkanoyl; adamantyl, substituted adamantyl form; aroyl; benzyl; furanoyl; pyranoyl; thiophene; pyrroyl; X, (CH, π is 0-2; 0; S or NH; is (CH, n is 0-2; 0; S or NH; Or R 3 and R 4 are:
Figure imgf000020_0001
其中 R9为下列任意一种取代基: H; C,- Cfi的垸基; 含有包括卤素原子、 -^的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 C「 C6的垸基; C2- 的烯基; 含有包括卤素 原子、 (「(:6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的烯基; C2-C6的 炔基;含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、两个或者三个取代的 C2-Ce 的炔基; C3-C6的环垸基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个 或者三个取代的(:3- C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (,-( 4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 -( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- (^的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的呋喃基; 含有包括卤素原子、 c4的垸基、 硝基、羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 -( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括 素原子、 C,- (:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- c6的垸酰基; 含 有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c,-c6的烷 酰基; C2_C6的烯酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 的烯酰基; C2_C6的炔酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-ce的炔酰基; c3-cB的环烷酰基; 含有包括卤素 原子、 c,-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环垸酰基; 金 刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 为(CH2) n, n为 0- 2; 0; S或者 NH; Wherein R 9 is any one of the following substituents: H; C, -C fi fluorenyl; any one, two or three substituted C's including a halogen atom, a -oxy group or a hydroxyl group C 6 fluorenyl; C 2 -alkenyl; containing any one, two or three substituted C 2 - (: 6 olefins including a halogen atom, (": 6 decyloxy or hydroxy group a C 2 -C 6 alkynyl group; any one, two or three substituted C 2 -C e alkynyl groups including a halogen atom, an alkoxy group of d- or a hydroxyl group; C 3 -C embankment 6 cycloalkyl group; a halogen atom-containing optionally include, d- alkoxy or hydroxy group including one, two or three substituents of (: 3 - C 6 cycloalkyl; aryl; benzyl; furan group; tetrahydropyranyl; thienyl; pyrrolyl; pyridyl; include a halogen atom-containing, (, - (alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide group 4 , any mercapto, methylthio, ethylthio, including one, two or three aryl group substituents; include a halogen atom-containing, - (4 embankment group, Any one, two or three substituted pyridyl groups including a carboxy group, a carboxy group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three of d-(^ thiol, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio a substituted furanyl group; containing a halogen atom, a sulfhydryl group of c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group Any one, two or three substituted pyranyl groups; containing a halogen atom, -( 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, fluorenyl group) , methylthio, ethylthio, including any one, two or three substituents thienyl; comprising pigment containing atoms, C, - (: 4 alkyl, nitro, carboxyl, aldehyde, alkoxy , amine group, amide group, carboxamide group, sulfhydryl group, methylthio group, Any one, two or three substituted pyrrolyl groups including an ethylthio group; a decanoyl group of d-c 6 ; any one, two or three containing a halogen atom, a decyloxy group or a hydroxyl group of d- a substituted alkanoyl group of c, -c 6 ; an enoyl group of C 2 -C 6 ; any one, two or three substituted enoyl groups including a halogen atom, a decyloxy group of d-Ce or a hydroxyl group Alkynyl group of C 2 _C 6 ; acetylene group of any one, two or three substituted c 2 -c e containing a halogen atom, a decyloxy group or a hydroxyl group of d-Ce; c 3 -c B a cycloalkanoyl group; any one, two or three substituted c 3 -c 6 cyclodecanoyl groups including a halogen atom or a hydroxyl group of c, -c 6 ; adamantyl formyl group, substituted Adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; (CH 2 ) n , n is 0-2; 0; S or NH;
或者 R3, ^分别为- Kxi RiOr R 3 , ^ are - K x i Ri respectively .
X2R11 X 2 R 11
其中 Rin, Ru各自独立为下列任意一种取代基: H; C,- 的烷基; 含有包括卤素原子、 C「C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的烷基; C2- (^的烯基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- Cs的 烯基; c2-c6的炔基; 含有包括卤素原子、 c,-^的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 c2- C6的炔基; C3- C6的环垸基; 含有包括卤素原子、 C- 的烷氧基或羟基在内 的任意一个、两个或者三个取代的 c3-c6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 c,-c4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d-c4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 c,-c4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d- 的垸基、 硝基、羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括 素原子、 c「c4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; c,-c6的烷酰基; 含有包括卤素原子、 d-c6的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 Cr"C6的垸酰基; C2-C6的烯酰基; 含有包括卤素原子、 d-C6的烷氧基或羟基在内的 任意一个、 两个或者三个取代的 C2-C6的烯酰基; C2-C6的炔酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2-cfi的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 c,-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3- (:6的 环垸酰基; 金刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH , n为 0- 2; 0; S或者 NH; X2为(CH , n为 0- 2; 0; S或者 NH。 Wherein R in, Ru are each independently any of the following substituent groups: H; C, - alkyl; containing optionally include halogen atoms, C "C 6 alkoxy or hydroxy, including one, two or three Substituted d-alkyl; C 2 -(^ alkenyl; any one, two or three substituted C 2 - C s containing a halogen atom, a decyloxy group or a hydroxyl group of d- Alkenyl; C 2 -C 6 alkynyl group; a halogen atom include containing, C, - ^ alkoxy or hydroxy embankment any inner one, two or three substituents of c 2 - C 6 alkynyl group; a C a cycloalkyl group of 3 - C 6 ; any one, two or three substituted c 3 -c 6 cycloalkyl groups including a halogen atom, an alkoxy group of C- or a hydroxyl group; an aryl group; a benzyl group ; furanyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing fluorenyl group including a halogen atom, c, -c 4 , nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carbon Any one, two or three substituted aryl groups including an amide group, a fluorenyl group, a methylthio group, an ethylthio group; a thiol group including a halogen atom, dc 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group Any one, two or three substituted pyridyl groups, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; a fluorenyl group containing a halogen atom, c, -c 4 , Nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethyl sulphide Any one, two or three substituted furanyl groups; including halogen atom, alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, sulfhydryl group, methyl sulfide Any one, two or three substituted pyranyl groups including a thiol group; a fluorenyl group including a halogen atom, d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group , any carbon amide group, a mercapto group, methylthio, ethylthio, including one, two or three substituents thienyl; comprising pigment containing atoms, c "c 4 alkyl with a nitro group, a carboxyl group, an aldehyde group Any one, two or three substituted pyrrolyl groups, an alkoxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; an alkanoyl group of c, -c 6 ; Any one, two or three substituted Cr"C 6 decanoyl groups including a halogen atom, a dc 6 alkoxy group or a hydroxyl group; a C 2 -C 6 enoyl group; containing a halogen atom, dC 6 Any one, two or three of alkoxy or hydroxy a C 2 -C 6 alkenoyl group; a C 2 -C 6 alkynyl group; any one, two or three substituted c 2 -c containing a halogen atom, a decyloxy group or a hydroxyl group of d- fi alkynyl group; c 3 -c 6 cycloalkyl group embankment; includes any halogen atom-containing, C, -C 6 alkoxy or hydroxy embankment inner one, two or three substituents of C 3 - (: 6 Cyclodecanoyl; adamantyl, substituted adamantyl; aroyl; benzyl; furanoyl; pyranoyl; thiophene; pyrrolyl; X, (CH, n 0-2 0; S or NH; X 2 is (CH, n is 0-2; 0; S or NH.
另外优选地,该类化合物或其在药物学上可接受的盐是以药物组合物的形式,或单独, 或与药物学上可接受的载体或赋形剂联合提供。 本发明还提供了包括上述化合物的药物, 用于预防和 /或治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心 血管疾病和神经退行性疾病 (如 Alzheimer' s病) 等。  Further preferably, the compound or a pharmaceutically acceptable salt thereof is provided in the form of a pharmaceutical composition, either alone or in combination with a pharmaceutically acceptable carrier or excipient. The invention also provides a medicament comprising the above compound for preventing and/or treating metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases (eg Alzheimer's) Ill).
再一方面, 本发明涉及预防和 /或治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰 岛素抵抗和肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s病) 等的方法。 该 方法包括对需要或愿意接受治疗或预防的对象, 给予有效量的、 选择性地调节胰高血糖素 样肽一 1受体的化合物或其药物学上可接受的盐, 以预防或治疗上述疾病或症状。优选地, 上述代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血管疾病和神 经退行性疾病 (如 Alzheimer' s病) 等通过给予有效量的由以下通式 I或 II表示的化合 物或其药物学上可接受的盐来预防或治疗:
Figure imgf000022_0001
In a further aspect, the invention relates to methods of preventing and/or treating metabolic disorders, including but not limited to diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease. The method comprises administering to a subject in need or willing to receive treatment or prevention an effective amount of a compound which selectively modulates the glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof for preventing or treating the above Disease or symptom. Preferably, the above metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases (such as Alzheimer's disease), etc., by administering an effective amount of the following Formula I or a compound represented by II or a pharmaceutically acceptable salt thereof for prevention or treatment:
Figure imgf000022_0001
及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化 物或其金属配合物。 And all of its stereo and optical isomers, or prodrugs having the same pharmacological effects, esters thereof, solvates thereof or metal complexes thereof.
其中 X和 Y 分别为(CH , n为 0-2; 0; S或者. NH。  Where X and Y are respectively (CH, n is 0-2; 0; S or .NH.
其中 R,, R2各自独立地为下列任意一种取代基: 氢; 卤素; 垸烃; 环垸经; 羟基; 硝 基; 羧基; 醛基; 烷氧基; 胺基; 胺垸基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基。 Wherein R, R 2 are each independently one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxyl; aldehyde; alkoxy; amine; amidoxime; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
R3, R4各自独立地为下列任意一种取代基: 氢; 垸烃; 环垸烃; 垸氧基; 胺基; 胺垸 基; 酰胺基; 碳酰胺基; 烷硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 R 3 , R 4 are each independently any one of the following substituents: hydrogen; anthracene; cyclononene; anthracene; amine; amidoxime; amide; carboxamide; alkylthio; Substituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
另一方面, 本发明涉及联合制剂, 该联合制剂包括一种具有选择性调节胰高血糖素样 肽一 1 受体, 尤其是激活该受体功能的化合物, 或其药物学上可接受的盐, 或单独, 或与 药物学上可接受的载体或赋形剂组合存在。 该化合物具有以下通式 I或 II的结构:  In another aspect, the present invention relates to a combination preparation comprising a compound having a selective modulation of a glucagon-like peptide-1 receptor, particularly a function of activating the receptor, or a pharmaceutically acceptable salt thereof Or alone or in combination with a pharmaceutically acceptable carrier or excipient. This compound has the structure of the following formula I or II:
Figure imgf000022_0002
Figure imgf000022_0002
及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化物或 其金属配合物。 And all of its stereo and optical isomers, or prodrugs, esters, solvates or metal complexes thereof having the same pharmacological action.
其中 X和 Y 分别为(CH , n为 0- 2; 0; S或者 NH。  Where X and Y are respectively (CH, n is 0-2; 0; S or NH.
其中 , R2各自独立地为下列任意一种取代基: 氢; 卤素; 垸烃; 环垸烃; 羟基; 硝 基; 羧基; 醛基; 垸氧基; 胺基; 胺垸基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基。 Wherein R 2 is each independently any one of the following substituents: hydrogen; halogen; anthracene; a cyclic hydrocarbon; a hydroxyl group; a nitro group; a carboxyl group; an aldehyde group; an anthracene group; an amine group; an amine group; an amide group; Carboxamide; fluorenyl; sulfhydryl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
R3, 各自独立地为下列任意一种取代基: 氢; 垸烃; 环垸烃; 烷氧基; 胺基; 胺烷 基; 酰胺基; 碳酰胺基; 烷硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 R 3 , each independently of any of the following substituents: hydrogen; anthracene; cyclononene; alkoxy; amine; alkane Amide; carboxamide; alkylthio; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted a thienyl group; a substituted or unsubstituted pyrrolyl group.
本发明提供了包括上述联合制剂的药盒。 本发明还进一歩提供了应用上述联合制剂用 于预防和 /或治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血 管疾病和神经退行性疾病 (如 Alzheimer' s病) 等, 达到选择性地激动胰高血糖素样肽一 1受体的药效, 改善患者的症状和生命质量。  The present invention provides a kit comprising the above combined preparation. The present invention further provides the use of the above combined preparations for the prevention and/or treatment of metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases (eg Alzheimer's). Disease, etc., to achieve selective stimulation of the glucagon-like peptide-1 receptor, improve the patient's symptoms and quality of life.
为了阐明发明内容且不受其局限, 对发明分成以下几个小节进行详细描述。  In order to clarify the contents of the invention and not to be limited thereto, the invention will be described in detail in the following subsections.
A定义  A definition
除非另有定义, 本发明所用的技术和科学上的术语, 与本发明所属领域的通用技术的 一般理解具有相同意义。 本处提到的来源于基因库和其他数据库的所有专利, 申请, 公布 的申请和其他出版物和序列被全面收入引用作为参考。 如果本节阐明的定义与本专利参用 的来源于基因库和其他数据库的所有专利, 申请, 公布的申请和其他出版物和序列被收入 和引用的定义阐述相反, 或不一致时, 以本节阐明的定义为准。  The technical and scientific terms used in the present invention have the same meaning as the general understanding of the general art in the field to which the invention pertains, unless otherwise defined. All patents, applications, published applications and other publications and sequences derived from the Gene Bank and other databases referred to herein are referenced in full revenue. If the definitions set forth in this section are inconsistent with, or inconsistent with, all patents, applications, published applications, and other publications and sequences derived from the Gene Bank and other databases referenced in this patent, or inconsistent, The definition of clarification shall prevail.
本文所用, "一"或 "一个"指 "至少一个" 或 "一个或多个" 。  As used herein, "a" or "an" refers to "at least one" or "one or more."
本文所用, "代谢紊乱性疾病"系指由各种原因造成的糖、 脂肪或蛋白质等代谢失调 而引起的相关症状和 /或疾病。  As used herein, "metabolic disorder" refers to a related symptom and/or disease caused by metabolic disorders such as sugar, fat or protein caused by various causes.
本文所用, "糖尿病"指一种多病因的代谢性疾病, 特点是慢性高血糖, 伴随因胰岛 素分泌及 /或作用缺陷引起的糖、 脂肪和蛋白质代谢紊乱。 随着糖尿病得病时间的延长, 身体内的代谢紊乱如得不到很好地控制, 可导致眼、 肾、 神经、 血管和心脏等组织等器官 的慢性并发症, 以致最终发生失明、 下肢坏疽、 尿毒症、 脑中风或心肌梗死, 甚至危及生 命。  As used herein, "diabetes" refers to a multi-pathogenic metabolic disease characterized by chronic hyperglycemia accompanied by disorders of sugar, fat and protein metabolism caused by insulin secretion and/or dysfunction. As the time of diabetes is prolonged, the metabolic disorders in the body are not well controlled, leading to chronic complications of tissues such as the eyes, kidneys, nerves, blood vessels and heart, resulting in blindness, gangrene in the lower limbs, Uremic, stroke or myocardial infarction, even life-threatening.
本文所用, "胰岛素抵抗"是指体内周围组织对胰岛素的敏感性降低, 肌肉、 脂肪等 靶组织对胰岛素促进葡萄糖摄取的作用发生了抵抗。胰岛素抵抗普遍存在于 2型糖尿病中, 几乎占 90%以上, 是 2型糖尿病的发病主要因素之一。  As used herein, "insulin resistance" refers to a decrease in the sensitivity of tissues surrounding the body to insulin, and target tissues such as muscles and fats are resistant to insulin-induced glucose uptake. Insulin resistance is prevalent in type 2 diabetes, accounting for more than 90%, and is one of the main factors in the development of type 2 diabetes.
本文所用, "肥胖症"是指体内脂肪的量过多, 男人体重超过理想体重的 25%或女人 体重超过理想体重的 30%的现象。 遗传因素、 下丘脑病患、 内分泌紊乱、 饮食过量和活动 太少都是产生肥胖症的原因。  As used herein, "obesity" refers to an excess of body fat, a male weighing more than 25% of the ideal body weight, or a woman weighing more than 30% of the ideal body weight. Genetic factors, hypothalamic disease, endocrine disorders, overeating and too little activity are all causes of obesity.
本文所用, "阿尔茨海默病 (Alzheimer s Disease, AD, 又称早老性痴呆 Alzheimer' s dementia) 是一种神经系统的进行性蜕变性疾病, 临床上表现为智力水平的慢性削弱及记 忆的慢性丢失。  As used herein, Alzheimer's disease (Alzheimer's disease, also known as Alzheimer's dementia) is a progressive degenerative disease of the nervous system, clinically characterized by chronic impairment of intelligence and memory. Chronic loss.
本文所用, "心血管疾病"包括心脏病、 肺心病、 高血压和高脂血症等。 具有 "发病 率高, 死亡率高, 致残率高, 复发率高" 以及 "并发症多" 的特点。  As used herein, "cardiovascular disease" includes heart disease, pulmonary heart disease, hypertension, and hyperlipidemia. It has the characteristics of "high incidence, high mortality, high disability rate, high recurrence rate" and "more complications".
本文所用的用于治疗某一特定疾病的化合物的 "有效量" 指足够改善或在某种程度 上减轻与此病相伴的症状的量。 这一剂量可以单一剂量给药, 也可按照治疗方案给药。 这 一剂量可治愈疾病, 但典型的是为了改善该症状而给药。 为改善症状重复给药可能是需要 的。 As used herein, an "effective amount" of a compound used to treat a particular disease means sufficient improvement or to some extent Reduce the amount of symptoms associated with this disease. This dose can be administered in a single dose or in accordance with a therapeutic regimen. This dose cures the disease, but is typically administered to improve the condition. Repeated administration to improve symptoms may be desirable.
本文所用, "药物学上可接受的盐、 酯或其他衍生物" 包括领域技术人员用己知方 法易于制备的任何盐, 酯或衍生物。 这样衍生和生成的化合物可对动物和人给药, 不具有 毒性作用。 该化合物或是具有药物活性, 或是药物前体。  As used herein, "pharmaceutically acceptable salts, esters or other derivatives" include any salt, ester or derivative which is readily prepared by one skilled in the art using known methods. The compounds thus derived and produced can be administered to animals and humans without toxic effects. The compound is either pharmaceutically active or a prodrug.
本文所用, "治疗 "指疾病和症状用任何方式得以改善, 或其他有益的改变。 治疗也 包括本发明化合物在药物上的应用。  As used herein, "treatment" means that the disease and symptoms are improved in any way, or other beneficial changes. Treatment also includes the use of the compounds of the invention in medicine.
本文所用, 给予某一特定药物组合物 "改善" 某一特定疾病的症状是指任何减轻, 无论永久的, 临时的, 长时期的, 短暂的, 都能归因于或与该药物组合物的施用有关。  As used herein, administration of a particular pharmaceutical composition to "improve" the symptoms of a particular disease means any reduction, whether permanent, temporary, prolonged, transient, can be attributed to or associated with the pharmaceutical composition. Relevant application.
本文所用, "基本上纯" 是指足够均匀, 通过本领域技术人员为评价纯度使用的标 准分析方法探测不出杂质, 所述标准分析方法有如薄层层析法 (TLC), 凝胶电泳和高效液 相色谱法 (HPLC)。 或者足够纯也指即使进一步纯化也不能改变该物质可探测到的理化特 性, 例如酶活性和生物活性。 用于纯化化合物制得基本上化学纯的方法, 是本领域技术人 员所公知的。 然而基本上化学纯的化合物可以是立体异构体或同分异构体的混合物。 在这 种情况下, 进一步纯化也许会增加化合物的比活性。  As used herein, "substantially pure" means sufficiently uniform that no impurities can be detected by standard analytical methods used by those skilled in the art to evaluate purity, such as thin layer chromatography (TLC), gel electrophoresis, and High performance liquid chromatography (HPLC). Or sufficiently pure also means that even further purification does not alter the physicochemical properties detectable by the substance, such as enzymatic activity and biological activity. Methods for producing substantially chemically pure compounds for purification are well known to those skilled in the art. However, a substantially chemically pure compound can be a stereoisomer or a mixture of isomers. In this case, further purification may increase the specific activity of the compound.
本文所用, "药物前体"是指一种体内给药的化合物, 该化合物可被代谢, 或转化为 生物学上、 药物学上或治疗学上的活性形式。 为了制造药物前体, 药物活性化合物将被修 饰, 使该活性化合物通过代谢过程再产生。 药物前体可被设计成改变其代谢稳定性, 或运 输特性的前体, 以掩盖其副作用或毒性, 改良药物的味觉, 或改变其他特性。 凭借药代动 力学及药物体内代谢的知识, 一旦药物学上活性化合物为已知, 本领域技术人员就可以设 计出该化合物的药物前体。 [参 Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, 1985, pages 388-392]。  As used herein, "prodrug" refers to a compound that is administered in vivo and which can be metabolized or converted into a biologically, pharmaceutically or therapeutically active form. To produce a prodrug, the pharmaceutically active compound will be modified to reproduce the active compound by metabolic processes. Prodrugs can be designed to alter their metabolic stability, or to transport precursors of properties, to mask their side effects or toxicity, to improve the taste of the drug, or to alter other properties. By virtue of pharmacokinetics and knowledge of the metabolism of the drug in the body, once the pharmaceutically active compound is known, one skilled in the art can design a prodrug of the compound. [See Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, 1985, pages 388-392].
术语 "基本上"相同或均勾或相似, 按照本领域技术人员对相关技术的理解可在上下 文中有所改变, 并且一般为至少 70%, 优选为至少 80%, 更优为至少 90%, 最优为至少 95% 相同。  The terms "substantially" are the same or are either hooked or similar, and the understanding of the relevant art may vary in the context, and is generally at least 70%, preferably at least 80%, more preferably at least 90%, The optimal is at least 95% identical.
这里所用的 "组合物"指任何混合物。 可以是溶液、 混悬液、 液体、 粉末、 油膏、 水 性的、 非水性的或它们的任何组合。  As used herein, "composition" refers to any mixture. It may be a solution, suspension, liquid, powder, ointment, aqueous, non-aqueous or any combination thereof.
这里所用的 "联合"指两种或多种之间的任何联合。  As used herein, "union" refers to any association between two or more.
这里使用的术语 "对象"包括人和动物, 例如, 狗, 猫, 牛, 猪, 啮齿动物等。 有经 验的实施者应可理解对象为适于并愿意对代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛 素抵抗和肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s 病) 等进行治疗和预 防。  The term "object" as used herein includes humans and animals, for example, dogs, cats, cows, pigs, rodents, and the like. Experienced practitioners should understand that the subject is suitable and willing to deal with metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular disease and neurodegenerative diseases (such as Alzheimer's disease). Treatment and prevention.
这里使用的任何保护性基团, 氨基酸和其他化合物的缩写, 与它们通用的、 公认的缩 写或 IUPAC- IUB委员会颁布生化命名一致, 除非特别说明。 B胰高血糖素样肽一 1受体调节剂 Any of the protective groups, abbreviations of amino acids and other compounds used herein, are consistent with their general, recognized abbreviations or the biochemical nomenclature issued by the IUPAC-IUB Commission, unless otherwise stated. B glucagon-like peptide-1 receptor modulator
本发明提供胰高血糖素样肽一 1受体功能的调节剂,增加了预防和 /或治疗代谢紊乱性 疾病(包括但不局限于糖尿病、胰岛素抵抗和肥胖症)、 心血管疾病和神经退行性疾病(如 The present invention provides a modulator of glucagon-like peptide-1 receptor function, which increases the prevention and/or treatment of metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases. Sexual diseases (such as
Alzheimer' s病)等药物的成员。 本发明涉及由以下通式 I或 II表示的化合物, 或其药物 学上可接受的盐: Member of the drug such as Alzheimer's disease. The present invention relates to a compound represented by the following formula I or II, or a pharmaceutically acceptable salt thereof:
Figure imgf000025_0001
Figure imgf000025_0001
及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化物或 其金属配合物。 And all of its stereo and optical isomers, or prodrugs, esters, solvates or metal complexes thereof having the same pharmacological action.
其中 X和 Y 分别为(CH , n为 0- 2; 0; S或者 NH。  Where X and Y are respectively (CH, n is 0-2; 0; S or NH.
其中 Rt, R2各自独立地为下列任意一种取代基: 氢; 卤素; 垸烃; 环垸烃; 羟基; 硝 基; 羧基; 醛基; 垸氧基; 胺基; 胺烷基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基。 Wherein R t , R 2 are each independently any one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxy; aldehyde; methoxy; amine; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
R3, R4各自独立地为下列任意一种取代基: 氢; 垸烃; 环垸烃: 垸氧基; 胺基; 胺垸 基; 酰胺基; 碳酰胺基; 垸硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 R 3 , R 4 are each independently any one of the following substituents: hydrogen; anthracene hydrocarbon; a cyclic anthracene: anthracenyloxy; an amine group; an amine group; an amide group; a carboxamide group; a thiol group; Substituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
本发明的化合物可以是一个特定的立体异构体, 例如 R-或 S-构型, 或它们的混合物, 例如, 外消旋混合物。 这里考虑的化合物包括所有具有药物活性的化合物种类, 或其溶液 或混合物。 还包括其水合类型, 例如这些化合物的水溶液, 水解产物或电离产物; 并且这 些化合物可含有不同数量的结合水分子。  The compound of the present invention may be a specific stereoisomer, such as the R- or S-configuration, or a mixture thereof, for example, a racemic mixture. The compounds contemplated herein include all classes of pharmaceutically active compounds, or solutions or mixtures thereof. Also included are hydration types thereof, such as aqueous solutions, hydrolysates or ionized products of these compounds; and these compounds may contain different amounts of bound water molecules.
本发明的化合物可按照任何合适的方法来制备或合成。 优选地, 用以下面 F节中引证 的合成法制备该化合物。  The compounds of the invention may be prepared or synthesized according to any suitable method. Preferably, the compound is prepared by the synthetic method cited in Section F below.
另外优选地,该化合物或其药物学上可接受的盐以药物组合物的形式提供,或者单独, 或者与一种药物学上可接受的载体或赋形剂结合。  Further preferably, the compound or a pharmaceutically acceptable salt thereof is provided in the form of a pharmaceutical composition, either alone or in combination with a pharmaceutically acceptable carrier or excipient.
本发明的化合物可用任何合适的酸以其药物学上可接受的盐的形式来制备。 例如, 无 机酸如盐酸、 氢溴酸、 硝酸、 硫酸、 磷酸等; 有机酸诸如甲酸、 乙酸、 丙酸、 苯甲酸、 马 来酸、 富马酸、 琥珀酸、 酒石酸、 柠檬酸等; 烷基磺酸如甲基磺酸、 乙基磺酸等; 芳基磺 酸如苯磺酸、 对甲苯磺酸等均可使用。 The compounds of the invention may be prepared in the form of their pharmaceutically acceptable salts with any suitable acid. For example, inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.; organic acids such as formic acid, acetic acid, propionic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, etc.; Sulfonic acid such as methanesulfonic acid, ethylsulfonic acid, etc.; arylsulfonate An acid such as benzenesulfonic acid or p-toluenesulfonic acid can be used.
c治疗和预防方法  c treatment and prevention methods
本发明涉及用于预防和 /或治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵 抗和肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s 病) 等的方法。 该方法包 括对需要或愿意接受治疗或预防的对象, 给予有效量的、 选择性地激动胰高血糖素样肽一 1受体的化合物或其药物学上可接受的盐来治疗或预防上述疾病或症状。  The present invention relates to methods for preventing and/or treating metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease. The method comprises administering to a subject in need or willingness to receive treatment or prevention an effective amount of a compound that selectively agonizes the glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof for treating or preventing the above-mentioned diseases. Or symptoms.
优选地, 上述疾病通过给予有效量的由以下通式 I或 II表示的化合物或其药物学上 可接受的盐来治疗或预防:  Preferably, the above disease is treated or prevented by administering an effective amount of a compound represented by the following formula I or II or a pharmaceutically acceptable salt thereof:
Figure imgf000026_0001
及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化物或 其金属配合物。
Figure imgf000026_0001
And all of its stereo and optical isomers, or prodrugs having the same pharmacological effects, esters thereof, solvates thereof or metal complexes thereof.
其中 X和 Y 分别为(CH2)„, n为 0- 2; 0; S或者 NH。 Wherein X and Y are respectively (CH 2 ) „, n is 0-2; 0; S or NH.
其中 R,, R2各自独立地为下列任意一种取代基: 氢; 卤素; 垸烃; 环垸烃; 羟基; 硝 基; 羧基; 醛基; 烷氧基; 胺基; 胺垸基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基。 Wherein R, R 2 are each independently one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxy; aldehyde; alkoxy; amine; amidoxime; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
R3, 各自独立地为下列任意一种取代基: 氢; 烷烃; 环垸烃; 烷氧基; 胺基; 胺烷 基; 酰胺基; 碳酰胺基; 垸硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 R 3 , each independently of any of the following substituents: hydrogen; alkane; cycloalkylene; alkoxy; amine; amine alkyl; amide; carboxamide; thiol; substituted or unsubstituted aryl Substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
可以用本方法防治任何对象, 优选哺乳动物, 更优选人。  Any subject can be controlled by this method, preferably a mammal, more preferably a human.
本方法可用来防治代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s病) 等。 优选的疾病或症状是任何由胰岛 素分泌和 /或功能障碍引起或伴随的疾病或症状。  The method can be used to control metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular diseases and neurodegenerative diseases (such as Alzheimer's disease). A preferred disease or condition is any disease or condition caused or accompanied by insulin secretion and/or dysfunction.
在预防和 /或治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症) 时, 可单独使用或与其他已经上市或将要上市的糖尿病治疗药物包括胰岛素增敏剂联合使 用本发明的化合物。 任何合适的代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和 肥胖症) 治疗药物均可与本发明的化合物联合使用。 其中, 典型的胰岛素增敏剂包括罗格 列酮和吡格列酮等。  In the prevention and/or treatment of metabolic disorders, including but not limited to diabetes, insulin resistance and obesity, the invention may be used alone or in combination with other diabetes therapeutics, including insulin sensitizers that are already on the market or to be marketed. compound of. Any suitable metabolic disorder (including but not limited to diabetes, insulin resistance, and obesity) therapeutic agents can be used in combination with the compounds of the present invention. Among them, typical insulin sensitizers include rosiglitazone and pioglitazone.
在本发明的优选实施方案中, 使用本发明化合物时不给予上述胰岛素增敏剂。 更优选 地, 用本发明的化合物治疗或预防因使用上述已经上市或将要上市的糖尿病治疗药物 (包 括胰岛素增敏剂) 而产生抗药性或毒副反应所引起的疾病或症状。 In a preferred embodiment of the invention, the above insulin sensitizer is not administered when the compound of the invention is used. More preferred The compound of the present invention is used to treat or prevent a disease or symptom caused by the use of the above-mentioned diabetes treatment drugs (including insulin sensitizers) which have been marketed or will be marketed to cause drug resistance or side effects.
可以通过任何合适的方法单独以本发明的化合物给药, 或与其他合适的糖尿病治疗药 物包括胰岛素增敏剂联合使用。 例如, 可以通过腔内注射, 皮下注射, 静脉内注射, 肌内 注射, 真皮内注射, 口服或局部以本发明的化合物给药, 或以其药物学上可接受的盐给药。  Administration of the compounds of the invention alone or in combination with other suitable diabetes therapeutics including insulin sensitizers can be by any suitable method. For example, it can be administered by intracavitary injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, orally or topically, with a compound of the present invention, or with a pharmaceutically acceptable salt thereof.
在具体实施方案中, 本方法进一步包括对给药对象的疾病或症状进行诊断和预后评 估。 可以使用任何适合的方法用于诊断和评估相关疾病或症状及其预后。 诊断和预后可以 基于检测和 /或鉴定任何或所有的体内物质, 例如糖化血红蛋白、 酶、 抗原、 抗体、 核酸 或其他病理性和临床标记物等以及相关症状。 例如, 可以使用国际专利 W0 01/44815和美 国专利 5, 571, 674揭示的诊断或预后方法。  In a specific embodiment, the method further comprises performing a diagnosis and prognosis assessment of the disease or condition of the subject to whom it is administered. Any suitable method can be used to diagnose and assess the associated disease or condition and its prognosis. Diagnosis and prognosis can be based on detecting and/or identifying any or all of the in vivo material, such as glycated hemoglobin, enzymes, antigens, antibodies, nucleic acids or other pathological and clinical markers, and related symptoms. For example, a diagnostic or prognostic method disclosed in International Patent No. WO 01/44815 and U.S. Patent No. 5,571,674 can be used.
D联合制剂, 药盒和联合用药的方法  D combined preparation, kit and method of combination
另一方面, 本发明也涉及联合制剂, 这种联合包括一种选择性调节胰高血糖素样肽一 1 受体功能的化合物, 或其药物学上可接受的盐, 和一种或多种代谢紊乱性疾病治疗药物 包括胰岛素增敏剂。  In another aspect, the invention also relates to a combination formulation comprising a compound that selectively modulates glucagon-like peptide-1 receptor function, or a pharmaceutically acceptable salt thereof, and one or more Therapeutic drugs for metabolic disorders include insulin sensitizers.
优选地, 这种联合用药包括本发明化合物或其药物学上可接受的盐和一种或多种代谢 紊乱性疾病治疗药物包括胰岛素增敏剂, 该化合物由以下通式 I或 Π表示:  Preferably, such a combination comprises a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutic agent for one or more metabolic disorders including an insulin sensitizer, which is represented by the following formula I or Π:
Figure imgf000027_0001
Figure imgf000027_0001
及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化 物或其金属配合物。 And all of its stereo and optical isomers, or prodrugs having the same pharmacological effects, esters thereof, solvates thereof or metal complexes thereof.
其中 X和 Y 分别为(CH2) n, n为 0- 2; 0; S或者 NH。 Wherein X and Y are each (CH 2 ) n and n is 0-2; 0; S or NH.
其中 R R2各自独立地为下列任意一种取代基: 氢; 卤素; 垸烃; 环垸烃; 羟基; 硝 基; 羧基; 醛基; 烷氧基; 胺基; 胺烷基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基。 Wherein RR 2 is each independently one of the following substituents: hydrogen; halogen; anthracene; cycloalkyl; hydroxy; nitro; carboxy; aldehyde; alkoxy; amine; amine alkyl; Amido; thiol; sulfhydryl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted thienyl; substituted or unsubstituted pyrrolyl.
R3, R4各自独立地为下列任意一种取代基: 氢; 垸烃; 环垸烃; 垸氧基; 胺基; 胺垸 基; 酰胺基; 碳酰胺基; 垸硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 在本发明的联合制剂中可以使用任何合适的糖尿病治疗药物包括胰岛素增敏剂。 在一 个特定实施方案中, 用于本发明联合制剂中可以包括上述糖尿病治疗药物包括胰岛素增敏 剂中的一种或多种。 R 3 , R 4 are each independently any of the following substituents: hydrogen; anthracene; cyclononene; anthracene; amine; amine sulfhydryl; amide; carbonamide; thiol; Substituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl. Any suitable therapeutic agent for diabetes, including insulin sensitizers, can be used in the combination formulations of the invention. In a specific embodiment, one or more of the above-described diabetes therapeutic agents including insulin sensitizers may be included in the combined preparation of the present invention.
在另一个特定实施方案中, 提供了一种治疗或预防由胰岛素分泌和 /或功能障碍引起 或伴随的疾病或症状的方法, 该方法包括对需要和愿意接受治疗或预防的对象给予有效量 的上述联合制剂, 或其药物学上可接受的盐, 从而治疗或预防上述疾病或症状。  In another specific embodiment, a method of treating or preventing a disease or condition caused or accompanied by insulin secretion and/or dysfunction is provided, the method comprising administering an effective amount to a subject in need and willing to receive treatment or prevention The above combined preparation, or a pharmaceutically acceptable salt thereof, thereby treating or preventing the above diseases or symptoms.
在另一个特定实施方案中, 提供了一个药盒, 其中包括本发明的化合物或其药物学上 可接受的盐以及使用上述化合物或其药物学上可接受的盐来防治由胰岛素分泌和 /或功能 紊乱引起或伴随的疾病或症状的使用说明。  In another specific embodiment, there is provided a kit comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and the use of the above compound or a pharmaceutically acceptable salt thereof for controlling secretion and/or secretion by insulin Instructions for the use of a disease or condition caused by or associated with a dysfunction.
在再一个实施方案中, 提供了一个药盒, 包括上述联合制剂及使用所述联合制剂治疗 或预防由胰岛素分泌和 /或功能紊乱引起或伴随的疾病或症状的使用说明。  In still another embodiment, a kit is provided comprising the combination described above and instructions for using the combination to treat or prevent a disease or condition caused or accompanied by insulin secretion and/or dysfunction.
E配方和剂量  E formula and dosage
根据本发明, 本发明的化合物, 单独或与其它药剂, 载体或赋形剂联合, 为任何合适 的给药途径制定制剂, 例如腔内注射、 皮下注射、 静脉内注射、 肌内注射、 真皮内注射、 口服或局部用药。 本方法可以使用注射给药制剂, 以单剂量的形式在安瓿, 或多剂量容器 中与添加的缓冲剂注射给药。 制剂可采取以下形式如混悬液、 溶液或在油性或水性媒介中 的乳液。 制剂可以含有配方试剂如混悬剂、 稳定剂和 /或分散剂。 此外, 使用前, 活性成 分可以粉末形式与合适的载体, 无菌无热源水或其他溶剂构成剂型。 本发明的局部用药可 采用泡沫, 凝胶, 软膏, 油膏, 转皮膜片, 或膏状物。  According to the invention, the compounds of the invention, alone or in combination with other agents, carriers or excipients, are formulated for any suitable route of administration, for example, intraluminal, subcutaneous, intravenous, intramuscular, intradermal Injection, oral or topical. The method can be administered by injection in a single dose in an ampoule, or in a multi-dose container with an added buffer. The formulations may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles. The formulations may contain formulating agents such as suspending, stabilizing and/or dispersing agents. In addition, the active ingredient may be in a powder form with a suitable vehicle, sterile non-pyrogenic water or other solvent before use. The topical medicament of the present invention may be a foam, a gel, an ointment, an ointment, a transdermal patch, or a paste.
本发明中可以使用的用于给药的药用组合物和方法包括, 但不局限于, 美国专利 5, 736, 154、 6, 197, 801 Bl、 5, 741, 511、 5, 886, 039、 5, 941, 868、 6, 258, 374B1和 5, 686, 102 所阐述的内容。  Pharmaceutical compositions and methods for administration that may be used in the present invention include, but are not limited to, U.S. Patents 5,736,154, 6,197, 801 Bl, 5,741,511, 5, 886, 039 5, 941, 868, 6, 258, 374B1 and 5, 686, 102.
治疗或预防的剂量大小会因病情的严重性和给药途径而有所变化。 剂量和用药频度会 因年龄、 体重、 健康状况和病人个体反应不同而不同。  The size of the dose to be treated or prevented will vary depending on the severity of the condition and the route of administration. The dose and frequency of administration will vary with age, weight, health status, and individual patient response.
需要指出的是 (诊治医生也应知道), 根据毒性和副反应, 必须采取必要措施终止、 中断或降低治疗剂量。 相反, 如果临床反应不明显 (排除毒性和副反应), 医生应适当调 整治疗方案, 提高剂量。  It should be pointed out that (the doctor should also know), according to toxicity and side effects, necessary measures must be taken to terminate, interrupt or reduce the therapeutic dose. Conversely, if the clinical response is not obvious (excluding toxicity and side effects), the doctor should adjust the treatment plan to increase the dose.
任何合适的给药途径均可被采用。剂型包括片剂, 锭剂, 豆状胶囊, 分散剂, 悬浮剂, 溶液, 胶囊, 膜片及类似物等。  Any suitable route of administration can be employed. Dosage forms include tablets, lozenges, lenticular capsules, dispersing agents, suspending agents, solutions, capsules, films and the like.
在实际应用中, 本发明的化合物, 单独或与其他制剂联合, 可以按照一般药物学混合 技术与药物载体或赋形剂, 例如 β—环糊精和 2—羟基一丙基一 β—环糊精紧密混和。 根 据投药的需要, 可采用通用载体、 局部或非肠道途径的特殊载体。 制备非肠道剂型, 例如 静脉内注射或灌输的组合物, 可采用类似的药物媒质, 本领域技术人员所公知的水, 乙二 醇,油,缓冲剂,糖, 防腐剂,脂质体等。这种非肠道组合物的例子包括,但不限制于 5%W/V 的右旋糖, 生理盐水或其他溶液。本发明的化合物的总剂量, 单独或和其他制剂联合给药, 可用小瓶静脉注射液给药, 体积大约从 1毫升到 2000毫升。 根据给药的总剂量, 稀释液 量也会不同。 In a practical application, the compound of the present invention, alone or in combination with other preparations, may be in accordance with a general pharmaceutical mixing technique with a pharmaceutical carrier or excipient such as β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin. Finely mixed. Depending on the needs of the administration, a special carrier, a local or parenteral route, may be employed. For the preparation of parenteral dosage forms, such as compositions for intravenous injection or infusion, similar pharmaceutical vehicles can be employed, water, glycols, oils, buffers, sugars, preservatives, liposomes, etc., which are well known to those skilled in the art. . Examples of such parenteral compositions include, but are not limited to, 5% W/V Dextrose, saline or other solution. The total dose of the compound of the present invention, alone or in combination with other preparations, can be administered in vial vials in a volume of from about 1 ml to about 2000 ml. The amount of diluent will vary depending on the total dose administered.
本发明还提供了实现治疗方案的药盒。 该药盒将有效剂量的本发明化合物以药物学上 可接受的形式单独或与其他试剂联合, 包含在一个或多个容器中。 优选的药物形式是与无 菌盐水, 右旋糖溶液, 缓冲溶液, 或其他药物学上可接受的无菌液体合用。 或者, 组合物 可被冻干或干燥; 在这种情况下, 药盒任选地进一步将一种药物学上可接受的溶液, 优选 无菌的溶液包含在一个容器中, 以重新组成复合物形成用于注射目的的溶液。 典型的药物 学上可接受的溶液是生理盐水和右旋糖溶液。  The invention also provides a kit for achieving a therapeutic regimen. The kit comprises an effective amount of a compound of the invention in a pharmaceutically acceptable form, alone or in combination with other agents, in one or more containers. The preferred pharmaceutical form is in combination with sterile saline, dextrose solution, buffer solution, or other pharmaceutically acceptable sterile liquid. Alternatively, the composition may be lyophilized or dried; in this case, the kit optionally further comprises a pharmaceutically acceptable solution, preferably a sterile solution, in a container to reconstitute the complex A solution for injection purposes is formed. Typical pharmaceutically acceptable solutions are physiological saline and dextrose solutions.
在另一个实施方案中, 本发明的药盒进一步包含用于注射组合物的优选以无菌形式包 装的针或针筒和 /或包装的酒精垫。 可任选地包括供医生或患者使用的说明书。  In another embodiment, the kit of the present invention further comprises a needle or syringe and/or a packaged alcohol pad for injection of the composition, preferably in a sterile form. Instructions for use by a doctor or patient may optionally be included.
F制备方法  F preparation method
本发明中所用原料 (0601— 0610) 参照中国专利 (申请号: 200310109331. 0) 中所描 述的合成方法合成。 本发明是通过如下步骤实施的:  The raw materials (0601 - 0610) used in the present invention were synthesized in accordance with the synthesis method described in the Chinese patent (Application No.: 200310109331. 0). The invention is implemented by the following steps:
Figure imgf000029_0001
取化合物 1 ( leq) 和化合物 2 ( leq) 溶于适量的二氯甲烷、 水、 二氯乙烷、 DMS0、 二氧六环或上述溶剂的混合溶剂中 (或加入催化量的二苯酮), 反应温度控制在 0° (:〜 60°C 间, 置于 150W高压汞灯或自然光下光照 1天到 2个月, 期间用 HPLC检测跟踪反应。 冷冻 干燥除去溶剂, 剩余物用反相硅胶柱层析分离得到产物。
Figure imgf000029_0001
Compound 1 ( leq) and compound 2 ( leq) are dissolved in a suitable amount of dichloromethane, water, dichloroethane, DMS0, dioxane or a solvent mixture of the above solvents (or a catalytic amount of benzophenone is added) , the reaction temperature is controlled between 0 ° (: ~ 60 ° C, placed in a 150W high pressure mercury lamp or natural light for 1 day to 2 months, during the period by HPLC to detect the reaction. Freeze drying to remove the solvent, the residue with reversed-phase silica gel The product was isolated by column chromatography.
附图说明  DRAWINGS
图 1. 报告基因方法检测化合物对 GLP- 1R的激动作用  Figure 1. Reporter gene method to detect the agonistic effects of compounds on GLP-1R
具体实施方式  detailed description
实验仪器及试剂  Experimental instruments and reagents
HP1100 HPLC 系统, 具备二元梯度泵、 在线真空脱气机、 自动进样器、 柱温箱和光电 二极管阵列检测器。 色谱柱为 ZORBAX SB-C18 (2. 1 x 150 mm, 3. 5 μηι), 流动相为乙腈 / 水 65 : 35, 流速为 0. 2 ml/min, 检测波长为 254 亂 熔点采用 IA6304型熔点仪测定; NMR 由 Varian Mercury-300和 Varian Mercury Plus 400型核磁共振仪测得 (溶剂为 CDCl:i, CD30D或 DMSO-de ) ; ESI- MS由 AB Mariner型质谱仪测得, EI由 Finnigan MAT95型质谱仪 测得。 合成中所用原料除特别指明来源外均为市售产品。 下面的具体实施例对本发明作进一步阐述, 但不限制本发明。 HP1100 HPLC system with binary gradient pump, online vacuum degasser, autosampler, column oven and photodiode array detector. The column is ZORBAX SB-C18 (2.11 x 150 mm, 3. 5 μηι), the mobile phase is acetonitrile/water 65: 35, the flow rate is 0. 2 ml/min, the detection wavelength is 254. The melting point is IA6304 type melting point. NMR was measured by Varian Mercury-300 and Varian Mercury Plus 400 NMR (solvent: CDCl :i , CD 3 0D or DMSO-de); ESI-MS was measured by AB Mariner mass spectrometer, EI by Measured by a Finnigan MAT95 mass spectrometer. The materials used in the synthesis are commercially available products unless otherwise specified. The following specific examples are intended to further illustrate the invention but are not intended to limit the invention.
实施例 1: 化合物 GLP- A- 1的制备  Example 1: Preparation of Compound GLP-A-1
NMR定标: δ H 2.50 ppm (DMSO- d6)。 NMR calibration: δ H 2.50 ppm (DMSO-d 6 ).
Figure imgf000030_0001
Figure imgf000030_0001
将化合物 0601 (1 g)溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 1 ml 水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩 余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-A-1。  Compound 0601 (1 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high-pressure mercury lamp for 3 days, 1 ml of water was added, and irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-A-1 was obtained.
'Η醒 R (300MHz, DMSO -d6) 10.118 (2H, br. s) , 8.615 (2H, br. s), 8.095 (2H, dd, =4.8 Hz, J2=l.2 Hz), 8.027 (2H, dd, /,=3.9 Hz, /2=1.5 Hz), 7.569 (4H, d, 8.4 Hz), 7.365 (4H, d, 8.7 Hz), 7.318 (2H, dd, Ji=3.9 Hz, /2=5.1 Hz), 7.280 (2H, m), 7.260 (2H, ra), 7.203 (2H, br. d, 8· 1 Hz), 4.981 (2H, s), 3.228 (6H, s), 2.015 (6H, s;)。 'Wake up R (300MHz, DMSO -d 6 ) 10.118 (2H, br. s) , 8.615 (2H, br. s), 8.095 (2H, dd, =4.8 Hz, J 2 =l.2 Hz), 8.027 (2H, dd, /, =3.9 Hz, / 2 =1.5 Hz), 7.569 (4H, d, 8.4 Hz), 7.365 (4H, d, 8.7 Hz), 7.318 (2H, dd, Ji=3.9 Hz, / 2 = 5.1 Hz), 7.280 (2H, m), 7.260 (2H, ra), 7.203 (2H, br. d, 8· 1 Hz), 4.981 (2H, s), 3.228 (6H, s), 2.015 ( 6H, s;).
实施例 2: 化合物 GLP-A-2的制备  Example 2: Preparation of Compound GLP-A-2
NMR定标: δ H 2· 50 ppm (DMSO- d6)。 NMR calibration: δ H 2 · 50 ppm (DMSO-d 6 ).
Figure imgf000030_0002
将化合物 0602 (10 g)溶于适量的 DMS0中, 置于 150W高压汞灯下照射 3天, 加入 1 ml 水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩 余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-A - 2。
Figure imgf000030_0002
Compound 0602 (10 g) was dissolved in an appropriate amount of DMS0, placed under a 150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-A-2 was obtained.
'Η匪 R (300 MHz, DMSO-de) δ 8.770 (2Η, br. s), 8.090 (2H, d, J=5.1 Hz), 8.026 (2H, d, 7=3.9 Hz), 7.2-7.5 (18H, m), 5.011 (2H, s), 3.231 (6H, s)。  'Η匪R (300 MHz, DMSO-de) δ 8.770 (2Η, br. s), 8.090 (2H, d, J=5.1 Hz), 8.026 (2H, d, 7=3.9 Hz), 7.2-7.5 ( 18H, m), 5.011 (2H, s), 3.231 (6H, s).
实施例 3: 化合物 GLP- B- 1的制备  Example 3: Preparation of Compound GLP-B-1
NMR定标: δ H 2.50 ppm (DMSO- d6)。 NMR calibration: δ H 2.50 ppm (DMSO-d 6 ).
Figure imgf000031_0001
将化合物 0603 (1.5 g) 溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 1 ml水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP- B-l。
Figure imgf000031_0001
Compound 0603 (1.5 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. A pale yellow powdery solid compound GLP-Bl was obtained.
Ή NMR (300 MHz, DMSO— d6) δ 9.532 (2H, br.s), 8.433 (2H, br. s) , 7.534 (4H, m), 7.428 (4H, d, 8.7 Hz), 7.329 (4H, d, ^8.4 Hz), 7.234 (6H, m), 4.912 (2H, s), 1.453 (18H, s)。 NMR NMR (300 MHz, DMSO-d 6 ) δ 9.532 (2H, br. s), 8.433 (2H, br. s), 7.534 (4H, m), 7.428 (4H, d, 8.7 Hz), 7.329 (4H , d, ^8.4 Hz), 7.234 (6H, m), 4.912 (2H, s), 1.453 (18H, s).
实施例 4: 化合物 GLP-B- 2的制备  Example 4: Preparation of Compound GLP-B-2
NMR定标: δ H 2.50 ppm (DMSO- de)。 NMR calibration: δ H 2.50 ppm (DMSO-d e ).
Figure imgf000032_0001
将化合物 0604 (2.7 g) 溶于适量的 DMS0中, 置于.150W高压汞灯下照射 3天, 加入 1 ml水, 继续照射 20-25天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-B-2。
Figure imgf000032_0001
Compound 0604 (2.7 g) was dissolved in an appropriate amount of DMS0, placed under a .150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and the irradiation was continued for 20-25 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. A pale yellow powdery solid compound GLP-B-2 was obtained.
'Η NMR (300 MHz, DMS0_d6) δ 9.585 (2H, br. s), 8.451 (2H, br. s), 7.456 (4H, d, 8.7 Hz), 7.2-7.4 (12H, m), 7.1-7.2 (8H, m), 6.854 (2H, d, 7.8 Hz), 4.926 (2H, s), 4.384 (4H, s), 1.463 (18H, s)。 'Η NMR (300 MHz, DMS0_d 6 ) δ 9.585 (2H, br. s), 8.451 (2H, br. s), 7.456 (4H, d, 8.7 Hz), 7.2-7.4 (12H, m), 7.1- 7.2 (8H, m), 6.854 (2H, d, 7.8 Hz), 4.926 (2H, s), 4.384 (4H, s), 1.463 (18H, s).
实施例 5: 化合物 GLP-B- 3的制备  Example 5: Preparation of Compound GLP-B-3
NMR定标: δ H 2.51 ppm (DMSO- d6)。 NMR calibration: δ H 2.51 ppm (DMSO-d 6 ).
Figure imgf000032_0002
Figure imgf000032_0002
将化合物 0605 (1.4 g) 溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 lml水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP- B-3。  Compound 0605 (1.4 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high-pressure mercury lamp for 3 days, and 1 ml of water was added thereto, and the irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-B-3 was obtained.
Ή NMR (300 MHz, DMSO— d6) δ 9.554 (2H, br. s), 8.527 (2H, br. s), 7.420 (4H, d, 8.4 Hz), 7.283 (4H, d, 8.7 Hz), 7.215 (2H, br. s), 7.137 (2H, d, ^9.0 Hz), 7.092 (2H, d, J=8.1 Hz), 4.916 (2H, br. s) , 3.229 (6H, s), 2.257 (6H, s), 1.450 (18H, s)。 NMR NMR (300 MHz, DMSO-d 6 ) δ 9.554 (2H, br. s), 8.527 (2H, br. s), 7.420 (4H, d, 8.4 Hz), 7.283 (4H, d, 8.7 Hz), 7.215 (2H, br. s), 7.137 (2H, d, ^9.0 Hz), 7.092 (2H, d, J=8.1 Hz), 4.916 (2H, Br. s) , 3.229 (6H, s), 2.257 (6H, s), 1.450 (18H, s).
实施例 6: 化合物 GLP-B- 4的制备  Example 6: Preparation of Compound GLP-B-4
NMR定标: δ H 2.50 ppm (DMSO- d6)。 Scaling NMR: δ H 2.50 ppm (DMSO- d 6).
Figure imgf000033_0001
将化合物 0606 (2.2 g) 溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 1 ml水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-B - 4。
Figure imgf000033_0001
Compound 0606 (2.2 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-B-4 was obtained.
lH NMR (300 MHz, DMS0—d6) δ 9.565 (2H, br. s), 8.215 (2H, br. s), 7.464 (8H, s), 7.436 (2H, m), 7.122 (2H, m), 6.991 (2H, dd, Ji=4.5 Hz, J2=3.9 Hz) , 5.055 (2H, s), 1.465 (18H, s)。 lH NMR (300 MHz, DMS0-d 6 ) δ 9.565 (2H, br. s), 8.215 (2H, br. s), 7.464 (8H, s), 7.436 (2H, m), 7.122 (2H, m) , 6.991 (2H, dd, Ji=4.5 Hz, J 2 = 3.9 Hz), 5.055 (2H, s), 1.465 (18H, s).
实施例 7: 化合物 GLP- B- 5的制备  Example 7: Preparation of Compound GLP-B-5
NMR定标: δ H 2.50 ppm (DMSO- d6)。 NMR calibration: δ H 2.50 ppm (DMSO-d 6 ).
Figure imgf000033_0002
将化合物 0607 (3.4 g) 溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 lml水, 继续照射 20- 25天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-B-5。 Ή NMR (300 MHz, DMSO— d6) δ 9.661 (2H, br. s), 8.220 (2H, m), 7.495 (4H, d, 8.4 Hz), 7.428 (4H, d, 8.7 Hz), 7.4—7.6 (4H, m), 7.305 (4H, m), 5.875 (2H, s), 1.467 (18H, s)。
Figure imgf000033_0002
Compound 0607 (3.4 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high pressure mercury lamp for 3 days, and 1 ml of water was added thereto, and the irradiation was continued for 20-25 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-B-5 was obtained. NMR NMR (300 MHz, DMSO-d 6 ) δ 9.661 (2H, br. s), 8.220 (2H, m), 7.495 (4H, d, 8.4 Hz), 7.428 (4H, d, 8.7 Hz), 7.4- 7.6 (4H, m), 7.305 (4H, m), 5.875 (2H, s), 1.467 (18H, s).
实施例 8: 化合物 GLP-B-6的制备  Example 8: Preparation of Compound GLP-B-6
NMR定标: δ H 2.50 ppm (DMSO- d6)。 NMR calibration: δ H 2.50 ppm (DMSO-d 6 ).
Figure imgf000034_0001
Figure imgf000034_0001
将化合物 0608 (5 g) 溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 1 ml 水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩 余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-B-6。  Compound 0608 (5 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-B-6 was obtained.
Ή NMR (300 MHz, DMS0—d6) δ 9.584 (2H, br. s), 8.927 (2H, br. s), 8.055 (2H, d, ^5.1 Hz), 7.977 (2H, d, J=2.7 Hz) , 7.631 (4H, d, ^8.4 Hz), 7.546 (4H, d, J=9.0 Hz), 7.489 (4H, d, 8.7 Hz), 7.275 (2H, dd, J,=4.5 Hz, J2=3.9 Hz), 7.053 (4H, d, 8.7 Hz), 5.298 (2H, s), 1.481 (18H, s)。 NMR NMR (300 MHz, DMS0-d 6 ) δ 9.584 (2H, br. s), 8.927 (2H, br. s), 8.055 (2H, d, ^5.1 Hz), 7.977 (2H, d, J=2.7 Hz) , 7.631 (4H, d, ^8.4 Hz), 7.546 (4H, d, J=9.0 Hz), 7.489 (4H, d, 8.7 Hz), 7.275 (2H, dd, J,=4.5 Hz, J 2 =3.9 Hz), 7.053 (4H, d, 8.7 Hz), 5.298 (2H, s), 1.481 (18H, s).
实施例 9: 化合物 GLP- B-7的制备  Example 9: Preparation of Compound GLP-B-7
NMR定标: δ H 2.50 ppm (DMS0_d6)。 NMR calibration: δ H 2.50 ppm (DMS0_d 6 ).
Figure imgf000035_0001
Figure imgf000035_0001
将化合物 0609 (2.6 g) 溶于适量的 DMS0中, 置于 150W高压汞灯下照射 3天, 加入 1 ml水, 继续照射 25-30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP- B-7。  Compound 0609 (2.6 g) was dissolved in an appropriate amount of DMS0, placed under a 150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-B-7 was obtained.
Ή NMR (300 MHz, DMS0-d6) δ 9.542 (2Η, br.s), 8.306 (2Η, br. s), 7.2-7.5 (22H, m), 6.903 (4H, d, ^8.7 Hz), 5.066 (4H, s), 4.797 (2H, s), 1.462 (18H, s)。 NMR NMR (300 MHz, DMS0-d 6 ) δ 9.542 (2Η, br.s), 8.306 (2Η, br. s), 7.2-7.5 (22H, m), 6.903 (4H, d, ^8.7 Hz), 5.066 (4H, s), 4.797 (2H, s), 1.462 (18H, s).
实施例 10: 化合物 GLP-C-1的制备  Example 10: Preparation of Compound GLP-C-1
NMR定标: δ H 2.50 ppm (DMSO— d6)。 NMR calibration: δ H 2.50 ppm (DMSO-d 6 ).
Figure imgf000035_0002
将化合物 0610 (4.5 g) 溶于适量的 DMSO中, 置于 150W高压汞灯下照射 3天, 加入 1 ml水, 继续照射 25- 30天, 期间用 HPLC检测跟踪反应。 反应完毕, 冷冻干燥除去溶剂, 剩余物用反相硅胶柱层析分离。 得到浅黄色粉状固体化合物 GLP-C-1。
Figure imgf000035_0002
Compound 0610 (4.5 g) was dissolved in an appropriate amount of DMSO, placed under a 150 W high pressure mercury lamp for 3 days, 1 ml of water was added, and the irradiation was continued for 25-30 days, during which time the reaction was followed by HPLC. After completion of the reaction, the solvent was removed by lyophilization, and the residue was separated by reversed silica gel column chromatography. The pale yellow powdery solid compound GLP-C-1 was obtained.
Ή NMR (300 MHz, DMS0—d6) δ 8.513 (2H, br.s), 7347 (4H, m), 7.267 (4H, d, 7· 8 Hz), 7.190 (4H, d, J=7.8 Hz) , 7.143 (2H, d, J^l.5 Hz) , 7.042 (2H, d, J=l.5 Hz), 4.880 (2H, s), 2.292 (6H, s), 2.137 (6H, s)。 实施例 11 : 化合物 GLP-D-1的制备 NMR定标: δ H 2. 50 ppm (DMSO- d6)。 NMR NMR (300 MHz, DMS0-d 6 ) δ 8.513 (2H, br.s), 7347 (4H, m), 7.267 (4H, d, 7· 8 Hz), 7.190 (4H, d, J=7.8 Hz ), 7.143 (2H, d, J^l.5 Hz), 7.042 (2H, d, J=l.5 Hz), 4.880 (2H, s), 2.292 (6H, s), 2.137 (6H, s) . Example 11: Preparation of compound GLP-D-1 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000036_0001
Figure imgf000036_0001
实施例 12: 化合物 GLP- D-2的制备 NMR定标: δ H 2. 50 ppm (DMSO- d6)。 Example 12: Preparation of Compound GLP- D-2 calibration of NMR: δ H 2. 50 ppm (DMSO- d 6).
Figure imgf000036_0002
实施例 13: 化合物 GLP-D-3的制备 NMR定标: δ H 2. 50 ppm (DMSO- d6)。
Figure imgf000036_0002
Example 13: Preparation of compound GLP-D-3 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000037_0001
实施例 14: 化合物 GLP-D- 4的制备
Figure imgf000037_0001
Example 14: Preparation of Compound GLP-D-4
NMR定标: δ H 2. 50 ppm (DMSO- d6)。 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000037_0002
实施例 15: 化合物 GLP-D- 5的制备 NMR定标: δ H 2. 50 ppm (DMS0-de)。
Figure imgf000037_0002
Example 15: Preparation of compound GLP-D-5 NMR calibration: δ H 2. 50 ppm (DMS0-d e ).
Figure imgf000038_0001
Figure imgf000038_0001
实施例 16: 化合物 GLP-D- 6的制备Example 16: Preparation of Compound GLP-D-6
NMR定标: δ H 2. 50 ppm (DMSO- d6)。 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000038_0002
Figure imgf000038_0002
实施例 17: 化合物 GLP-D- 7的制备 NMR定标: δ H 2. 50 ppm (DMSO- d6)。 Example 17: Preparation of compound GLP-D-7 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000039_0001
Figure imgf000039_0001
实施例 18: 化合物 GLP-D-8的制备Example 18: Preparation of Compound GLP-D-8
NMR定标: δ H 2. 50 ppm (DMS0_d6)。 NMR calibration: δ H 2. 50 ppm (DMS0_d 6 ).
Figure imgf000039_0002
Figure imgf000039_0002
实施例 19: 化合物 GLP-D-9的制备Example 19: Preparation of Compound GLP-D-9
NMR定标: δ H 2. 50 ppm (DMSO- de)。 NMR calibration: δ H 2. 50 ppm (DMSO-d e ).
Figure imgf000040_0001
Figure imgf000040_0001
实施例 20: 化合物 GLP-D- 10的制备 NMR定标: δ H 2. 50 ppm (DMSO- d6)。 Example 20: Preparation of compound GLP-D-10 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000040_0002
Figure imgf000040_0002
实施例 21 : 化合物 GLP- D- 11的制备 NMR定标: δ H 2. 50 ppm (DMSO- de)。 Example 21: Preparation of compound GLP-D-11 NMR calibration: δ H 2. 50 ppm (DMSO-d e ).
Figure imgf000041_0001
Figure imgf000041_0001
实施例 22: 化合物 GLP- D- 12的制备Example 22: Preparation of Compound GLP-D-12
NMR定标: δ H 2. 50 ppm (DMSO- d6)。 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000041_0002
Figure imgf000041_0002
实施例 23: 化合物 GLP-D- 13的制备 Example 23: Preparation of Compound GLP-D-13
NMR定标: δ H 2. 50 ppm (DMSO- d6)。 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000042_0001
Figure imgf000042_0001
实施例 24: 化合物 GLP-D- 14的制备 NMR定标: δ H 2. 50 ppra (DMS0-d6)。 Example 24: Preparation of compound GLP-D-14 NMR calibration: δ H 2. 50 ppra (DMS0-d 6 ).
Figure imgf000042_0002
实施例 25: 化合物 GLP-D-15的制备
Figure imgf000042_0002
Example 25: Preparation of Compound GLP-D-15
NMR定标: δ H 2. 50 ppm (DMSO- d6)。 NMR calibration: δ H 2. 50 ppm (DMSO-d 6 ).
Figure imgf000043_0001
Figure imgf000043_0001
实施例 26: 化合物 GLP-D- 16的制备 匪 R定标: δ H 2. 50 ppm (DMSO- d6)。 Example 26: Preparation of Compound GLP-D- R 16 bandit calibration: δ H 2. 50 ppm (DMSO- d 6).
Figure imgf000044_0001
Figure imgf000044_0001
实施例 27: 生物活性测试试验 Example 27: Biological Activity Test
1. 报告基因表达检测  Reporter gene expression detection
GLP- 1R为 G蛋白偶联受体, 当 GLP- 1R与激动剂结合后, G蛋白的 G a 亚单位被活化, 刺激腺苷酸环化酶, 导致细胞内 cAMP水平升高。 因前胰岛素基因的启动子区域存在 cAMP 反应元件, cAMP与该反应元件结合后, 启动前胰岛素基因的转录, 从而刺激胰岛素的表达 和分泌 (Diabetes, 2000, Vol. 49 : 1156-1164)。 本实验方法采用稳定转染 GLP-1R 受体 基因表达载体和受 cAMP反应元件调节的荧光素酶报告基因表达载体的人胚肾细胞株 (HEK 293),检测其对被测化合物的反应(Cell Biology, 1992, Vol. 89 : 8641-8645; Proc. Natl. Acad. Sci. U. S. A. 1987, Vol. 84 : 3434-3438)。 在对化合物进行筛选时, 可诱导荧光素 酶报告基因表达的样品, 视为具有 GLP-1R激动活性。  GLP-1R is a G protein-coupled receptor. When GLP-1R binds to an agonist, the G a subunit of the G protein is activated to stimulate adenylate cyclase, resulting in an increase in intracellular cAMP levels. Since the cAMP response element exists in the promoter region of the proinsulin gene, cAMP binds to the response element to initiate transcription of the pre-insulin gene, thereby stimulating insulin expression and secretion (Diabetes, 2000, Vol. 49: 1156-1164). In this experimental method, a human embryonic kidney cell strain (HEK 293) stably transfected with a GLP-1R receptor gene expression vector and a luciferase reporter gene expression vector regulated by a cAMP response element was used to detect its response to a test compound (Cell). Biology, 1992, Vol. 89: 8641-8645; Proc. Natl. Acad. Sci. USA 1987, Vol. 84: 3434-3438). A sample that induces expression of a luciferase reporter gene when screened for a compound is considered to have GLP-1R agonistic activity.
1. 1 试验材料与仪器  1. 1 Test materials and instruments
细胞株: GLP- 1R和荧光素酶稳定表达的 HEK 293/GLP-lR+Luc 细胞株 (国家新药筛选 中心自建)  Cell line: HEK 293/GLP-lR+Luc cell line stably expressed by GLP-1R and luciferase (National New Drug Screening Center self-built)
胎牛血清 (GIBC0公司)  Fetal bovine serum (GIBC0)
DMEM培养基 (GIBC0公司)  DMEM medium (GIBC0 company)
Steady- Glo™荧光素酶分析系统 (Promega公司)  Steady-GloTM Luciferase Assay System (Promega)
GLP- 1标准品 (Sigma公司)  GLP-1 standard (Sigma)
G418 ( Invitrogen公司)  G418 (Invitrogen)
Forma二氧化碳培养箱 (Forma公司); Victor2读板机 (Wallac公司); Forma Carbon Dioxide Incubator (Forma); Victor 2 plate reader (Wallac);
待测化合物: GLP-A- 1、 GLP- B- 3、 GLP-B- 6、 GLP-B-7  Test compound: GLP-A-1, GLP-B-3, GLP-B-6, GLP-B-7
1. 2 试验方法  1. 2 Test methods
HEK293/GLP1R+Luc细胞以 20, 000个 /100 μΐ/孔接入 96孔培养板, 以含 10%胎牛血清 和 500 μ§/πι1 G418的 DMEM培养基于 37°C培养过夜。将 GLP- 1标准品和待测化合物 GLP- A - 1、 GLP- B- 3、 GLP- B- 6、 GLP- B-7分别稀释至一定浓度梯度, 然后以 1 μΐ/孔加入上述 96孔微 量培养板中。在 37° (:, 5%C02条件下培养 6小时。按 Steady-G10 TM荧光素酶分析系统试剂盒 说明检测荧光素酶活性, Victor2读板机进行读数。 HEK293/GLP1R+Luc cells were inserted into 96-well culture plates at 20,000/100 μΐ/well, and cultured overnight at 37 ° C in DMEM medium containing 10% fetal calf serum and 500 μ § /πι 1 G418. The GLP-1 standard and the test compounds GLP-A-1, GLP-B-3, GLP-B-6, and GLP-B-7 were each diluted to a certain concentration gradient, and then added to the above 96 wells at 1 μM/well. In microplates. Incubate for 6 hours at 37° (:, 5% CO 2 ). Luciferase activity was measured by the Steady-G1 0 TM Luciferase Assay System Kit, and the Victor 2 reader was used for reading.
1. 3 试验结果  1. 3 test results
研究结果表明 (图 1, 表 1和表 2), 化合物 GLP-A-K GLP-B- 3、 GLP-B- 6、 GLP-B- 7 均显示一定的激动活性。 以 10 nM的 GLP-1所诱导的萤光素酶活性为 100%, 上述各化合 物的最高反应效率分别为 48. 8 %、 45. 3%、 49. 3%和 19. 1 % , 其中化合物 GLP- A- 1的 EC5。 值为 318. 2 nM。 同一试验系统中 GLP- 1的 EC5。值为 0. 11 nM。 The results of the study showed that (Fig. 1, Table 1 and Table 2), the compounds GLP-AK GLP-B-3, GLP-B-6, and GLP-B-7 all showed certain agonistic activities. The luciferase activity induced by 10 nM of GLP-1 is 100%, and the highest reaction efficiencies of the above compounds are 48.8 %, 45.3%, 49.3% and 19.1%, respectively, of the compound EC 5 of GLP-A-1. The value is 318. 2 nM. EC 5 of GLP-1 in the same test system. The value is 0. 11 nM.
表 1. 报告基因检测化合物 GLP- B-3和 GLP-B- 6的激动活性  Table 1. The agonistic activity of the reporter gene detection compounds GLP-B-3 and GLP-B-6
(%反应, 以 10 nM GLP-1的反应为 100%)  (% reaction, 100% reaction with 10 nM GLP-1)
相对 GLP-1的激动活性 (%)  Relative agonistic activity of GLP-1 (%)
终浓度 (nM)  Final concentration (nM)
GLP-B-3 GLP-B-6  GLP-B-3 GLP-B-6
200000 33. 0 49. 3  200000 33. 0 49. 3
66667 45. 3 8. 9  66667 45. 3 8. 9
22222 39. 2 3. 4  22222 39. 2 3. 4
7407 16. 9 0. 2  7407 16. 9 0. 2
2469 5. 9 -0. 2  2469 5. 9 -0. 2
823 1. 5 - 0. 4  823 1. 5 - 0. 4
274 0. 0 -0. 4  274 0. 0 -0. 4
0 0. 0 0. 0 表 2. 报告基因检测化合物 GLP- B- 7和 GLP- A- 1的激动活性  0 0. 0 0. 0 Table 2. Induction activity of reporter gene detection compounds GLP-B-7 and GLP-A-1
(%反应, 以 10 nM GLP-1的反应为 100%)  (% reaction, 100% reaction with 10 nM GLP-1)
GLP-B-7 GLP-A-1 GLP-B-7 GLP-A-1
300000 19. 7 48. 8  300000 19. 7 48. 8
100000 13. 2 51. 1  100000 13. 2 51. 1
33333 6. 4 58. 0 t't' 33333 6. 4 58. 0 T't'
0·0 o'o 0 0·0 o'o 0
ε·ο- Zlf  ε·ο- Zlf
ε ·ο_  ε ·ο_
0*19 ο·ο OL£ 0*19 ο·ο OL£
6f 9 ΐΐΐΐΐ  6f 9 ΐΐΐΐΐ
89.Z00/.00ZN3/X3d 60..90/800Ζ OAV 89.Z00/.00ZN3/X3d 60..90/800Ζ OAV

Claims

权 利 要 求 书 Claim
1、 一类由以下通式 I或 II表示的具有取代环丁垸结构的化合物或其药物学上可接受 的盐及其所有的立体和光学异构体, 或者与其具有相同药理作用的前药、 其酯、 其溶剂化 物或其金属配合物: A compound having a substituted cyclobutane structure represented by the following formula I or II, or a pharmaceutically acceptable salt thereof, and all stereo and optical isomers thereof, or a prodrug having the same pharmacological action thereto , its ester, its solvate or its metal complex:
Figure imgf000047_0001
Figure imgf000047_0001
其中 X和 Y 分别为(C¾)„, n为 0-2; 0; S或者 NH; Where X and Y are respectively (C3⁄4)„, n is 0-2; 0; S or NH;
其中 R,, R2各自独立地为下列任意一种取代基: 氢; 卤素; 垸烃; 环垸烃; 羟基; 硝 基; 羧基; 醛基; 垸氧基; 胺基; 胺垸基; 酰胺基; 碳酰胺基; 巯基; 垸硫基; 醚; 硫醚; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或未取代的呋喃基; 取代或未取代的 吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯基; Wherein R, R 2 are each independently any one of the following substituents: hydrogen; halogen; anthracene; cyclohexane; hydroxy; nitro; carboxy; aldehyde; methoxy; amine; amidoxime; Carboxamide; mercapto; sulfonyl; ether; thioether; substituted or unsubstituted aryl; substituted or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; Substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl;
R3, !^各自独立地为下列任意一种取代基: 氢; 烷烃; 环烷烃; 垸氧基; 胺基; 胺垸 基; 酰胺基; 碳酰胺基; 垸硫基; 取代或未取代的芳基; 取代或未取代的吡啶基; 取代或 未取代的呋喃基; 取代或未取代的吡喃基; 取代或未取代的噻吩基; 取代或未取代的吡咯 基。 R 3 , ! ^ Each independently is any of the following substituents: hydrogen; alkane; cycloalkane; anthracene; amine; amidino; amide; carboxamide; sulfonyl; substituted or unsubstituted aryl; Or unsubstituted pyridyl; substituted or unsubstituted furyl; substituted or unsubstituted pyranyl; substituted or unsubstituted thienyl; substituted or unsubstituted pyrrolyl.
2、 根据权利要求 1所述的具有取代环丁烷结构的化合物, 其特征在于:  2. A compound having a substituted cyclobutane structure according to claim 1, wherein:
X、 Y 分别是 (CH2) n, r 为 0- 2; 0; S或者 NH; R,、 R2分别各自独立为:
Figure imgf000047_0002
X and Y are respectively (CH 2 ) n , r is 0-2; 0; S or NH; R, and R 2 are each independently:
Figure imgf000047_0002
其中 R5为下列任意一种取代基: H; d- 的垸基; 含有包括卤素原子、 d- C6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 (^-(:6的垸基; C2-C6的烯基; 含有包括卤素 原子、 C,- C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的(:2-(:6的烯基; C2-C3的 炔基;含有包括卤素原子、 C -Ce的垸氧基或羟基在内的任意一个、两个或者三个取代的 c2-ce 的炔基; C3- C6的环垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个 或者三个取代的(:3- 的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 C,-C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C,_C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d-c4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 d- (^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 d- (:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- c6的垸酰基; 含 有包括卤素原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C,- C6的垸 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d-Cs的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2- Ce的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 d- (:6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- ce的炔酰基; c3-c6的环烷酰基; 含有包括卤素 原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环烷酰基; 金 刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 吡喃甲酰基; 乂1为(01 , n为 0- 2; 0; S或者 NH; Wherein R 5 is any one of the following substituents: H; a fluorenyl group of d-; any one, two or three substituted groups including a halogen atom, a decyloxy group of d-C 6 or a hydroxyl group (^- (: 6 fluorenyl; C 2 -C 6 alkenyl; any one, two or three substituted (including 2 - () containing a halogen atom, C, -C 6 alkoxy group or hydroxyl group : 6 alkenyl group; a C 2 -C 3 alkynyl group; a halogen atom contain any includes, C -Ce group or hydroxyl group of the embankment, including one, two or three substituents of c 2 -c e alkynyl a C 3 -C 6 cycloalkyl group; any one, two or three substituted (: 3 -cyclodecyl) groups containing a halogen atom, a C, a C 6 -oxy group or a hydroxyl group; group; a benzyl group; furyl; tetrahydropyranyl; thienyl; pyrrolyl; pyridyl; include a halogen atom-containing, C, -C 4 alkyl with a nitro group, a carboxyl group, an aldehyde group, an amine group, amide groups, carboxamide, mercapto, methylthio, ethylthio, including one, two or three aryl group substituents; include a halogen atom-containing, C, _C 4 embankment , Nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide group, a mercapto group, a methylthio group, B Any one, two or three substituted pyridyl groups including a thio group; an alkyl group including a halogen atom, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group Any one, two or three substituted furanyl groups including a methylthio group and an ethylthio group; containing a halogen atom, a fluorenyl group of dc 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, Any one, two or three substituted pyranyl groups including an amide group, a carboxamide group, a fluorenyl group, a methylthio group and an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group Any one, two or three substituted thienyl groups, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, d- Any one, two or three substitutions of ( 4 ) thiol, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Pyrrolyl; d-c 6 decanoyl; Any one, two or three substituted C,-C 6 decanoyl groups such as a halogen atom, a d-Ce alkoxy group or a hydroxyl group; a c 2 -c 6 enoyl group; containing a halogen atom, d- Any one, two or three substituted c 2 - C e enoyl groups of a C 垸 oxy or hydroxy group; a C 2 - C 6 acetylene group; containing a halogen atom, d- (: 6垸) Any one, two or three substituted c 2 - c e alkynyl groups such as an oxy group or a hydroxyl group; a c 3 -c 6 cycloalkanoyl group; a decyloxy group or a hydroxyl group containing a halogen atom, dc 6 Any one, two or three substituted c 3 -c 6 cycloalkanoyl groups; adamantyl formyl, substituted adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; Acyl; pyrrolyl; pyranoyl; 乂1 is (01, n is 0-2; 0; S or NH;
R3, R4分别为:
Figure imgf000048_0001
R 3 and R 4 are:
Figure imgf000048_0001
其中 R6为下列任意一种取代基: H; d- C6的烷基; 含有包括卤素原子、 d- (:6的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 (:,-^的垸基; C2-C3的烯基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- 的烯基; C 的 炔基;含有包括卤素原子、 C -C的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3-C6的环垸基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 ( 的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (:,-( 4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (:,-( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- (^的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 (:,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; (:,-( 6的烷酰基; 含 有包括卤素原子、 G- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c,-c6的垸 酰基; C2-C6的烯酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 cr-c6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- cfi的环烷酰基; 含有包括卤素 原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3- c6的环垸酰基; 金 刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 为(CH2) n, n为 0-2; 0; S或者 NH; Wherein R 6 is any one of the following substituents: H; d-C 6 alkyl; or any one, two or three substituted including a halogen atom, d- (: 6 alkoxy group or hydroxyl group) a thiol group of (:, -^; an alkenyl group of C 2 -C 3 ; any one, two or three substituted C 2 -alkenyl groups including a halogen atom, a decyloxy group of d- or a hydroxyl group; Any one, two or three substituted C 2 -C 6 alkynyl groups including a halogen atom, a C-C decyloxy group or a hydroxyl group; a C 3 -C 6 ring enthalpy group; optionally include a halogen atom-containing, or hydroxyl group dC embankment 6 of the inner one, two or three substituents (the embankment cycloalkyl group; an aryl group; a benzyl group; furyl; tetrahydropyranyl; thienyl; pyrrolyl; pyridyl; include halogen atoms contained, (:, - (4 embankment, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide group, a mercapto group, a methylthio group, b thio, including any one, two or three aryl group substituents; include a halogen atom-containing, (:, - (4 embankment group, a nitro group, Any one, two or three substituted pyridyl groups including an aldehyde group, an aldehyde group, an oxo group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; - any one, two or three substitutions of thiol, nitro, carboxy, aldehyde, alkoxy, amino, amido, carboxamido, decyl, methylthio, ethylthio a furanyl group; optionally containing a halogen atom, a thiol group of d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group One, two or three substituted pyranyl groups; containing a halogen atom, (:, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group) Any one, two or three substituted thienyl groups including a fluorenyl group, a methylthio group, an ethylthio group; a thiol group including a halogen atom, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, Amido, carboxamide, sulfhydryl, methylthio, ethanesulfide Including any one, two or three substituents pyrrolyl; (: - alkanoyl (6; containing Any one, two or three substituted c, -c 6 decanoyl groups including a halogen atom, a methoxy group or a hydroxyl group of G-; a C 2 -C 6 enoyl group; containing a halogen atom, d Any one, two or three substituted c 2 -c 6 enoyl groups such as a decyloxy group or a hydroxy group; a c 2 -c 6 alkynyl group; containing a halogen atom, c r -c 6 Any one, two or three substituted c 2 - c 6 alkynyl groups such as a decyloxy group or a hydroxyl group; a c 3 - c fi cycloalkanoyl group; a decyloxy group or a hydroxyl group including a halogen atom, dc 6 Any one, two or three substituted c 3 - c 6 cyclodecanoyl groups; adamantyl, substituted adamantyl form; aroyl; benzyl; furanoyl; pyroyl; thiophene Formyl; pyrroyl group; (CH 2 ) n , n is 0-2; 0; S or NH;
或者 R3, 分别为:
Figure imgf000049_0001
Or R 3 , respectively:
Figure imgf000049_0001
其中 R7, R8各自独立为下列任意一种取代基: H; d- 的烷基; 含有包括卤素原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的烷基; C2- ( 6的烯基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (^的 烯基; C2- (:6的炔基; 含有包括卤素原子、 C,- cfi的烷氧基或羟基在内的任意一个、 两个或者 三个取代的 C2- ^的炔基; C3_C6的环烷基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内 的任意一个、两个或者三个取代的 c3- c6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括 - ^的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳 酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤 素原子、 d-c4 烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲 硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (:,-0<的 烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在 内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧 基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧基、 醛基、 烷氧 基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取 代的噻吩基; 含有包括卤素原子、 d- (:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺 基、碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡咯基; c -c6 的烷酰基; 含有包括卤素原子、 c,- c6的垸氧基或羟基在内的任意一个、 两个或者三个取代 的(:,-(:6的烷酰基; c2-c6的烯酰基; 含有包括卤素原子、 c,- c6的烷氧基或羟基在内的任意 一个、 两个或者三个取代的 c2- c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 ( 的 烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-cfi的环烷酰基; 含有包括卤素原子、 C,- C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 (3-(:6的 环烷酰基; 金刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X (CH2)„, n为 0- 2; 0; S或者 NH; X2为(CH , n为 0-2; 0; S或者 NH; Wherein R 7 and R 8 are each independently a substituent of any of the following: H; d-alkyl; any one, two or three substitutions including a halogen atom, an alkoxy group of d-Ce or a hydroxyl group. D-alkyl; C 2 - ( 6 alkenyl; any one, two or three substituted C 2 - (^ containing a halogen atom, C, -C6 oxime or hydroxyl group) Alkenyl; C 2 - (: 6 alkynyl; any one, two or three substituted C 2 - ^ alkynyl groups containing a halogen atom, C, - c fi alkoxy group or a hydroxyl group; a C 3 _C 6 cycloalkyl group; a cyclyl group of any one, two or three substituted c 3 - c 6 groups including a halogen atom, a decyloxy group or a hydroxyl group of d-Ce; an aryl group; a furanyl group; a pyrenyl group; a pyrenyl group; a pyrrolyl group; a pyridyl group; an alkyl group, a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, methylthio, ethylthio, including any one, two or three aryl group substituents; containing a halogen atom include, dc 4 alkyl, nitro, Any one, two or three substituted pyridyl groups including a aryl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; :, any one, two or three of -0< alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, ethylthio group a substituted furanyl group; containing a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and the like Any one, two or three substituted pyranyl groups; containing a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, Any one, two or three substituted thienyl groups including a methylthio group and an ethylthio group; containing a halogen atom, d- (: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine) Base, amide group, carboxamide group, sulfhydryl group, methylthio group, ethyl sulphide Any one, two or three substituted pyrrolyl groups; c a c 6 alkanoyl group; any one or two containing a halogen atom or a hydroxyl group including a halogen atom, c, - c 6 or Three substituted (:, -(: 6 alkanoyl; c 2 -c 6 alkenoyl; any one, two or three containing an alkoxy group including a halogen atom, c, - c 6 or a hydroxyl group) a substituted c 2 - c 6 alkenyl group; a C 2 -C 6 alkynyl group; optionally containing a halogen atom include, (alkoxy or hydroxy group including one, two or three substituents of c 2 -c 6 alkynyl group; c 3 -c fi cycloalkyl group; a halogen atom include containing, C, - any C 6 alkoxy or hydroxy inner one, two or three substituents of (3 - (: 6 Cycloalkanoyl; adamantyl, substituted adamantyl; aroyl; benzyl; furanoyl; pyranoyl; thiophene; pyrroyl; X (CH 2 ), n is 0- 2; 0; S or NH; X 2 is (CH, n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000050_0001
Or R 3 and R 4 are:
Figure imgf000050_0001
其中 为下列任意一种取代基: H; (:6的垸基; 含有包括卤素原子、 C「 C6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 d-C6的垸基; (:2-( 6的烯基; 含有包括卤素 原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的烯基; (2-(:6的 炔基;含有包括卤素原子、 Cr"C6的烷氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3-C6的环垸基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个 或者三个取代的(:3-(:6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (:,-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- ( 的烷基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d-C4的垸基、硝基、羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 -(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- 的烷酰基; 含 有包括卤素原子、 C,-C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C6的垸 酰基; C2-Ce的烯酰基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 C2-Cfi的烯酰基; C2-C6的炔酰基; 含有包括卤素原子、 d- (:6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- cfi的炔酰基; c3-c6的环垸酰基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环垸酰基; 金 刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X^ (CH , n为 0- 2 ; 0; S或者 NH; Wherein any one of the following substituent groups: H; (: alkyl with 6; dC one, two or three substituents containing optionally include halogen, C "C 6 alkoxy or hydroxy embankment of the inner embankment 6 of ( 2- ( 6 -alkenyl); an optionally, two or three-substituted C 2 -C 6 alkenyl group containing a halogen atom, a decyloxy group or a hydroxyl group of dC 6 ; ( 2- (: 6 alkynyl group; a halogen atom-containing optionally include, Cr "C 6 alkoxy or hydroxy inner one, two or three substituents of C 2 -C 6 alkynyl group of; C 3 -C 6 of Any one, two or three substituted (including 3 -(: 6 cycloalkyl; aryl; benzyl; furanyl) containing a halogen atom, a decyloxy group or a hydroxyl group of d- ; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, (:, - (: 4 fluorenyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide) Any one, two or three substituted aryl groups including a thiol group, a thiol group, an ethylthio group, and a halogen atom; Any one, two or three substituted pyridyl groups including a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three of an atom, d-(alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, thiol, methylthio, ethylthio) a substituted furanyl group; containing a halogen atom, a thiol group of a dC 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methyl group, an ethyl group, and an ethyl group Any one, two or three substituted pyranyl groups; containing a halogen atom, a C 4 fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, Any one, two or three substituted thienyl groups including a methylthio group and an ethylthio group; containing a halogen atom, -(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group) , amide group, carboxamide group, thiol group, methylthio group, Any of a group including two or three substituents pyrrolyl; D- alkanoyl; include a halogen atom-containing, C, -C 6 alkoxy or hydroxy inner any one, two or three a substituted C 6 decanoyl group; a C 2 -C e enoyl group; any one, two or three substituted C 2 -C fi containing a halogen atom, a decyloxy group or a hydroxyl group of dC 6 Alkenoyl; C 2 -C 6 alkynyl; alkynyl group containing any one, two or three substituted c 2 - c fi including a halogen atom, d- (: 6 decyloxy or hydroxy group; a cyclodecanoyl group of c 3 -c 6 ; any one, two or three substituted c 3 -c 6 cyclodecanoyl groups including a halogen atom, a decyloxy group or a hydroxyl group of d-; an adamantyl group , substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X^ (CH, n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000050_0002
Or R 3 and R 4 are:
Figure imgf000050_0002
其中 R1(), Ru各自独立为下列任意一种取代基: H; 的垸基; 含有包括卤素原子、 Cr"Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的(^-(:6的垸基; (2-( 6的烯基; 含有包括卤素原子、 c,-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2- c6的 烯基; c2-c6的炔基; 含有包括 ¾素原子、 c「 c6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 c2-c6的炔基; C3- C6的环垸基; 含有包括卤素原子、 d- 的烷氧基或羟基在内 的任意一个、两个或者三个取代的 c3-c6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (^( 的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d- (:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 -(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 c,-c4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 d- 的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 焼基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-Ce的烷酰基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 c,-c6的垸酰基; c2-c6的烯酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的 任意一个、 两个或者三个取代的 c2- c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 c,-cfi 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- c6的环烷酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3- C6的 环垸酰基; 金刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH , n为 0- 2; 0; S或者 NH; 为(CH , n为 0-2; 0; S或者 NH; Wherein R 1( ) , Ru are each independently a substituent of any of the following: H; an fluorenyl group; any one, two or three substitutions including a halogen atom, a decyloxy group of Cr "C e or a hydroxyl group (^-(: 6垸 ;; ( 2 - ( 6 alkenyl; Any one, two or three substituted c 2 - c 6 alkenyl groups including a halogen atom, c, -c 6 decyloxy group or a hydroxyl group; c 2 -c 6 alkynyl group; atom, any c "c embankment 6 alkoxy or hydroxy, including one, two or three substituents of c -C 6 alkynyl group of 2; C 3 - C 6 cycloalkyl group of embankment; include a halogen atom-containing, Any one, two or three substituted c 3 -c 6 cycloalkyl groups such as d-alkoxy or hydroxy; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; Pyridyl; containing any halogen atom, (alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) One, two or three substituted aryl groups; containing a halogen atom, d- (: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carboxamide group, thiol group, methylthio, ethylthio, including any one, two or three substituted pyridyl; contains include halogen atoms, - (: 4 Any one, two or three substituted furyl groups including a nitro group, a carboxy group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; optionally include a halogen atom, c, -c 4 alkyl with a nitro group, a carboxyl group, an aldehyde group, embankment group, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including one, Two or three substituted pyranyl groups; containing an alkyl group including a halogen atom, d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methyl group, Any one, two or three substituted thienyl groups including an ethylthio group; including a halogen atom, a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group Any one, two or three substituted pyrrolyl groups such as a methylthio group or an ethylthio group; an alkanoyl group of d-Ce; or an alkoxy group including a halogen atom, d- or a hydroxyl group; Two or three substituted c, -c 6 decanoyl; c 2 -c 6 alkenyl group; a halogen atom-containing optionally include, d- or hydroxyl group of the embankment, including one, two or three substituents of c 2 - c 6 alkenyl group; a C 2 -c 6 alkynyl of Any one, two or three substituted c 2 - c 6 alkynyl groups containing a halogen atom, c, -c fi alkoxy group or a hydroxyl group; c 3 - c 6 cycloalkanoyl group; Any one, two or three substituted C 3 -C 6 cyclodecanoyl groups including a halogen atom, a decyloxy group of d-Ce or a hydroxyl group; adamantyl, substituted adamantyl form; aroyl group Benzyl; furanoyl; pyranoyl; thiophene; pyrroyl; X, (CH, n is 0-2; 0; S or NH; (CH, n is 0-2; 0 ; S or NH;
当 R', R2分别各自独立为:
Figure imgf000051_0001
When R', R 2 are each independently:
Figure imgf000051_0001
其中 R12, R13各自独立为下列任意一种取代基: H: - 的垸基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- C6的烷基; C2- C6的烯基; 含有包括卤素原子、 C,- CB的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- ( 的 烯基; C2-C3的炔基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者 三个取代的 C2-C6的炔基; C3- C6的环烷基; 含有包括卤素原子、 d- Ce的垸氧基或羟基在内 的任意一个、两个或者三个取代的 c3-c6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- (^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d_ (^的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 c,-c4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 ( 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 ^- 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (:,-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-C6的垸酰基; 含有包括卤素原子、 C Ce的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 d- C6的垸酰基; C2- Ce的烯酰基; 含有包括卤素原子、 C,- 的垸氧基或羟基在内的 任意一个、两个或者三个取代的 c2-c6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 - 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- c6的环垸酰基; 含有包括卤素原子、 c,- Cfi的垸氧基或羟基在内的任意一个、 两个或者三个取代的 ( ce的 环垸酰基; 金刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH2) n, n为 0-2; 0; S或者 NH; 为(CH , n为 0- 2; 0; S或者 NH时, Wherein R 12 and R 13 are each independently a substituent of any of the following: H: - anthracenyl; any one, two or three substituted ds including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; An alkyl group of C 6 ; a C 2 - C 6 alkenyl group; any one, two or three substituted C 2 - (containing a fluorenyloxy group or a hydroxyl group including a halogen atom, C, - C B ) Alkenyl; C 2 -C 3 alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group containing a halogen atom, d-alkoxy or hydroxy; C 3 - a cycloalkyl group of C 6 ; a mono-, two- or three-substituted c 3 -c 6 cyclodecyl group containing a halogen atom, a decyloxy group or a hydroxyl group of d-C e ; an aryl group; a benzyl group ; furanyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, d- (indenyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide) Any one, two or three substituted aryl groups including a thiol group, a thiol group, a methylthio group, and an ethylthio group; Containing any one or two including a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group Or three substituted pyridyl groups; containing a halogen group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methyl group Any one, two or three substituted furanyl groups including an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carbon amide any group, a mercapto group, methylthio, ethylthio, including one, two or three of the substituents pyranyl; containing a halogen atom include, ^ - alkyl with, nitro, carboxyl, aldehyde, oxygen embankment 4 Any one, two or three substituted thienyl groups including an amino group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and a halogen atom, (:, - (: 4 ) Sulfhydryl, nitro, carboxyl, aldehyde, decyloxy, amine, Any one, two or three substituted pyrrolyl groups such as an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; a decanoyl group of dC 6 ; an alkoxy group containing a halogen atom, C Ce or Any one, two or three substituted d-C 6 decanoyl groups such as a hydroxyl group; a C 2 - C e enoyl group; any one containing a halogen atom, a C, a decyloxy group or a hydroxyl group , two or three substituted c 2 -c 6 enoyl groups; C 2 -C 6 alkynyl groups; containing any one, two or three substitutions including a halogen atom, a fluorenyloxy group or a hydroxyl group a c 2 - c 6 alkynyl group; a c 3 - c 6 cyclodecanoyl group; any one, two or three substituted groups including a halogen atom, c, -C fi alkoxy group or a hydroxyl group ( Cyclodecanoyl c e ; adamantyl formyl, substituted adamantyl formyl; aroyl; benzyl; furanoyl; pyranoyl; thiophene; pyrroyl; X, (CH 2 ) n , n is 0-2; 0; S or NH; is (CH, n is 0-2; 0; S or NH,
R3) 分别为:
Figure imgf000052_0001
R 3) are:
Figure imgf000052_0001
其中 为下列任意一种取代基: H; (「(:6的垸基; 含有包括卤素原子、 (:,-( 6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 C,- C6的垸基; C2-C6的烯基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:2 6的烯基; C2- ( 6的 炔基;含有包括卤素原子、 - 的垸氧基或羟基在内的任意一个、两个或者三个取代的 c2-c6 的炔基; C3-C6的环烷基; 含有包括卤素原子、 C,-^的烷氧基或羟基在内的任意一个、 两个 或者三个取代的 C3- C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- ( 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 0(:4的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的呋喃基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括 素原子、 C,- 的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 - (^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-Ce的垸酰基; 含 有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c,-c6的垸 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2- Ce的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 (:,-(:6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3- c6的环垸酰基; 金 刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 为(CH2)„, n为 0-2; 0; S或者 NH; Wherein is any one of the following substituents: H; ("(: 6 fluorenyl; containing any one, two or three substituted including a halogen atom, (:, - ( 6 decyloxy or hydroxy) 26 is alkenyl: containing optionally include a halogen atom, d- or hydroxyl group of the embankment, including one, two or three of the substituents (; C 2 -C 6 alkenyl group; a C 6 alkyl with the - C, groups; C 2 - (6 alkynyl; include a halogen atom-containing, - or any embankment hydroxyl group including one, two or three substituents of c 2 -c 6 alkynyl group; C 3 -C 6 a cycloalkyl group; any one, two or three substituted C 3 -C 6 cycloalkyl groups including a halogen atom, a C, or an alkoxy group; a aryl group; a benzyl group; a pyranyl group; a pyrenyl group; a pyrrolyl group; a pyridyl group; a pyridyl group; a fluorenyl group, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group , methylthio, ethylthio, including any one, two or three aryl group substituents; containing a halogen atom include, dC alkyl with 4-nitro Any one, two or three substituted pyridyl groups including a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; Any one, two or three substitutions of 4 : alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio a furanyl group; optionally containing a halogen atom, a thiol group of d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group One, two or three substituted pyranyl groups; containing an alkyl group, a C, a alkyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a group Any one, two or three substituted thienyl groups including a thio group or an ethylthio group; Any one or two containing a halogen atom, a -(^ thiol group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group) two or three substituents pyrrolyl; d-Ce acyl group of the embankment; containing optionally include a halogen atom, dc embankment 6 alkoxy or hydroxy, including one, two or three substituents of C, -C 6 acyl embankment An alkenoyl group of c 2 -c 6 ; an enoyl group containing any one, two or three substituted c 2 - C e including a halogen atom, a decyloxy group of dc 6 or a hydroxyl group; C 2 - C 6 Alkynyl; alkynyl group containing any one, two or three substituted c 2 - c 6 groups including a halogen atom, (:, - (: 6 decyloxy group or hydroxy group); c 3 -c 6 Cyclodecanoyl; any one, two or three substituted c 3 - c 6 cyclodecanoyl groups including a halogen atom, a decyloxy group of d- or a hydroxy group; an adamantyl group, a substituted adamantyl group Aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; Is (CH 2 )„, n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000053_0001
Or R 3 and R 4 are:
Figure imgf000053_0001
其中 R7, R8各自独立为下列任意一种取代基: H; ( (:6的烷基; 含有包括卤素原子、 C,-C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 d- C6的烷基; (:2-(:6的烯基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的 烯基; C2-C6的炔基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2- (:6的炔基; C3- C6的环垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3- C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (^-(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C,-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 C, - C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 c,-c4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 - 的垸基、 硝基、羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 -(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-C6的垸酰基; 含有包括卤素原子、 d- cfi的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 c,- c6的烷酰基; c2-c6的烯酰基; 含有包括卤素原子、 d- c6的烷氧基或羟基在内的 任意一个、 两个或者三个取代的 c2-c6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 d-C6 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- c6的环垸酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (:3-(:6的 环垸酰基; 金刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; 为(01 , n为 0-2; 0; S或者 NH; 为(CH2) n, n为 0-2; 0; S或者 NH; Wherein R 7 and R 8 are each independently a substituent of any of the following: H; ((: 6 alkyl; one or two, including a halogen atom, C, -C 6 alkoxy group or a hydroxyl group) Or an alkyl group of three substituted d-C 6 ; (: 2 - (: 6 alkenyl; any one, two or three substituted including a halogen atom, an alkoxy group of d- or a hydroxyl group) C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; any one, two or three substituted C 2 - (: 6 containing a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; Alkynyl; C 3 -C 6 cycloalkyl; any one, two or three substituted C 3 - C 6 ring containing a halogen atom, C, -C 6 decyloxy or hydroxy group Alkyl; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, (^-(: 4 alkyl, nitro, carboxyl, aldehyde, alkoxy) Any one, two or three substituted aryl groups including an amino group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any prime atom, C, -C 4 alkyl with a nitro group, a carboxyl group, an aldehyde group, embankment group, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including one, two Or three substituted pyridyl groups; containing a halogen group including a halogen atom, C, -C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methyl group Any one, two or three substituted furanyl groups including an ethylthio group; a mercapto group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group Any one, two or three substituted pyranyl groups including a carbamide group, a fluorenyl group, a methylthio group, an ethylthio group, a thiol group including a halogen atom, a nitro group, a carboxy group, an aldehyde group, Any one, two or three substituted thienyl groups including an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; and a fluorene group including a halogen atom, -(: 4 Base, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carbon Any one, two or three substituted pyrrolyl groups including an amide group, a fluorenyl group, a methylthio group, an ethylthio group; a decanoyl group of dC 6 ; an alkoxy group or a hydroxyl group containing a halogen atom, d-c fi within any one, two or three substituents of c, - c 6 alkanoyl; C 2 -c 6 alkenyl group; a halogen atom-containing optionally include, d- c 6 alkoxy or hydroxy, including a , two or three substituted c 2 -c 6 enoyl groups; C 2 -C 6 alkynyl groups; containing any one, two or three including a halogen atom, an alkoxy group of dC 6 or a hydroxyl group Substituted c 2 - c 6 alkynyl; c 3 - c 6 cyclodecanoyl; any one, two or three substituted (including 3) including a halogen atom, a d-oxyl group or a hydroxyl group (: 3 -(: 6 of Cyclodecanoyl; adamantyl formyl, substituted adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; (01, n is 0-2; 0; S or NH; is (CH 2 ) n , n is 0-2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000054_0001
Or R 3 and R 4 are:
Figure imgf000054_0001
其中 R9为下列任意一种取代基: H; d- C6的烷基; 含有包括卤素原子、 d- 的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 (^-(:6的垸基; C2- ( 6的烯基; 含有包括卤素 原子、 d-C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的(:2-(6的烯基; (:2-( 6的 炔基;含有包括卤素原子、 (^-(:6的垸氧基或羟基在内的任意一个、两个或者三个取代的 c2-c6 的炔基; C3-Ce的环垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个 或者三个取代 C3-Cfi的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d-C4的烷基、 硝基.. 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C, - 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- C4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 0>的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 d-c4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- c6的垸酰基; 含 有包括卤素原子、 c,-c6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c,- c6的垸 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- 的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3-c6的环烷酰基; 含有包括卤素 原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-cfi的环烷酰基; 金 刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X,为(CH , n为 0-2; 0; S或者 NH; Wherein R 9 is any one of the following substituents: H; an alkyl group of d-C 6 ; any one, two or three substituted groups including a halogen atom, a decyloxy group of d- or a hydroxyl group (^- (: alkyl with 6; C 2 - (6 alkenyl group; a halogen atom-containing optionally include, dC 6 alkoxy or hydroxy, including one, two or three substituents of (: 2 - (6-ene (: 2 -( 6 alkynyl; alkynyl group containing any one, two or three substituted c 2 -c 6 including a halogen atom, (^-(: 6 decyloxy or hydroxy group) a C 3 -C e cycloalkyl group; any one, two or three substituted C 3 -C fi cycloalkyl groups including a halogen atom, a C,-C 6 decyloxy group or a hydroxyl group; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing alkyl group including a halogen atom, dC 4 , nitro: carboxyl group, aldehyde group, decyloxy group, amine group, amide group Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a thiol group including a halogen atom, C, - Any one, two or three substituted pyridyl groups including a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one or two of an atom, a sulfhydryl group of a d-C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, or a three-substituted furyl group; containing a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, Any one, two or three substituted pyranyl groups; containing an alkyl group including a halogen atom, dc 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group Any one, two or three substituted thienyl groups including a methylthio group and an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group , carboxamide, sulfhydryl, methylthio, Thio, including any one, two or three substituents pyrrolyl; d- c embankment 6 acyl; include a halogen atom-containing, c, alkoxy or hydroxy -C 6 including any one, two, Or three substituted c, - c 6 decanoyl groups; c 2 - c 6 enoyl groups; any one, two or three substituted c groups including a halogen atom, a decyloxy group or a hydroxyl group of d- 2 -c 6 enoyl; c 2 -c 6 alkynyl; any one, two or three substituted c 2 - c 6 alkyne containing a halogen atom, a decyloxy group or a hydroxyl group of d- acyl; c 3 -c 6 cycloalkyl group; a halogen atom includes contain any, or a hydroxyl group dC embankment 6 of the inner one, two or three of c 3 -c fi substituted cycloalkyl group; an adamantyl embankment Formyl, substituted adamantyl formyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X, (CH, n is 0-2; 0; S or NH;
或者 R3, 分别为:
Figure imgf000054_0002
其中 R,。, Ru各自独立为下列任意一种取代基: H; C,- 的垸基; 含有包括卤素原子、 d-G的垸氧基或羟基在内的任意一个、 两个或者三个取代的 - 的烷基; (:2-(:6的烯基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- C6的 烯基; C2- (:6的炔基; 含有包括卤素原子、 d-C6的烷氧基或羟基在内的任意一个、 两个或者 三个取代的 C2- Cfi的炔基; C3-C6的环垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 -(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d- 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 -(:4的院基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 (^-( 4的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的吡喃基; 含有包括卤素原子、 垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (^ 4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; C,-C6的烷酰基; 含有包括卤素原子、 d-C6的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 d-Ce的垸酰基; C2-C6的烯酰基; 含有包括卤素原子、 Ct-Ce的垸氧基或羟基在内的 任意一个、两个或者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 c,-c6 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3- cfi的环垸酰基; 含有包括卤素原子、 C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (:3-(:6的 环垸酰基; 金刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X,为(CH2) n, n为 0- 2; 0; S或者 NH; 为(CH , π为 0 - 2; 0; S或者 ΝΗ;
Or R 3 , respectively:
Figure imgf000054_0002
Where R,. , Ru each independently is any one of the following substituents: H; C, - fluorenyl; any one, two or three substituted - alkyl groups including a halogen atom, a decyloxy group or a hydroxyl group of dG (: 2 -(: 6 alkenyl; any one, two or three substituted C 2 -C 6 alkenyl group including a halogen atom, a decyloxy group of dC 6 or a hydroxyl group; C 2 - (: 6 alkynyl; any one, two or three substituted C 2 - C fi alkynyl group including a halogen atom, an alkoxy group of dC 6 or a hydroxyl group; a C 3 -C 6 ring enthalpy Any one, two or three substituted C 3 -C 6 cyclodecyl groups containing a halogen atom, a C,-C 6 decyloxy group or a hydroxyl group; an aryl group; a benzyl group; a furyl group; Pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, -(: 4 alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, Any one, two or three substituted aryl groups including a methylthio group and an ethylthio group; a thiol group including a halogen atom, d-, Any one, two or three substituted pyridyl groups including a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one or two of atoms, -(: 4 , nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) three substituted furanyl; containing a halogen atom include, (^ - (4 alkyl, nitro, carboxyl, aldehyde, embankment group, an amine group, an amide group, a carbonamide group, a mercapto group, a methylthio group, b Any one, two or three substituted pyranyl groups including a thio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group , methylthio, ethylthio, including any one, two or three substituents thienyl; include a halogen atom-containing, (4 ^ embankment group, a nitro group, a carboxyl group, an aldehyde group, an amine group , amide group, carboxamide group, sulfhydryl group, methylthio group Ethylthio, including any one, two or three substituents pyrrolyl; C, -C 6 alkyl group; a halogen atom-containing optionally include, dC 6 alkoxy or hydroxy, including one, two, or a three-substituted d-Ce decanoyl group; a C 2 -C 6 enoyl group; any one, two or three substituted c 2 - including a halogen atom, a Ct-Ce decyloxy group or a hydroxyl group ; An alkenoyl group of c 6 ; an alkynyl group of c 2 -c 6 ; any one, two or three substituted c 2 -c 6 containing a fluorenyloxy group or a hydroxyl group including a halogen atom, c, -c 6 Alkynyl; c 3 - c fi cyclodecanoyl; any one, two or three substituted (: 3 -(: 6 cyclodecanoyl) containing a halogen atom, a C 6 decyloxy group or a hydroxyl group ; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; X, (CH 2 ) n , n 0-2; 0; S or NH; is (CH, π is 0 - 2; 0; S or ΝΗ;
另外优选地, 当 R R2分别各自独立为:
Figure imgf000055_0001
Further preferably, when RR 2 is each independently:
Figure imgf000055_0001
其中 RH为下列任意一种取代基: H; (:,-(:6的垸基; 含有包括卤素原子、 (:6的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 d- C6的烷基; (:2-(:6的烯基; 含有包括卤素 原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:2-(:6的烯基; (:2-(:6的 炔基;含有包括卤素原子、 C,- C6的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3- C6的环垸基; 含有包括卤素原子、 C,-^的垸氧基或羟基在内的任意一个、 两个 或者三个取代的^- 的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 ^_(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (:,_(:4的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括 素原子、 d-c4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 (,-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 (:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- c6的烷酰基; 含 有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d-C6的垸 酰基; c2- C6的烯酰基; 含有包括卤素原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-cfi的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 ( 6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环烷酰基; 含有包括卤素 原子、 CrCe的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3-C6的环垸酰基; 金 刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X (CH , n为 0-2 ; 0; S或者 NH时, Wherein RH is any one of the following substituents: H; (:, -(: 6 fluorenyl; any one, two or three substituted including a halogen atom, ( 6 alkoxy group or hydroxyl group) dC 6 alkyl; (: 2 - (: 6 alkenyl group; a halogen atom includes contain any, or a hydroxyl group dC embankment 6 of the inner one, two or three substituents of (: 2 - ( : 6 alkenyl; (: 2 -(: 6 alkynyl; any one, two or three substituted C 2 -C containing a halogen atom or a hydroxyl group including a halogen atom, C, - C 6 6 alkynyl group; C 3 - C 6 cycloalkyl group of embankment; include a halogen atom-containing, C, - ^ alkoxy or hydroxy embankment any inner one, two or three substituents of ^ - cycloalkyl group embankment; Aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; Containing halogen atoms including, _ ^ (: alkyl with arbitrary 4, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including a , two or three substituted aryl groups; containing a halogen atom, (^-(: 4 fluorenyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, Any one, two or three substituted pyridyl groups including a methylthio group and an ethylthio group; containing a halogen atom, (:, _(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, alkoxy group) , any amine, amide, carboxamide group, an group, methylthio, ethylthio, including one, two or three substituents furanyl; containing pigment atoms include, dc embankment 4 group, a nitro group, Any one, two or three substituted pyranyl groups including a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; (,-(: 4 thiol, nitro, carboxyl, aldehyde, decyloxy, amine Groups, amide groups, carboxamide, mercapto, methylthio, ethylthio, including one, two or three substituents thienyl; include halogen atoms contained, (: 4 embankment group, a nitro group, a carboxyl group Any one, two or three substituted pyrrolyl groups, an aldehyde group, an oxime group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a cyanyl group of d-c 6 Any one, two or three substituted dC 6 decanoyl groups including a halogen atom, a decyloxy group or a hydroxyl group; a c 2 - C 6 enoyl group; containing a halogen atom, d-Ce Any one, two or three substituted c 2 -c fi enoyl groups such as alkoxy or hydroxy; c 2 -c 6 alkynyl; containing a halogen atom, ( 6 decyloxy or hydroxy group) Any one, two or three substituted c 2 -c 6 alkynyl groups; c 3 -c 6 cycloalkanoyl group; any one containing a halogen atom, a decyloxy group of CrCe or a hydroxyl group; two or three substituents of C 3 -C 6 cycloalkyl group embankment; adamantyl embankment formyl, substituted gold When S or NH,; formyl alkoxy; aroyl; a benzyl group; furoyl; formyl pyran; thenoyl; pyrroyl; X (CH, n is 0-2; 0
R3, R4分别为:
Figure imgf000056_0001
R 3 and R 4 are:
Figure imgf000056_0001
其中 Re为下列任意一种取代基: H; C,-C6的烷基; 含有包括卤素原子、 d- (:6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 d- 的垸基; C2-C6的烯基; 含有包括卤素 原子、 C「C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的烯基; (:「(:6的 炔基;含有包括卤素原子、 Ci-Ce的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2-C6 的炔基; C3- C6的环垸基; 含有包括卤素原子、 C「Ce的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 C3- Cfi的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- (^的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C, - 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (^ 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、(:,-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 d- 的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 ^_(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-Ce的垸酰基; 含 有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- C6的垸 酰基; c2-c6的烯酰基; 含有包括卤素原子、 c,-cfi的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 d- c6的烷氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- c6的环垸酰基; 含有包括卤素 原子、 c,-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3-c6的环垸酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X2为(CH2) n, n为 0-2; 0; S或者 NH; Wherein Re is any one of the following substituents: H; C, -C 6 alkyl; or any one, two or three substituted including halogen atom, d- (: 6 decyloxy or hydroxy group) C 2 includes contain any halogen atoms, C "C 6 alkoxy or hydroxy embankment inner one, two or three substituents of - (d- group of embankment;; C 2 -C 6 alkenyl group of: 6 Alkenyl; (: "( 6 : alkynyl; any one, two or three substituted C 2 -C 6 alkynyl group including a halogen atom, a decyloxy group or a hydroxyl group of Ci-Ce; C 3 - C 6 cycloalkyl group embankment; includes any containing a halogen atom, C "C e is a hydroxyl group or embankment, including one, two or three substituents of C 3 - C fi cycloalkyl; aryl; Benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing a halogen atom, d-(^ alkyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, Any one, two or three substituted aryl groups including a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; and a fluorene including a halogen atom, C, - Any one, two or three substituted pyridyl groups, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; Any one, two or three of a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group or an ethylthio group. a substituted furanyl group; containing a halogen atom, (:, -(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, fluorenyl group, methylthio group, Any one, two or three substituted pyranyl groups including an ethylthio group; an alkyl group including a halogen atom, d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, Amide groups, carboxamide, mercapto, methylthio, ethylthio, including one, two or three substituents thienyl; containing a halogen atom include, ^ _ (: 4 embankment group, a nitro group, a carboxyl group Any one, two or three substituted pyrrolyl groups, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; a decanoyl group of d-Ce; Any one, two or three substituted d-C 6 decanoyl groups including a halogen atom, a decyloxy group or a hydroxyl group; a c 2 -c 6 alkenoyl group; containing a halogen atom, c, Any one, two or three substituted c 2 -c 6 alkenoyl groups of -c fi alkoxy or hydroxy; C 2 -C 6 alkynyl; containing a halogen atom, d-c 6 Any one, two or three substituted c 2 - c 6 alkynyl groups, alkoxy or hydroxy; c 3 - c 6 cyclodecanoyl; containing a halogen atom including a halogen atom, c, -c 6 including a hydroxyl group or any one, two or three substituents of c 3 -c 6 cycloalkyl group embankment; adamantyl embankment formyl, taking Adamantane formyl embankment; aryl group; a benzyl group; furoyl; formyl pyran; thenoyl; pyrroyl; X 2 is (CH 2) n, n is 0-2; 0; S, or NH;
或者 R3, 分别为:
Figure imgf000057_0001
Or R 3, respectively:
Figure imgf000057_0001
其中 R7, Rs各自独立为下列任意一种取代基: H; (:,-(:6的烷基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 垸基; C2- (:6的烯基; 含有包括卤素原子、 d-Cs的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的 烯基; (:2-(:6的炔基; 含有包括卤素原子、 ( Ce的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2 6的炔基; C3-C6的环垸基; 含有包括卤素原子、 d- C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3-C6的环烷基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 C,- (:4的烧基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (^-(:4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 - 的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 d-C4的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、 ( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; CrC6的垸酰基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个 取代的( - C6的垸酰基; C2-C6的烯酰基; 含有包括卤素原子、 (^-(:6的垸氧基或羟基在内的 任意一个、 两个或者三个取代的 C2-C6的烯酰基; C2- C6的炔酰基; 含有包括卤素原子、 c,-c6 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3- c6的环垸酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3- (:6的 环烷酰基; 金刚烷甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X (CH2)„, n为 0-2; 0; S或者 NH; X2为(CH2) n, n为 0- 2; 0; S或者 NH; Wherein R 7 and R s are each independently a substituent of any of the following: H; (:, - (: 6 alkyl; any one or two containing a halogen atom, a d-oxyl group or a hydroxyl group) Or a three-substituted fluorenyl group; a C 2 - (: 6 alkenyl group; any one, two or three substituted C 2 -C 6 containing a halogen atom, a decyloxy group or a hydroxyl group of d-Cs alkenyl; (: 2 - (: 6 alkynyl group; a halogen atom-containing include any, (the embankment of Ce alkoxy or hydroxy, including one, two or three substituents having 2 to C 6 alkynyl; C. 3 -C 6 cycloalkyl; any one, two or three substituted C 3 -C 6 cycloalkyl groups including a halogen atom, a d-C 6 decyloxy group or a hydroxyl group; an aryl group; ; furanyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing a halogen atom, C, - (: 4 alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide Any one, two or three substituted aryl groups, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one or two of (^-(: 4 alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) Or a three-substituted pyridyl group; containing a halogen atom, an alkyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group Any one, two or three substituted furan groups; containing a halogen atom, a thiol group of dC 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, methylthio, ethylthio, including any one, two or three of the substituents pyranyl; include halogen atom-containing, (4 embankment group, a nitro group, a carboxyl group, an aldehyde group, embankment group, an amine group, Any one, two or three substituted thienyl groups including an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, (^-(: 4 fluorenyl group, nitro group, Carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carbonyl group Any group, a mercapto group, methylthio, ethylthio, including one, two or three substituents pyrrolyl; CrC embankment 6 acyl; include a halogen atom-containing, C, -C 6 alkoxy or hydroxy embankment in Any one, two or three substituted (-C 6 decanoyl groups; C 2 -C 6 enoyl groups; containing any halogen atom, (^-( 6 decyloxy group or hydroxy group) One, two or three substituted C 2 -C 6 enoyl groups; C 2 -C 6 alkynyl groups; any one or two containing an alkoxy group including a halogen atom, c, -c 6 or a hydroxyl group c-three or a substituted alkynyl group of 2 -c 6; c 3 - c. 6 of the ring acyl embankment; Any one, two or three substituted C 3 - (: 6 cycloalkanoyl groups; adamantyl formyl, substituted adamantyl formyl group; aroyl group containing a halogen atom, a decyloxy group or a hydroxyl group of d- ; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; X (CH 2 ), n is 0-2; 0; S or NH; X 2 is (CH 2 ) n , n Is 0-2; 0; S or NH;
或者 R3, 分别为:
Figure imgf000058_0001
Or R 3, respectively:
Figure imgf000058_0001
其中 R9为下列任意一种取代基: H; ( ,-(:6的垸基; 含有包括卤素原子、 d- (:6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 (:「(:6的垸基; C2- C6的烯基; 含有包括卤素 原子、 d-C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的烯基; C2-C6的 炔基;含有包括卤素原子、 -c 的垸氧基或羟基在内的任意一个、两个或者三个取代的 c2-cfi 的炔基; C3- Ce的环烷基; 含有包括卤素原子、 C,-Cfi的烷氧基或羟基在内的任意一个、 两个 或者三个取代的(:3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- ( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基: 含有包括卤素原子、 d- (:4的烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的呋喃基; 含有包括卤素原子、 d-c4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 ( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括 素原子、: -(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- 的垸酰基; 含 有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- c6的烷 酰基; C2- C6的烯酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或 者三个取代的 c2- c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- ( 6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3-c6的环烷酰基; 含有包括卤素 原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3- ce的环垸酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X,为(CH2)„, n为 0- 2; 0; S或者 NH; Wherein R 9 is any one of the following substituents: H; (, - (: 6 fluorenyl; any one, two or three including a halogen atom, d- (: 6 decyloxy or hydroxy group) Substituted (: "(: 6 fluorenyl; C 2 - C 6 alkenyl; any one, two or three substituted C 2 - including a halogen atom, an alkoxy group of dC 6 or a hydroxyl group) An alkenyl group of C 6 ; a C 2 -C 6 alkynyl group; an alkynyl group containing any one, two or three substituted c 2 -c fi groups including a halogen atom, a decyloxy group of -c, or a hydroxyl group; a C 3 -C e cycloalkyl group; any one, two or three substituted (: 3 - C 6 cyclodecyl) groups including a halogen atom, C, -C fi alkoxy group or a hydroxyl group; Aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, d-( 4 fluorenyl, nitro, carboxyl, aldehyde, decyloxy, amine, Any one, two or three substituted aryl groups including an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, an alkane Any one, two or three substituted pyridyl groups including a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group: Any one or two of a halogen atom, d- (: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, fluorenyl group, methylthio group, ethylthio group) Or three substituted furanyl groups; containing a halogen atom, a fluorenyl group of dc 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethyl sulfide group, including any one, two or three of the substituents pyranyl; include halogen atom-containing, (4 embankment group, a nitro group, a carboxyl group, an aldehyde group, embankment group, an amine group, an amide group, carbonamide group Any one, two or three substituted thienyl groups including a fluorenyl group, a methylthio group, an ethylthio group; containing a sulfhydryl group, a - (: 4 fluorenyl group, a nitro group, a carboxyl group, an aldehyde group, an anthracene group) Base, amine group, amide group, carboxamide group, sulfhydryl group, methyl sulfide Any one, two or three substituted pyrrolyl groups including a thiol group; a decanoyl group of d-; any one, two or three containing a halogen atom, a decyloxy group of dc 6 or a hydroxyl group a substituted alkanoyl group of d-c 6 ; a C 2 -C 6 alkenoyl group; any one, two or three substituted c 2 - c containing a halogen atom, a decyloxy group or a hydroxyl group of d- 6 alkenoyl; C 2 -C 6 alkynyl group; a halogen-containing include any atom, D- (alkoxy or hydroxy embankment 6 of the inner one, two or three substituents of c 2 - C 6 alkynyl group ; c 3 -c 6 cycloalkyl group; a halogen atom includes contain any, or a hydroxyl group dC embankment 6 of the inner one, two or three substituents of c 3 - c e embankment cycloalkyl group; an adamantyl carboxylic embankment Acyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X, (CH 2 ), n is 0-2; NH;
或者 R3, I ^分别为: X2R11 Or R 3 , I ^ are: X2R11
其中 R1(), Ru各自独立为下列任意一种取代基: H; C,-C6的垸基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (:6的垸基; (:2-(:6的烯基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的 烯基; C2- (:6的炔基; 含有包括卤素原子、 (:,-(:6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2-C6的炔基; C3- C6的环垸基; 含有包括 素原子、 d-Cs的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3-C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (^-(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (:,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 C,- (^的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、(,-(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 d-C4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; Cr"C6的烷酰基; 含有包括卤素原子、 C,-C6的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 d- Ce的垸酰基; C2-C6的烯酰基; 含有包括 素原子、 d- Ce的垸氧基或羟基在内的 任意一个、两个或者三个取代的 C2- C6的烯酰基; C2-Ce的炔酰基; 含有包括卤素原子、 d-Cs 的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2-C6的炔酰基; C3- C6的环垸酰基; 含有包括卤素原子、 d-G的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:3-(:6的 环烷酰基; 金刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; 乂1为(0 , n为 0-2; 0; S或者 NH; X2为(CH , n为 0-2; 0; S或者 NH; Wherein R 1 ( ) , Ru are each independently a substituent of any of the following: H; a fluorenyl group of C, -C 6 ; any one or two containing a halogen atom, a decyloxy group or a hydroxyl group of d- or Three substituted (: 6 fluorenyl; (: 2 - (: 6 alkenyl; any one, two or three substituted C 2 containing a halogen atom, a d-oxyl group or a hydroxyl group) -C 6 alkenyl; C 2 - (: 6 alkynyl; any one, two or three substituted C 2 including a halogen atom, (:, - (: 6 decyloxy or hydroxy group) -C 6 alkynyl; C 3 -C 6 cyclodecyl; any one, two or three substituted C 3 -C 6 containing a sulfhydryl group or a hydroxyl group including a aryl group or d-Cs Cycloalkyl; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing halogen atom, (^-(: 4 fluorenyl, nitro, carboxyl, aldehyde, hydrazine) Any one, two or three substituted aryl groups including an oxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; a single atom, (^-(: 4 thiol, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) Two or three substituted pyridyl groups; containing a halogen atom, (:, -(: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, thiol group, Any one, two or three substituted furanyl groups including a methylthio group and an ethylthio group; containing a halogen atom, a C, a thiol group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group Any one, two or three substituted pyranyl groups including a amide group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and a halogen atom, (-, 4- , fluorenyl group, Any one, two or three substituted thienyl groups including a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; atoms, dC 4 alkyl group, a nitro group, a carboxyl group, an aldehyde group, embankment group, amine Amide groups, carboxamide, mercapto, methylthio, ethylthio, including one, two or three substituents pyrrolyl; Cr "C 6 alkoxy group; a halogen atom include containing, C, -C 6 Any one, two or three substituted d-C e decanoyl groups such as alkoxy groups or hydroxyl groups; C 2 -C 6 enoyl groups; containing a fluorenyloxy group including a prime atom, d-C e or Any one, two or three substituted C 2 -C 6 enoyl groups such as a hydroxyl group; a C 2 -C e alkynyl group; or an alkoxy group including a halogen atom, d-Cs or a hydroxyl group One, two or three substituted C 2 -C 6 alkynyl groups; C 3 -C 6 cyclodecanoyl group; any one, two or three containing a halogen atom, a decyloxy group or a hydroxyl group including dG Substituted (: 3 -(: 6 cycloalkanoyl; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; 乂1 is (0, n is 0-2; 0; S or NH ; X 2 is (CH, n is 0-2; 0; S or NH;
当 R R2分别各自独立为:
Figure imgf000059_0001
其中 R,5, R16各自独立为下列任意一种取代基: H; (:,-( 6的垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C,- 0>的垸基; C2- ( 的烯基; 含有包括卤素原子、 C,- C6的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C2- C6的 烯基; C2-C6的炔基; 含有包括! ¾素原子、 C「C6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 c2_c6的炔基; c3-ce的环烷基; 含有包括卤素原子、 c「 c6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 c3-c6的环烷基; 芳基; 苄基: 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 (^-^的院基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 (,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 -( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 c,-c4的垸基、 硝 基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的吡喃基; 含有包括卤素原子、 -( 4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 d- ( 的烧基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- 的垸酰基; 含有包括卤素原子、 d-C6的烷氧基或羟基在内的任意一个、 两个或者三个 取代的 d- c6的垸酰基; c2-c6的烯酰基; 含有包括卤素原子、 垸氧基或羟基在内的 任意一个、 两个或者三个取代的 c2- cfi的烯酰基; c2- cfi的炔酰基; 含有包括卤素原子、 c,-c6 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2-c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3- (:6的 环烷酰基; 金刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; X (CH2)„, n为 0- 2; 0; S或者 NH; 为(CH , n为 0- 2; 0; S或者 NH时,
When RR 2 is independent of each other:
Figure imgf000059_0001
Wherein R, 5 and R 16 are each independently one of the following substituents: H; (:, -( 6 fluorenyl; containing a halogen atom, C, -C 6 decyloxy or hydroxy group, any one of , two or three substituted C, -0>fluorenyl; C 2 - (alkenyl; Include a halogen atom-containing, C, - any C 6 alkoxy or hydroxy inner one, two or three substituents of C 2 - C 6 alkenyl; C 2 -C 6 alkynyl group; comprising comprising! ¾ prime atom, a C "6 alkoxy or hydroxy C embankment, including any of one, two or three substituents of c 2 _c 6 alkynyl group; a cycloalkyl group of c 3 -c e; include a halogen atom-containing, Any one, two or three substituted c 3 -c 6 cycloalkyl groups of c 6 decyloxy or hydroxy; aryl; benzyl: furyl; pyranyl; thienyl; pyrrole Pyridyl; containing a halogen atom, (^-^, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted aryl groups; containing a halogen atom, (, - (: 4 alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carbon amide) Any one, two or three substituted pyridyl groups including a thiol group, a thiol group, a methylthio group, and an ethylthio group; Arbitrary (4 embankment group, a nitro group, a carboxyl group, an aldehyde group, embankment group, amine, amide, carboxamide, mercapto, methylthio, ethylthio, including one, two or three substituents of a furanyl group; a fluorenyl group including a halogen atom, c, -c 4 , a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a thiol group, a methylthio group, an ethylthio group Any one, two or three substituted pyranyl groups; containing a halogen atom, - ( 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, fluorenyl group) Any one, two or three substituted thienyl groups including a methylthio group and an ethylthio group; containing a halogen atom, d-(alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group) Any one, two or three substituted pyrrolyl groups, an amide group, a carboxamide group, a decyl group, a methylthio group, an ethylthio group; a decanoyl group of d-; an alkoxy group containing a halogen atom, dC 6 Any one, two or three substituted d-c 6 a decanoyl group; an alkenoyl group of c 2 -c 6 ; an enoyl group having any one, two or three substituted c 2 - c fi including a halogen atom, a decyloxy group or a hydroxyl group; c 2 - c fi Any one, two or three substituted c 2 -c 6 alkynyl groups containing a halogen atom or a hydroxyl group including a halogen atom, c, -c 6 ; a c 3 -c 6 cyclodecanoyl group; Any one, two or three substituted C 3 - (: 6 cycloalkanoyl groups; adamantyl form, substituted adamantyl group, including a halogen atom, a decyloxy group of d-Ce or a hydroxyl group; Aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; X (CH 2 ), n is 0-2; 0; S or NH; (CH, n is 0- 2; 0; S or NH,
R3) I ^分别为:
Figure imgf000060_0001
R 3) I ^ are:
Figure imgf000060_0001
其中 R6为下列任意一种取代基: H; d- C6的烷基; 含有包括卤素原子、 C,- C6的烷氧基 或羟基在内的任意一个、 两个或者三个取代的 的垸基; C2- C6的烯基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的烯基; C2- 的 炔基;含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、两个或者三个取代的 C2 - C6 的炔基; C3- 的环烷基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 C,-C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 C「C4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 d- 的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括 素原子、 C「C4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 (:,-(:4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 (^的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d- 的垸酰基; 含 有包括卤素原子、 c,- C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- 的烷 酰基; C2-C6的烯酰基; 含有包括卤素原子、 d-Ce的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-ce的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- c6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3- c6的环垸酰基; 含有包括卤素 原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3 c6的环烷酰基; 金 刚垸甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; 为((¾ , n为 0- 2; 0; S或者 NH; Wherein R 6 is any one of the following substituents: H; an alkyl group of d-C 6 ; any one, two or three substituted groups including an alkoxy group including a halogen atom, C, -C 6 or a hydroxyl group; Alkyl; C 2 -C 6 alkenyl; any one, two or three substituted C 2 - (: 6 alkenyl; C containing a halogen atom, a decyloxy group or a hydroxyl group of d-; 2 - alkynyl; optionally include a halogen atom-containing, C, -C 6 alkoxy or hydroxy embankment inner one, two or three substituents of C 2 - C 6 alkynyl group; C 3 - cycloalkyl Any one, two or three substituted C 3 -C 6 cyclodecyl groups including a halogen atom, a decyloxy group or a hydroxyl group of dC 6 ; an aryl group; a benzyl group; a furyl group; a pyranyl group; ; thienyl; pyrrolyl; pyridyl; containing fluorenyl group including a halogen atom, C, -C 4 , nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, sulfhydryl group, methyl sulfide Any one, two or three substituted aryl groups including a thiol group, a thiol group containing a halogen atom, C "C 4 ", a nitro group, a carboxy group Base, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, sulfhydryl group, methylthio group, B Any one, two or three substituted pyridyl groups including a thio group; a fluorenyl group including a halogen atom, d-, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group , any mercapto, methylthio, ethylthio, including one, two or three substituents furanyl; containing pigment include atoms, C "4 alkyl with C, nitro, carboxyl, aldehyde, alkoxy Any one, two or three substituted pyranyl groups, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a halogen atom, (:, -(: 4 ) Any one, two or three substituted thienyl groups of an alkyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one or two containing a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group or an ethylthio group. Or three substituted pyrrolyl; d-decanoyl; Any one, two or three substituted d-alkanoyl groups including a halogen atom, c- or C 6 decyloxy group or a hydroxyl group; a C 2 -C 6 alkenoyl group; containing a halogen atom, d- Any one, two or three substituted c 2 -c e enoyl groups such as alkoxy groups or hydroxyl groups of Ce; c 2 -c 6 alkynyl groups; containing an oxygen atom including a halogen atom, d-c 6 Any one, two or three substituted c 2 - c 6 alkynyl groups including a hydroxyl group; a c 3 - c 6 cyclodecanoyl group; and a halogen atom or a hydroxyl group including a halogen atom, d- Any one, two or three substituted c 3 c 6 cycloalkanoyl; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; Pyrrolyl; is ((3⁄4, n is 0- 2; 0; S or NH;
或者 R3, R4分别为:
Figure imgf000061_0001
Or R 3 and R 4 are:
Figure imgf000061_0001
其中 R7, R8各自独立为下列任意一种取代基: H; -Ce的垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 d- Ce的垸基; C「Cfi 烯基; 含有包括卤素原子、 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 (:2-( 6的 烯基; C2-CB 炔基; 含有包括卤素原子、 的烷氧基或羟基在内的任意一个、 两个或者 三个取代的 C2-C6的炔基; C3-C6的环烷基; 含有包括卤素原子、 C6的烷氧基或羟基在内 的任意一个、两个或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 -(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d- (^的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、两个或者三个取代的吡啶基; 含有包括卤素原子、 d-C4的烷基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 ( (:4的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、两个或者三个取代的吡喃基; 含有包括卤素原子、 C,- C4的烷基、硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻吩基; 含有包括卤素原子、 d- ( 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; d-C6的垸酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 d- C6的垸酰基; c2-c6的烯酰基; 含有包括卤素原子、 d-c6的垸氧基或羟基在内的 任意一个、两个或者三个取代的 c2-c6的烯酰基; c2-c 的炔酰基; 含有包括卤素原子、 c,-cfi 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2-ce的炔酰基; C3 -( 的环垸酰基; 含有包括卤素原子、 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C3- ( 6的 环烷酰基; 金刚垸甲酰基、 取代金刚烷甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; 为((¾)„, n为 0-2; 0; S或者 NH; 为(CH , n为 0-2; 0; S或者 NH; Wherein R 7 and R 8 are each independently a substituent of any of the following: H; a thiol group of -Ce; any one, two or three containing a fluorenyloxy group or a hydroxyl group including a halogen atom, C, -C 6 a substituted decyl group of d-C e ; C "C fienyl ; any one, two or three substituted (including 2 - ( 6 olefins) including a halogen atom, a methoxy group or a hydroxyl group) a C 2 -C B alkynyl group; any one, two or three substituted C 2 -C 6 alkynyl groups including a halogen atom, an alkoxy group or a hydroxyl group; a C 3 -C 6 ring; Any one, two or three substituted C 3 -C 6 cyclodecyl groups including a halogen atom, a C 6 alkoxy group or a hydroxyl group; an aryl group; a benzyl group; a furyl group; group; thienyl group; a pyrrolyl group; a pyridyl group; contains include halogen atoms, - (: 4 embankment group, a nitro group, a carboxyl group, an aldehyde group, embankment group, an amine group, an amide group, a carbonamide group, a mercapto group, methylsulfanyl Any one, two or three substituted aryl groups including a thiol group, a halogen atom, a d- Any one, two or three substituted pyridyl groups including a carboxy group, a carboxy group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three substitutions of an alkyl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a decyl group, a methylthio group or an ethylthio group of dC 4 . a furan group; containing a halogen atom, ((: 4 thiol, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) Any one, two or three substituted pyranyl groups; containing an alkyl group including a halogen atom, C, -C 4 , a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group Any one, two or three substituted thienyl groups including a fluorenyl group, a methylthio group and an ethylthio group; containing a halogen atom, a fluorenyl group, a nitro group, a carboxy group, an aldehyde group, a decyloxy group, Amine, Any one, two or three substituted pyrrolyl groups such as an amide group, a carboxamide group, a decyl group, a methylthio group or an ethylthio group; a decanoyl group of dC 6 ; a decyloxy group having a halogen atom, d- or Any one, two or three substituted d-C 6 decanoyl groups such as a hydroxyl group; c 2 -c 6 enoyl group; any one containing a halogen atom, a decyloxy group of dc 6 or a hydroxyl group; Two or three substituted c 2 -c 6 enoyl groups; c 2 -c acetylene group; any one, two or three containing a halogen atom or a hydroxyl group including a halogen atom, c, -c fi a substituted c 2 -c e acetylene group; C 3 -(cyclodecanoyl; any one, two or three substituted C 3 - ( 6 ) containing a halogen atom, a methoxy group or a hydroxyl group Cycloalkanoyl; adamantyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; ((3⁄4) „, n is 0- 2; 0; S or NH; is (CH, n is 0-2; 0; S or NH;
或者 R3, 分别为:
Figure imgf000062_0001
Or R 3, respectively:
Figure imgf000062_0001
其中 R9为下列任意一种取代基: H; d- 的烷基; 含有包括卤素原子、 d-C6的垸氧基 或羟基在内的任意一个、 两个或者三个取代的 (:,-(:6的垸基; C2- (:6的烯基; 含有包括卤素 原子、 c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2- 的烯基; C2- (6的 炔基;含有包括卤素原子、 Ct-Ce的烷氧基或羟基在内的任意一个、两个或者三个取代的 C2-Ce 的炔基; c3- c6的环垸基; 含有包括卤素原子、 c「c6的垸氧基或羟基在内的任意一个、 两个 或者三个取代的 c3-c6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 d- 04的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 - 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (^(^的垸基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 - (:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的吡喃基; 含有包括卤素原子、 0(:4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的噻吩基; 含有包括卤素原子、 c,- c4的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; c,- cfi的烷酰基: 含 有包括卤素原子、 d-c6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c,-c6的烷 酰基; c2-c6的烯酰基; 含有包括卤素原子、 d- 的烷氧基或羟基在内的任意一个、 两个或 者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 C,- ( 6的垸氧基或羟基 在内的任意一个、 两个或者三个取代的 c2- c6的炔酰基; c3-c6的环垸酰基; 含有包括卤素 原子、 CrCe的烷氧基或羟基在内的任意一个、 两个或者三个取代的 C3-C6的环垸酰基; 金 刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰基; 噻吩甲酰 基; 吡咯甲酰基; X (CH2) n, n为 0-2; 0; S或者 NH; Wherein R 9 is any one of the following substituents: H; d-alkyl; any one, two or three substituted (:, -() containing a halogen atom, a decyloxy group or a hydroxyl group of dC 6 : alkyl with 6; C 2 - (: 6 alkenyl group; a halogen atom includes contain any, or a hydroxyl group, C 6 embankment inner one, two or three substituents of c 2 - alkenyl; C 2 - (6 alkynyl; optionally include a halogen atom-containing, Ct-Ce alkoxy or hydroxy group including one, two or three substituents of C 2 -C e alkynyl group; c 3 - c 6 of Any one, two or three substituted c 3 -c 6 cyclodecyl groups including a halogen atom, c "c 6 decyloxy group or hydroxy group; aryl; benzyl; furanyl ; tetrahydropyranyl; thienyl; pyrrolyl; pyridyl; include a halogen atom-containing, d- embankment 04 group, a nitro group, a carboxyl group, an aldehyde group, embankment group, an amine group, an amide group, a carbonamide group, a mercapto group Any one, two or three substituted aryl groups including a methylthio group and an ethylthio group; containing a halogen atom, a sulfhydryl group, and a nitrate Any one, two or three substituted pyridyl groups including a carboxyl group, an aldehyde group, a decyloxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; Any one, two or three of thiol, nitro, carboxy, aldehyde, decyloxy, amino, amide, carboxamide, sulfhydryl, methylthio, ethylthio Substituted furanyl; containing a halogen atom, - (: 4 fluorenyl, nitro, carboxyl, aldehyde, decyloxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio Any one, two or three substituted pyranyl groups; containing a halogen atom, 0 (: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group) , any mercapto, methylthio, ethylthio, including one, two or three substituents thienyl; include a halogen atom-containing, c, - c 4 embankment group, a nitro group, a carboxyl group, an aldehyde group, an oxygen embankment Base, amine group, amide group, carboxamide group, sulfhydryl group, methyl sulfide , Ethylthio, including any one, two or three substituents pyrrolyl; c, - c fi alkanoyl: containing optionally include a halogen atom, dc embankment 6 alkoxy or hydroxy, including one, two, Or a substituted alkanoyl group of c, -c 6 ; an alkenoyl group of c 2 -c 6 ; any one, two or three substituted cs including a halogen atom, an alkoxy group of d- or a hydroxyl group alkenyl group of 2 -c 6; C 2 -c 6 alkynyl group of; - c embankment any alkoxy or hydroxy (6, including one, two or three substituents of 2 - include a halogen atom-containing, C, c 6 alkynyl group; c 3 -c 6 cycloalkyl group embankment; includes any halogen atom-containing, alkoxy or hydroxy CRCE including one, two or three substituents of C 3 -C 6 cycloalkyl group of the embankment; Gold Cycloalkanoyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrrolyl; X (CH 2 ) n , n 0-2; 0; Or NH;
或者 R3, R4分别为:
Figure imgf000063_0001
Or R 3 and R 4 are:
Figure imgf000063_0001
其中 R1(>, Ru各自独立为下列任意一种取代基: H; d- C6的垸基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的(:,-( 6的垸基; C2-C6的烯基; 含有包括卤素原子、 d-C6的垸氧基或羟基在内的任意一个、 两个或者三个取代的 C2- (:6的 烯基; C2-G^炔基; 含有包括卤素原子、 C,-C6的垸氧基或羟基在内的任意一个、 两个或者 三个取代的 C2- C6的炔基; C3-C6的环垸基; 含有包括卤素原子、 C,- C6的垸氧基或羟基在内 的任意一个、两个或者三个取代的 C3- C6的环垸基; 芳基; 苄基; 呋喃基; 吡喃基; 噻吩基; 吡咯基; 吡啶基; 含有包括卤素原子、 的垸基、 硝基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的芳基; 含有包括卤素原子、 d-C4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡啶基; 含有包括卤素原子、 (:,_( 4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙 硫基在内的任意一个、 两个或者三个取代的呋喃基; 含有包括卤素原子、 烷基、 硝 基、 羧基、 醛基、 垸氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意 一个、 两个或者三个取代的吡喃基; 含有包括卤素原子、(:,-(:4的垸基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、 碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三 个取代的噻盼基; 含有包括 素原子、 (:,-( 4的烷基、 硝基、 羧基、 醛基、 烷氧基、 胺基、 酰胺基、碳酰胺基、 巯基、 甲硫基、 乙硫基在内的任意一个、 两个或者三个取代的吡咯基; C,-C6的烷酰基; 含有包括卤素原子、 C,- Ce的垸氧基或羟基在内的任意一个、 两个或者三个 取代的 c6的烷酰基; c2-ce的烯酰基; 含有包括卤素原子、 d-Ce的垸氧基或羟基在内的 任意一个、两个或者三个取代的 c2-c6的烯酰基; c2-c6的炔酰基; 含有包括卤素原子、 d- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c2-ce的炔酰基; c3-c6的环垸酰基; 含有包括卤素原子、 c- 的垸氧基或羟基在内的任意一个、 两个或者三个取代的 c3- ( 的 环垸酰基; 金刚烷甲酰基、 取代金刚垸甲酰基; 芳酰基; 苄酰基; 呋喃甲酰基; 吡喃甲酰 基; 噻吩甲酰基; 吡咯甲酰基; 乂1为((¾)„, n为 0- 2; 0; S或者 NH; 为(CH , n为 0- 2; 0; S或者 NH。 Wherein R 1 (> , Ru are each independently a substituent of any of the following: H; a fluorenyl group of d-C 6 ; any one of two, including a halogen atom, a C, a C 6 -oxy group or a hydroxyl group; Or three substituted (:, -( 6 fluorenyl; C 2 -C 6 alkenyl; any one, two or three substitutions including a halogen atom, a dC 6 decyloxy group or a hydroxyl group) C 2 - (: 6 alkenyl; C 2 -G^ alkynyl; any one, two or three substituted C 2 containing a halogen atom or a hydroxyl group including a halogen atom, C, -C 6 - an alkynyl group of C 6 ; a C 3 -C 6 cyclodecyl group; any one, two or three substituted C 3 - C containing a halogen atom or a hydroxyl group including a halogen atom, C, -C 6 6 cyclyl; aryl; benzyl; furyl; pyranyl; thienyl; pyrrolyl; pyridyl; containing a halogen atom, a sulfhydryl group, a nitro group, a carboxyl group, an aldehyde group, a decyloxy group, an amine Any one, two or three substituted aryl groups including a amide group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group, and a halogen atom, dC 4 Any one, two or three substituted pyridyl groups such as an alkyl group, a nitro group, a carboxyl group, an aldehyde group, an alkoxy group, an amine group, an amide group, a carboxamide group, a fluorenyl group, a methylthio group or an ethylthio group. Containing a halogen atom, (:, _ ( 4 alkyl, nitro, carboxyl, aldehyde, alkoxy, amine, amide, carboxamide, sulfhydryl, methylthio, ethylthio) Any one, two or three substituted furanyl groups; including halogen atom, alkyl group, nitro group, carboxyl group, aldehyde group, decyloxy group, amine group, amide group, carboxamide group, thiol group, methylthio group, B Any one, two or three substituted pyranyl groups including a thio group; containing a halogen atom, (:, -(: 4 fluorenyl group, nitro group, carboxyl group, aldehyde group, alkoxy group, amine group, Any one, two or three substituted thiopanyl groups including an amide group, a carboxamide group, a fluorenyl group, a methylthio group, an ethylthio group; containing a sulfonyl group, a (-, 4- (alkyl group, a nitro group) , carboxyl group, aldehyde group, alkoxy group, amine group, amide group, carboxamide group, Any one, two or three substituted pyrrolyl groups including a fluorenyl group, a methylthio group, an ethylthio group; a C,-C 6 alkanoyl group; a decyloxy group or a hydroxyl group containing a halogen atom, C, -C e Any one, two or three substituted c 6 alkanoyl groups; c 2 -c e alkenoyl group; any one or two containing a halogen atom, a d-Ce alkoxy group or a hydroxyl group Or three substituted c 2 -c 6 enoyl groups; c 2 -c 6 alkynyl groups; any one, two or three substituted c groups including a halogen atom, a decyloxy group or a hydroxyl group of d- An alkynyl group of 2 - c e ; a cyclodecanoyl group of c 3 -c 6 ; a ring of any one, two or three substituted c 3 - (including a halogen atom, a methoxy group or a hydroxyl group of c-) Decanoyl; adamantyl formyl, substituted adamantyl; aroyl; benzoyl; furoyl; pyranoyl; thiophene; pyrroyl; 乂1 is ((3⁄4)„, n is 0- 2; 0; S or NH; is (CH, n is 0-2; 0; S or NH.
3、根据权利要求 1至 2任意一项所述的具有取代环丁垸结构的化合物, 其特征在于当 分子中存在几何异构体时, 所述化合物为各种单独的几何异构体或者其混合物。  The compound having a substituted cyclobutane structure according to any one of claims 1 to 2, characterized in that, when geometric isomers are present in the molecule, the compounds are various individual geometric isomers or mixture.
4、 根据权利要求 1至 3任意一项所述的化合物, 其特征在于当分子中存在手性碳时, 所述化合物为消旋体或光学活性体。 4. A compound according to any one of claims 1 to 3, characterized in that when chiral carbon is present in the molecule, The compound is a racemate or an optically active body.
5、一种制备权利要求 1至 4中任一项所述具有取代环丁垸结构的化合物系列及其盐的 方法, 特征在于将反应物加入溶剂中利用普通光照或在高压汞灯光照下进行。  A method for producing a series of compounds having a substituted cyclobutane structure according to any one of claims 1 to 4, and a salt thereof, characterized in that the reactant is added to a solvent by ordinary light or under high-pressure mercury lamp illumination. .
6、根椐权利要求 5所述的具有取代环丁垸结构的化合物的制备方法, 其特征在于光照 反应溶剂为二氯甲垸、 水、 二氯乙垸、 DMS0、 二氧六环或上述溶剂的混合溶剂。  A method for producing a compound having a substituted cyclobutyl fluorene structure according to claim 5, wherein the light-reactive solvent is methylene chloride, water, dichloroacetic acid, DMS0, dioxane or the above solvent. Mixed solvent.
7、根据权利要求 5所述的具有取代环丁垸结构的化合物的制备方法, 其特征在于反应 温度为 0°C至 60°C。  The process for producing a compound having a substituted cyclobutane structure according to claim 5, wherein the reaction temperature is from 0 ° C to 60 ° C.
8、根据权利要求 5所述的具有取代环丁垸结构的化合物的制备方法, 其特征在于反应 时加入适当量的水使反应完全。  A process for the preparation of a compound having a substituted cyclobutane structure according to claim 5, characterized in that an appropriate amount of water is added during the reaction to complete the reaction.
9、根据权利要求 5所述的具有取代环丁垸结构的化合物的制备方法, 其特征在于反应 时所用的光可以是自然光, 更优选的是高压汞灯。  A method of producing a compound having a substituted cyclobutyl fluorene structure according to claim 5, wherein the light used in the reaction is natural light, more preferably a high pressure mercury lamp.
10、 根椐权利要求 5所述的具有取代环丁垸结构的化合物的制备方法, 其特征在于反 应时加入催化量的二苯酮促进反应进行。  A process for the preparation of a compound having a substituted cyclobutane structure according to claim 5, characterized in that a catalytic amount of benzophenone is added during the reaction to promote the reaction.
11、根据权利要求 1至 4中任意一项所述化合物或其可药用盐用于制备预防和 /或治疗 代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血管疾病和神经退 行性疾病 (如 Alzheimer' s病) 等的用途。  11. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use in the preparation of a prophylactic and/or therapeutic metabolic disorder (including but not limited to diabetes, insulin resistance and obesity), cardiovascular Uses of diseases and neurodegenerative diseases such as Alzheimer's disease.
12、 一种用于预防和 /或治疗代谢紊乱性疾病(包括但不局限于糖尿病、胰岛素抵抗和 肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s 病) 等的药物组合物, 该组合 物含有作为活性成分的权利要求 1至 4中任一项所述的化合物以及这类化合物在治疗上可 接受的盐类及其与其它分子或载体的连结物。  12. A pharmaceutical composition for preventing and/or treating metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease The composition contains, as an active ingredient, a compound according to any one of claims 1 to 4 and a therapeutically acceptable salt of such a compound and a linker with other molecules or carriers.
13、根据权利要求 12所述的药物组合物, 其特征在于进一步含有药物学上可接受的载 体和赋形剂。  13. A pharmaceutical composition according to claim 12 further comprising a pharmaceutically acceptable carrier and excipient.
14、如权利要求 12所述药物组合物, 其特征在于所述疾病或症状可以因对已经上市的 治疗药物产生耐药性或毒副反应而引起。  14. A pharmaceutical composition according to claim 12, characterized in that the disease or condition can be caused by resistance or toxic side effects to a therapeutic drug already marketed.
15、 一种联合制剂, 包括如权利要求 1至 4中任意一项所述化合物或其药物学上可接 受的盐和其他治疗药物。 .  A combination preparation comprising a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, and other therapeutic agents. .
16、 一种药盒, 其包括权利要求 1至 4中任意一项所述的化合物或其药物学上可接受 的盐, 以及使用所述化合物或其药物学上可接受的盐预防和 /或治疗代谢紊乱性疾病 (包 括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血管疾病和神经退行性疾病 (如 Alzheimer' s病) 等的说明。  A kit comprising the compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, and the use of the compound or a pharmaceutically acceptable salt thereof for prevention and/or prevention Descriptions for the treatment of metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, cardiovascular diseases and neurodegenerative diseases such as Alzheimer's disease.
17、 一种药盒, 其包括权利要求 15所述的联合制剂, 和使用所述联合制剂预防和 /或 治疗代谢紊乱性疾病 (包括但不局限于糖尿病、 胰岛素抵抗和肥胖症)、 心血管疾病和神 经退行性疾病 (如 Alzheimer' s病) 等的说明。  17. A kit comprising the combination of claim 15 and using the combination to prevent and/or treat metabolic disorders (including but not limited to diabetes, insulin resistance and obesity), cardiovascular Description of diseases and neurodegenerative diseases (such as Alzheimer's disease).
PCT/CN2007/002768 2006-12-05 2007-09-19 Substituted cyclobutane compounds, preparation methods and pharmaceutical uses thereof WO2008067709A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610119106.9 2006-12-05
CN2006101191069A CN101195612B (en) 2006-12-05 2006-12-05 Compound with substituted cyclobutane structure, production method and medicine use thereof

Publications (1)

Publication Number Publication Date
WO2008067709A1 true WO2008067709A1 (en) 2008-06-12

Family

ID=39491648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/002768 WO2008067709A1 (en) 2006-12-05 2007-09-19 Substituted cyclobutane compounds, preparation methods and pharmaceutical uses thereof

Country Status (2)

Country Link
CN (1) CN101195612B (en)
WO (1) WO2008067709A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195613B (en) * 2006-12-05 2012-08-08 中国科学院上海药物研究所 Compound with substituted tetratomic ring structure and medicine use thereof
WO2017112889A1 (en) 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1626521A (en) * 2003-12-12 2005-06-15 中国科学院上海药物研究所 Acceptor excitant of a class of pancreas hyperglycemia peptide-1, preparation method and usage
WO2006136101A1 (en) * 2005-06-24 2006-12-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Glucagon like peptide-1 receptor (glp-1r) regulators, preparation methods and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195613B (en) * 2006-12-05 2012-08-08 中国科学院上海药物研究所 Compound with substituted tetratomic ring structure and medicine use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1626521A (en) * 2003-12-12 2005-06-15 中国科学院上海药物研究所 Acceptor excitant of a class of pancreas hyperglycemia peptide-1, preparation method and usage
WO2006136101A1 (en) * 2005-06-24 2006-12-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Glucagon like peptide-1 receptor (glp-1r) regulators, preparation methods and uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHANG D.Y. ET AL.: "Reactions of halogen compounds with disodium enolate of succinosuccinic ester. 1. The reaction with iodoacetic ester", Database accession no. (50:40178) *
DATABASE CA [online] YONGJUN CHU ET AL.: "Synthesis and DNA binding studies of bis-intercalators with a novel spiro-cyclic linker", Database accession no. (145:118930) *
JOURNAL OF THE CHINESE CHEMICAL SOCIETY (TAIPEI, TAIWAN), vol. 2, 1955, pages 71 - 86 *
TETRAHEDRON, vol. 62, no. 23, 2006, pages 5536 - 5548 *

Also Published As

Publication number Publication date
CN101195612B (en) 2012-08-08
CN101195612A (en) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2008119238A1 (en) Substituted five membered heterocycle compounds, preparation method and medical use thereof
WO2009129696A1 (en) A kind of receptor signaling transoluction positive modulators, preparation methods and uses thereof
WO2007009389A2 (en) Substituted propanamide derivatives, preparation and use thereof
JP2016504282A (en) Dihydropyrazole GPR40 modulator
CA2613155C (en) Substituted cyclobutane,its preparation process and its medical use
EP2010492A2 (en) Aminomethyl pyridine derivatives, method for preparing same and therapeutic use thereof
EP1966173B1 (en) Heterocyclic derivatives, preparation and therapeutic use thereof
KR100764863B1 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
WO2008067709A1 (en) Substituted cyclobutane compounds, preparation methods and pharmaceutical uses thereof
WO2008067712A1 (en) Compounds having substituted cyclopropane structure, preparation method and uses thereof
WO2008067713A1 (en) Compounds having substituted cyclopentane structure, their preparation methods and medical uses
WO2008067711A1 (en) Compounds having substituted 4-members ring structure and their medicine uses
WO2008067710A1 (en) Substituted cyclohexane compounds, preparation methods and medicine uses thereof
WO2008119248A1 (en) Photochemical reaction preparative method of four-membered ring compounds
WO2020177752A1 (en) 1,2,4-triazole compound, preparation method therefor and pharmaceutical use thereof
CN107805213A (en) Benzene sulphur phenylacetic acid derivative, its preparation method and its purposes as medicine
WO2007009353A1 (en) Substituted thiazol-4-one compounds, preparation methods and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07816384

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07816384

Country of ref document: EP

Kind code of ref document: A1